BMJ Open

Safety and effectiveness of dose-sparing strategies for intramuscular seasonal influenza vaccine: A rapid scoping review

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2021-050596
Article Type:	Original research
Date Submitted by the Author:	25-Feb-2021
Complete List of Authors:	Lunny, Carole; UBC, DAPT Antony, Jesmin; St Michael's Hospital Li Ka Shing Knowledge Institute Rios, Patricia; Independent Researcher Williams, Chantal ; Independent Researcher Ramkissoon, Naveeta; St Michael's Hospital Li Ka Shing Knowledge Institute, Knowledge Translation Straus, Sharon; St Michael's Hospital Li Ka Shing Knowledge Institute; University of Toronto, Geriatric Medicine Tricco, Andrea; St Michael's Hospital Li Ka Shing Knowledge Institute, Knowledge Translation Program
Keywords:	VIROLOGY, IMMUNOLOGY, PUBLIC HEALTH

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Safety and effectiveness of dose-sparing strategies for intramuscular seasonal influenza vaccine:

A rapid scoping review

Carole Lunny[1,2*†] Email: carole.lunny@ubc.ca

Jesmin Antony[2*] Email: jesmin.antony@unityhealth.to

Patricia Rios[3] Email: patricia.rios@wchospital.ca

Chantal Williams[3] Email: chantal.williams@uhn.ca

Naveeta Ramkissoon[2] Email: naveeta.ramkissoon@unityhealth.to

Sharon E. Straus[2,4,5] Email: sharon.straus@unityhealth.to

Andrea C. Tricco[2,6] Email: andrea.tricco@unityhealth.to

[1]Cochrane Hypertension Review Group and the Therapeutics Initiative, University of British Columbia, Vancouver, BC

[2]Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada

[3]Independent Researcher

[4]Department of Medicine, University of Toronto, Toronto, Ontario, Canada

[5] Department of Geriatric Medicine, University of Toronto, Toronto, Ontario, Canada

[6] Epidemiology Division, Dalla Lana School of Public Health and Institute for Health, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada

*These authors contributed equally.

†Corresponding Author

Carole Lunny

MPH, PhD

Postdoctoral Fellow, Methodology and Research Synthesis

Cochrane Hypertension Group and the Therapeutics Initiative

University of British Columbia

xʷməθkʷəy̓əm (Musqueam) Territory

Vancouver, BC Canada

carole.lunny@ubc.ca

@carole_lunny

Affiliations:

SPOR Evidence Alliance, Unity Health, University of Toronto

University of Bristol

Word count: 3559

ABSTRACT

Background: The objective of this rapid scoping review was to identify dose-sparing strategies for intramuscular administration of seasonal influenza vaccines in healthy individuals of all ages.

Methods: Comprehensive literature searches were executed in MEDLINE, EMBASE, and the Cochrane library. The grey literature was searched via international clinical trial registries for relevant studies published in English in the last 20 years. References of the included systematic reviews and their primary studies were also scanned. Title/abstract and full-text screening were carried out by pairs of reviewers independently. Data extraction was conducted by a single reviewer and verified by a second reviewer. Our outcomes of interest were influenza infections, ICU admission, pneumonia, hospitalizations, adverse events, and mortality. Results were summarized descriptively.

Results: A total of 13 studies with 10,351 participants were included in the review and all studies were randomized control trials (RCTs) conducted between 2006 and 2019. The most common interventions were the trivalent influenza vaccine (n=10), followed by the quadrivalent influenza vaccine (n=4). Nine studies included infants/toddlers 6-36 months old and one of these studies also included children and adolescents. In these nine studies, no clinical effectiveness outcomes were reported. Of the four adult studies (≥ 18 years), two studies reported on effectiveness outcomes.

Conclusions: Due to the low number of studies in healthy adults and the lack of studies assessing confirmed influenza and influenza-like illness, there remains a need for further evaluation.

Keywords:

STRENGTHS AND LIMITATIONS OF THIS STUDY

Strengths:

- This rapid scoping review was conducted within a 6-week timeline and the methods were tailored to provide results to the stakeholders within 4 weeks.
- We did not restrict the search dates and study screening was completed in independently by two reviewers.

Limitations:

- We limited the selection of studies to those published in the English language, and data extraction was conducted by one abstractor and one verifier.
- Twelve dose-sparing RCTs were not included in the review because they did not include vaccines that were deemed of interest to the stakeholder, and/or did not provide sufficient data.

BACKGROUND

The symptoms of novel coronavirus disease (COVID-19) closely mimic those of seasonal influenza vaccine and health officials recommend vaccination against the flu to limit confounding of flu symptoms with COVID-19 symptoms. An anticipated shortage in influenza vaccine supplies was of concern.[1] This anticipated shortage did not happen however, and in the 2019-2020 flu season, influenza vaccination coverage among adults (42%) was similar to the previous season (42%). This question of vaccine shortage remains relevant in Canada and other jurisdictions for future COVID-19 and flue seasons. As a potential solution, health officials were interested in assessing the effectiveness of fractional dosing (e.g., half-doses) of currently available intramuscular influenza vaccines.

Fractional dosing, or dose sparing, strategies are those where less than the standard dose of hemagglutinin (HA) antigen, and thus less volume of vaccine, is administered, increasing the overall number of influenza vaccine doses available. In Canada, influenza vaccines are currently authorized for intramuscular administration only, apart from the live-attenuated influenza vaccine, which is administered intranasally.[2] Standard dose influenza vaccines contain 15 mcg of HA per strain and are delivered in 0.5 mL volume. Therefore, the total amount of HA in standard dose trivalent vaccines is 45 mcg, and the total amount of HA in standard dose quadrivalent vaccines is 60 mcg.

A scoping review of all the available dose sparing strategies for intramuscular administration of seasonal influenza vaccines currently approved in Canada for healthy populations had not been systematically conducted. With the resource-constraints for the influenza season due to COVID-19, there is a need to scope the evidence on the safety and effectiveness of dose-sparing strategies for intramuscular administration of seasonal influenza vaccines. The objective of this

rapid scoping review was to identify studies of dose-sparing strategies for administration of intramuscular seasonal influenza vaccines in healthy individuals of all ages. The results of this scoping review were used to inform a systematic review with meta-analysis by National Advisory Committee on Immunization (NACI) on the same topic [3].

METHODS

The Centre for Immunization and Respiratory Infectious Diseases of the Public Health Agency of Canada (PHAC) commissioned a rapid scoping review on the available methods for fractional dosing of seasonal influenza vaccines through the Canadian Institutes of Health Research (CIHR) Drug Safety and Effectiveness Network (DSEN) with a 6-week timeline for preliminary results.

Protocol

The methods for this review were guided by the updated reviewer manual for scoping reviews published by the Joanna Briggs Institute and the World Health Organization's guide to rapid reviews.[4, 5] Results are reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis extension to scoping reviews (PRISMA-ScR).[6] A protocol for this rapid review was disseminated through the Open Science Framework registry (https://osf.io/8mwz2/).

Literature search

Comprehensive literature searches were developed and executed by an experienced librarian in Ovid MEDLINE (**Appendix 1**), EMBASE using the OVID interface (**Appendix 2**), and the Cochrane library between 1946 and May 2020 (**Appendix 3**). The literature search was peer reviewed by a second librarian using the PRESS checklist (https://www.cadth.ca/resources/finding-evidence/press). The grey (i.e., difficult to locate or

unpublished) literature was searched via international clinical trial registries (i.e. clinicaltrials.gov, EU clinical trial register). References of relevant systematic reviews and included studies were also scanned.

Eligibility criteria

The eligibility criteria followed the Population, Intervention, Comparators, Outcome, Study design (PICOS) framework as follows:

- Population: Healthy humans of any age. Immunocompromised populations and animal studies were excluded. Examples of persons with weakened immune systems include those with HIV/AIDS; cancer and transplant patients who are taking certain immunosuppressive drugs; and those with inherited diseases that affect the immune system (e.g., congenital agammaglobulinemia, congenital IgA deficiency)[7].
- Intervention: Any dose-sparing strategy used to administer intramuscular seasonal influenza vaccines (eligible vaccines listed in **Appendix 4**). Eligible strategies included, but were not limited to, administrating less than the standard 15 ug HA antigen using multi-dose vials, half dosing, or pre-formulated products with reduced antigen quantity, or with revised vaccine dose schedules. Any studies examining monovalent pandemic vaccines, specialty/experimental vaccines (e.g., high dose), whole virus vaccines, or other routes of administration (e.g. intranasal, intradermal) were not eligible. Only vaccine products approved for use in Canada or equivalent formulations approved for use in other countries were eligible for inclusion. Concomitant administration with other vaccine products were included only if administered to both the intervention and the comparator groups.
- Comparator: Any of the interventions listed above, no intervention, or placebo.

- Outcomes: Lab-confirmed influenza infection (primary outcome), influenza-like illness or clinical/symptomatic diagnosis of influenza, hospitalization, intensive care unit (ICU) admission, pneumonia, mortality, and adverse events (local/systemic reactogenicity, vascular-related, serious). Reactogenicity represents the physical manifestation of the inflammatory response to vaccination, and can include injection-site pain, redness, swelling or induration at the injection site, as well as systemic symptoms, such as fever, myalgia, or headache.[8]
- Study designs: Randomized controlled trials (RCTs), non-randomised studies (e.g., quasi-RCTs, non-randomized trials, interrupted time series, controlled before after), and observational studies (e.g., cohort, case control) were included. Studies must have had a control or comparator group in order to be eligible for inclusion and as such, cross-sectional, case series, case reports, and qualitative studies were excluded.
- Publication status: We included full text and abstracts if they included data on safety or effectiveness.

Inclusion was also limited to studies written in the English language due to the short timelines for the conduct of this review.

Study selection

A screening form based on the eligibility criteria was prepared and pilot-tested with 30 studies with all members of the review team until sufficient agreement (>75%) was reached prior to both title/abstract (level 1) and full-text (level 2) screening. Subsequent screening at level 1 and level 2 were completed by pairs of reviewers working independently using the Knowledge Translation Program's proprietary screening software (synthesi.SR)[9]. Any discrepancies between reviewers were consistently resolved by a third independent reviewer.

Data extraction

Items for data collection included study characteristics (study design, year of publication, country of conduct, multi-center vs. single site), patient characteristics (mean age, age range, sex, vaccination history), intervention details (type of vaccine, vaccine manufacturer, dose, timing and administration of treatment), comparator details (comparator intervention, dose), and outcome results (influenza infections, ICU admission, pneumonia, hospitalizations, adverse events, mortality) at the longest duration of follow-up.

A standardized form for data extraction was developed and pilot tested by the entire review team using two pre-selected full-text RCTs to ensure understanding of the data items to be extracted, and congruence among reviewers. All included studies were extracted by one reviewer independently and then verified by a second reviewer.

Risk of bias assessment

As this was a scoping review, the risk of bias of studies was not assessed.[4]

Synthesis

The synthesis involved providing a descriptive summary of included studies with summary tables and detailed tables of study results. Study results were organized and tabulated according to patients (children vs adults), interventions, and outcomes and where available information on relevant subgroups.

RESULTS

Literature search

We screened 2,378 titles and abstracts from our database search and an additional 13 citations located through searching the grey literature and scanning references. Of these, 144 potentially relevant full-text articles were screened for eligibility (**Figure 1**). Twelve studies that assessed

dose-sparing strategies were excluded during full-text screening because the vaccine under study was not of interest or unclearly reported. We contacted authors of these 12 unclear studies and received 1 response confirming the vaccine was not of interest (see list of excluded studies in **Appendix 5**). Subsequently, 13 RCTs were included; five trial protocols were found and were denoted as duplicate/companion reports. No non-randomised or observational studies were found that fulfilled the eligibility criteria.

Study characteristics

Table 1 summarizes the characteristics of the 13 RCTs published between 2006 and 2019; and conducted mainly in the US, followed by Mexico, Canada and Finland. The majority of the studies evaluated trivalent vaccines (10/13 [77%]) and most were conducted in the 6-36 month-old pediatric population (9/13 [69%]). Almost all studies reported on reactogenicity and/or other adverse events, but only two studies reported on the effectiveness of our outcomes of interest (i.e., lab-confirmed influenza and influenza-like illness).

Full study and patient characteristic details for each study are reported in **Appendix 6** and treatment and outcome details in **Appendix 7**.

Table 1: Characteristics of included studies (n=13)

Characteristics	**Category**	**Frequency (%)**
Date of publication	2006-2010	4 (30.8)
	2011-2015	5 (38.4)
	2016-2020	4 (30.8)
Multi-center or single site	Multi-centre	8 (61.5)
	Single centre	2 (15.4)
Countries of conduct[a]	USA	8 (61.5)
	Mexico	3 (23.1)
	Canada	2 (15.4)
	Finland	2 (15.4)
	Belgium	1 (7.7)
	Hong Kong	1 (7.7)
	Taiwan	1 (7.7)

	Thailand	1 (7.7)
Populations[a,b]	Infants/Toddlers (6-36 months)	9 (69.2)
	Children (37 months – 17 years)	1 (7.7)
	Adults (18-64 years)	3 (23.1)
	Older adults (≥65)	1 (7.7)
Treatments[a,c]	Trivalent influenza vaccine (TIV)	10 (76.9)
	Quadrivalent influenza vaccine (QIV)	4 (30.8)
Outcomes[a]	Effectiveness	2 (15.4)
	Local and Systemic Reactogenicity	12 (92.3)
	Adverse events	10 (76.9)

[a]Each study can fit into more than one category so the total percentage will not add up to 100%
[b]One study includes both infants/toddlers and children, and another includes both adults and seniors
[c]One study includes both TIV and QIV arms

RCTs in healthy children (<18 years old)

Nine studies included infants/toddlers 6-36 months old and one study also included children and adolescents (**Table 2**). None of these studies reported results on the effectiveness outcomes that were relevant to our review and established *a priori*, however all of them reported on safety outcomes.

207 ***Table 2: Nine RCTs conducted in children (6 months – 17 years)***

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
TRIVALENT AND QUADRIVALENT INFLUENZA VACCINES (TIV/QIV)									
Cioppa, 2011[10]	October 2008 – March 2009 Belgium	NR - TIV, **7.5-µg/strain** [2 x 0.25mL dose]	20.0 months (7.0)	6- <36 months	43.5	NR	25	Local and Systemic reactogenicity Adverse events	Reactogenicity of the 7.5-µg TIV/QIV formulations was slightly lower than for the corresponding 15-µg formulations. The majority of unsolicited AEs were mild or moderate in severity and none of the SAEs was considered to be related to the study vaccine.
		Agrippal - TIV, **15-µg/strain** [2 x 0.5mL dose]	15.0 months (8.8)	6- <36 months	43.5	NR	22		
		NR - QIV, **7.5-µg/strain** [2 x 0.25mL dose]	18.0 months (8.9)	6- <36 months	43.5	NR	25		
		NR - QIV, **15-µg/strain** [2 x 0.5mL dose]	15.2 months (7.8)	6- <36 months	43.5	NR	28		
		Vaxigrip (Sanofi Pasteur), **7.5-µg/strain** [2 x 0.25mL dose]	16.1 months (8.5)	6- <36 months	43.5	NR	26		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
Skowronski, 2011[11]	September 2008 – December 2008 Canada	Vaxigrip (Sanofi-Pasteur), 15-µg/strain **[2 x 0.5mL dose**]	13.2 months (5.1)	6-23 months	53.2	0	124	Local and Systemic reactogenicity Adverse events	Local reactions generally were less common in infants than toddlers and more common with full doses versus half doses, but none of these differences were significant. One serious adverse event was reported: a toddler in the half dose group was hospitalized with pneumonia 28 days after the first vaccination. The event was deemed unlikely related to the vaccine.
		Vaxigrip (Sanofi-Pasteur), 15-µg/strain **[2 x 0.25mL dose]**	12.8 months (5.0)	6-23 months	53.2	0	128		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
									Compared with 0.25-mL half-dosing, administration of 2 full 0.5-mL doses of trivalent inactivated influenza vaccine can increase antibody response without increasing reactogenicity in previously unimmunized infants aged 6 to 11 months.
Langley, 2012[12]	November 2008 – August 2009 Canada	Fluviral F1 (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	18.2 months (9.06)	6-35 months	47.9	42.6	164	Local and Systemic reactogenicity Adverse events	Fluviral F1 group had 1 case of pneumonia resolved. Fluviral F2 group had 1 case of
		Fluviral F2 (Sanofi-Pasteur), **15-µg/strain** [1 x 0.5mL dose]	17.5 months (8.27)	6-35 months	47.9	42.6	167		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
		Vaxigrip (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	17.0 months (8.33)	6-35 months	47.9	42.6	43		bronchial hyper-reactivity in resolving stage. The 0.5-mL dose of the study vaccine, when administered to children aged 6–35 months, resulted in a modest but not statistically significant improvement in immunogenicity with clinically similar safety and reactogenicity compared with the 0.25-mL dose.
Pavia-Ruz, 2013[13]	October 2008-March 2009	Fluarix (GSK), **15-µg/strain** [1 x 0.5mL dose]	21.2 months (8.37)	6-35 months	51	30.1	1018	Local and Systemic reactogenicity	The reactogenicity and safety

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
	Hong Kong, Mexico, Taiwan, Thailand, and the USA	Fluarix (GSK), **7.5-µg/strain** [1 x 0.25 mL dose]	21.2 months (8.03)	6-35 months	51	30.1	1018	Adverse events	profile of the study vaccine did not appear to be affected by doubling the dose. One participant in the Flu-15µg group had two SAEs, (apnea and cyanosis) which were considered by the investigator to be possibly related to vaccination. The subject was hospitalized and the events resolved on the same day as they occurred.
		Fluzone (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	21.1 months (8.20)	6-35 months	51	30.1	1031		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
Halasa, 2015[14]	2010-2012 USA	Fluzone (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	13.5	6-35 months, 12-35 months	52	13.2	80	Local and Systemic reactogenicity	No significant differences between the full-dose or half-dose groups for either the fully primed or naive cohorts for systemic reactions or local reactions when both seasons were combined. The only significant difference in the 2011–2012 season was that 8 of 48 (16.7%) participants in the half-dose group compared with 32 of 96 (33.3%) in the full-dose group had increased
		Fluzone (Sanofi Pasteur), **15-µg/strain** [1 x 0.5 mL dose]	14.5				163		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
									redness at the injection site (P < .05). No significant differences between the groups in AE, SAE, or onset of chronic medical conditions between the dose groups in either the naive or fully primed cohorts, and none of the SAEs were deemed related to the vaccine.
Phung, 2016[15]	September 2010-January 2011 Finland	FLUAD (NR), NR [**1 x 0.5mL dose**]	68.7 months (18)	6-35 months	55.8	85.7	60	Local and Systemic reactogenicity Adverse events	*Trial protocol with no author conclusions.*
		FLUAD (NR), NR [**1 x 0.25 mL dose]**	60.4 months (23.2)	6-35 months	55.8	85.7	75		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
		Agrippal S1 (NR), NR [**1 x 0.5mL dose**]	68 months (17.1)	6-35 months	55.8	85.7	51		
		Agrippal S1 (NR), NR [**1 x 0.25mL dose**]	32.4 months (1.9)	6-35 months	55.8	85.7	11		
Jain, 2017[16]	2014-2015 Influenza Season USA and New Mexico	Flulaval (GSK), **15-µg/strain** [1 x 0.5mL dose]	19.7 months (8.7)	6-35 months	46.9	57.5	1013	Local and Systemic reactogenicity Adverse events	None of the febrile seizures or the SAEs were considered by the investigator to be related to vaccination. Double-dose vaccines may improve protection against influenza B in some young children and simplifies annual influenza vaccination by
		Fluzone (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	19.9 months (8.9)	6-35 months	46.9	57.5	1028		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
									allowing the same vaccine dose to be used for all eligible children and adults.
Ojeda, 2019[17]	December 2017-January 2018 Mexico	Vaxigrip Tetra (Sanofi Pasteur) **PFS 15-µg/strain** [1 x 0.5mL dose]	NR (6 months – 17 years)	6 months – 17 years	46.4	NR	149	Local and Systemic reactogenicity Adverse events	Solicited systemic reactions were reported in more infants aged 6 − 35 months in the MDV group than in the PFS group however this was not clinically significant. AE not considered related to a study vaccine. There were no differences in reactogenicity or safety
		Vaxigrip Tetra (Sanofi Pasteur) **MDV 15-µg/strain** [1 x 0.5mL dose]	NR (6 months – 17 years)	6 months – 17 years	46.4	NR	153		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
									between the two vaccine formats. These results showed that the MDV format of QIV was as safe and immunogenic as the PFS format in infants, children, and adolescents. These findings support the use of MDV QIV as a resource-saving alternative for seasonal influenza vaccination.
Robertson, 2019[18]	September 2016 – March 2017	Fluzone (Sanofi Pasteur) **15-µg/strain** [1x0.5mL dose]	20.5 months (8.55)	6-35 months	49.7	47.25	992	Local and Systemic reactogenicity	No significant differences between full- and half-dose

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
	USA	Fluzone (Sanofi Pasteur) **7.5-µg/strain** [1x0.25 dose]	20.4 months (8.75)	6-35 months	49.7	47.25	949	Adverse events	groups. AE leading to study discontinuation/ SAE not considered vaccine-related. A full dose vaccine was immunogenic and had a safety profile comparable to that of a half dose, with no new safety concerns observed.

Abbreviations: AE – adverse events; GMR - geometric mean ratio; GMFR – geometric mean fold rise; GMT - geometric mean antibody titer; HA - hemagglutinin; HAI - hemagglutination inhibition; ID – intradermal; IM – intramuscular; ITT – intent-to-treat; MDV – multi-dose vials, n – number of people with condition, N – sample size of treatment arm, NR – not reported, PFS – prefilled dose, SAEs – serious adverse events

Safety outcomes

Trivalent influenza vaccines

Six of the included RCTs assessed trivalent influenza vaccines (TIV) in young children (6-36 months) and reported on local and systemic reactogenicity outcomes and other adverse events.[10-14, 19] Two RCTs compared the administration of full (0.5mL) and half (0.25mL) doses of the same standard 15µg/strain vaccine.[11, 19] The first RCT compared two full versus two half doses of TIV in previously unimmunized infants (6-11 months) and toddlers (12-23 months) using Vaxigrip (15µg/strain).[11] The study found that in the infants group, two full 0.5-mL doses of vaccine did not increase reactogenicity. Local reactions were less common in infants than toddlers and more common with full doses versus half doses, but the differences were not statistically significant. An identified clinical trial registry compared a single intramuscular injection of 0.5mL to 0.25mL of FLUAD or Agrippal and showed comparable numbers of children with reactogenicity outcomes and other adverse events across the groups, but no significance levels or conclusions were provided by the investigators upon contact.[19] The objective of three of the included RCTs was to examine the impact of administering the full adult dose of 15µg/strain vaccines compared with the usual children's dose of 7.5µg/strain in infants and toddlers.[12-14] A multicenter RCT was conducted in Canada assessing the safety of full-dose Fluviral TIV (15µg/strain) compared with the half-dose (7.5µg/strain) and an active comparator Vaxigrip (7.5µg/strain).[12] Compared with the half-dose, the full-dose vaccine resulted in clinically similar reactogenicity and safety. A similar three-arm RCT to assess the use of Fluarix at two different dose levels (7.5µg/strain and 15µg/strain) compared to an established control vaccine Fluzone (7.5µg/strain) also found the reactogenicity and safety profile of Fluarix did not appear to be affected by doubling the dose, but one participant in the 15µg group had two

serious adverse events (apnea and cyanosis) that were considered by the investigator to be possibly related to vaccination.[13] A third multicenter RCT compared the 15 µg/strain formulation to the 7.5µg/strain formulation of Fluzone (Sanofi Pasteur) administered to young children across multiple influenza seasons.[14] This study also found no statistically significant differences between the full-dose or half-dose groups for systemic reactions, local reactions or adverse events when both seasons were combined; however, in the 2011–2012 season, 8 of 48 (16.7%) participants in the half-dose group compared with 32 of 96 (33.3%) in the full-dose group had increased redness at the injection site ($P < .05$).

Cioppa et al. (2009) was the only trial that compared the safety and tolerability of both TIV and QIV vaccine formulations.[10] The vaccine arms of interest were a QIV 15-µg/strain, TIV 15-µg/strain, QIV 7.5-µg/strain, TIV 7.5-µg/strain, and a control Vaxigrip TIV 7.5-µg/strain vaccine. Reactogenicity of the 7.5-µg TIV/QIV formulations was slightly lower than for the corresponding 15-µg formulations, but there was no difference in reactogenicity between TIV and QIV vaccines.

Quadrivalent influenza vaccines

Four of the included RCTs evaluated quadrivalent influenza vaccines (QIV) in children.[10, 16-18] All of the studies reported reactogenicity outcomes and other adverse events. The Cioppa et al. (2009) RCT reported both TIV and QIV vaccines and the results are reported above.[10] Two studies compared full-dose QIV to pediatric 7.5µg/strain Fluzone. In the first RCT, full dose Fluzone had a similar safety profile to half-dose Fluzone with a single adverse event being attributed to the study vaccine.[18] Similarly, the second study found that full-dose Flulaval may improve protection against influenza in some young children when compared to low-dose Fluzone, and in this RCT, none of the adverse events were considered to be study-related as

reported by the investigator.[16] The final trial evaluated Vaxigrip Tetra (15µg/strain) administered to children and adolescents in two different formats.[17] Vaxigrip administered as a single dose using a pre-filled syringe (PFS) was compared to a 10-dose multi-dose vial (MDV). Systemic reactions were reported in more infants aged 6 − 35 months in the MDV group than in the PFS group; however this difference was not clinically significant. The authors concluded that there was no difference in reactogenicity or safety between the two vaccine formats in infants, children, and adolescents.

RCTs in healthy adults (≥18 years old)

One RCT included healthy adults over 18 years, two studies included healthy adults from 18-45 and 18-65 years old, and one study included older healthy adults (≥ 65 years) (**Table 3**). Two studies reported on effectiveness outcomes and three on reactogenicity and other adverse events. All four RCTs evaluated Fluzone QIV.

269 *Table 3: Four RCTs conducted in adults (≥18 years old)*

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Relevant Outcomes	Author reported conclusions
QUADRIVALENT INFLUENZA VACCINES (QIV)									
Kramer, 2006[20]	October 2004 – November 2004 USA	Fluzone (Aventis Pasteur), **15-µg/strain** [1 x 0.5mL dose]	NR (>18 years)	>18 years	NR	NR	222	Lab-confirmed influenza Influenza-like illness Adverse events	There was no significant difference between the full-dose and half-dose groups in the diagnosis of influenza or in the proportion of participants self-reporting four or more symptoms consistent with influenza-like illness. No adverse events were noted by participants from either group or reported to the IRB during the course of the study
		Fluzone (Aventis Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	NR (>18 years)	>18 years	NR	NR	222		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Relevant Outcomes	Author reported conclusions
Engler, 2008[21]	November 2004 – December 2004 USA	Fluzone (Aventis Pasteur), **15-µg/strain** [1 x 0.5mL dose]	NR (18 – 64 years)	18-64 years	43.4	0	554	Influenza-like illness Hospital/ER visits Local and Systemic reactogenicity Adverse events	The relative risk of medical visits and hospitalizations for influenza-like illnesses were similar in the half- and full-dose group regardless of age, and there was no evidence of ILI symptom differences by sex or dose during the 21 days after immunizations. Although injection site pain was greater for full- vs half-dose (19.9% vs 14.4%; p=.01), when analyzed for clinically significant pain levels significant
		Fluzone (Aventis Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	NR (18 – 64 years)	18-64 years	43.4	0	556		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Relevant Outcomes	Author reported conclusions
									dose-dependent pain differences were not identified. Joint and/or muscle pain were significantly different (p=.02 and p=.03, respectively) by dose. No other adverse event differed significantly by dose.
Belshe, 2007[22]	NR USA	Fluzone (Sanofi-Pasteur), **15-µg/strain** [1 x 0.5mL dose]	31.5 years (9.6)	18-49 years	71.2	0	31	Local and Systemic reactogenicity	Intradermal (ID) vaccine induced significantly more local inflammatory response than Intramuscular (IM) vaccine but this did not translate into an
		Fluzone (Sanofi-Pasteur), **9-µg/strain** [1 x 0.3mL dose]	31.2 years (9.4)	18-49 years	71.2	0	32		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Relevant Outcomes	Author reported conclusions
		Fluzone (Sanofi-Pasteur), **6-µg/strain** [1 x 0.2mL dose]	30.1 years (10.3)	18-49 years	71.2	0	31		increased immune response for ID vaccines compared to IM (primary comparison of this study was ID vs IM doses)
		Fluzone (Sanofi-Pasteur), **3-µg/strain** [1 x 0.1mL dose]	31.9 years (10.3)	18-49 years	71.2	0	31		
Chi, 2010[23]	August 2007-2008 USA	Fluzone (Sanofi Pasteur), **15-µg/strain** [1 x 0.5mL dose]	75.6 years (6.8)	>65 years	17.8	94.6	65	Local and Systemic reactogenicity Adverse events	The two SAEs were acute coronary syndrome and appendicitis and neither were judged to be related to influenza vaccination
		Fluzone (Sanofi Pasteur), **9-µg/strain** [1 x 0.3mL dose]	75.2 years (7.7)	>65 years	17.8	94.6	64		

Abbreviations: AE – adverse events, GMT - geometric mean antibody titer; HA - hemagglutinin; ID – intradermal; ILI – influenza-like illness; IM – intramuscular; MDV – multi-dose vials, n – number of people with condition, N – sample size of treatment arm, NR – not reported, PFS – prefilled syringe, SAE – serious adverse events

Effectiveness outcomes

Two of the included RCTs that examined the same vaccine (Fluzone manufactured by Aventis Pasteur) in healthy adult populations reported effectiveness outcomes including lab-confirmed influenza infections, influenza like illness, and/or hospitalizations or emergency room visits after vaccination.[20, 21] The RCT by Kramer et al. (2006) found that 3.6% of participants receiving a 15-µg/strain dose of vaccine reported influenza like illness compared to 6.8% of participants that received a 7.5-µg/strain dose.[20] However, only one participant in the RCT that received the 15-µg/strain dose was confirmed via laboratory analysis to have influenza. The authors concluded that half-dose and full-dose vaccinations appear to be similarly effective based on the low rate of influenza infections and similar symptom surveys between both groups but acknowledge that further studies examining immunogenicity are needed to confirm.

A similar RCT by Engler et al. (2008) that compared a 15-µg/strain dose of Fluzone vaccine to a 7.5-µg/strain dose found equal proportions of participants reporting influenza like illness (9.7% vs 9.9%) and hospitalizations or emergency room visits (0.3% v 0.2%).[21] The authors found the relative risk of medical visits or hospitalizations between both groups was the same even when adjusting for age and that age, sex, nor dose had an influence on the severity of influenza like illness symptoms.

Safety outcomes

Three of the included studies in adult populations reported adverse events that occurred during the trial while one RCT indicated that no adverse events were recorded for the duration of their trial.[20-23] All three studies reporting adverse events compared different doses of Fluzone vaccine including 3-µg, 6-µg, 7.5-µg, 9-µg, and 15-µg per strain doses.

Two of the studies were carried out in healthy adult populations and one RCT was conducted in older healthy adults (>60 years of age).[21-23] One RCT found that joint or muscle pain following vaccination was statistically significantly higher in the full dose (15-µg) group compared to the half-dose (7.5-µg) group and that while injection site pain initially appeared to be statistically significantly higher in the full dose group, when adjusted to include only clinically significant pain levels (>3 out of 5 on a visual analogue scale) the difference was no longer statistically significant.[21] The RCT found no differences in occurrence or severity of any other adverse effects. Similarly, one RCT comparing four different doses of Fluzone (3-µg, 6-µg, 9-µg, and 15-µg per strain) did not report any differences between the IM vaccination groups.[22] Finally, the RCT in older adults also found no difference in the occurrence or severity of adverse events in the low dose (9-µg) versus high dose (15-µg) group and found no serious adverse events that were considered related to the vaccine.[23]

DISCUSSION

PHAC commissioned this rapid scoping review to identify the evidence for efficacy and safety of fractional influenza vaccine dosing for intramuscular administration of seasonal influenza vaccines in healthy individuals of all ages that have been evaluated in human trials. Thirteen RCTs published between 2006 and 2019 comparing standard/full-dose and half/low-dose vaccines were included in this scoping review after a comprehensive search of three electronic databases, trial registries and references of relevant systematic reviews. The majority of the included RCTs were conducted in children and evaluated trivalent influenza vaccines (TIV). In young, healthy children, there were no effectiveness outcomes of interest reported. However, local reactogenicity, systemic reactogenicity and adverse events were comparable across the full-dose and half-dose TIV and QIV vaccine arms. In addition, the authors of one RCT in children

and adolescents that compared full-dose QIV using pre-filled syringes (PFS) versus multi-dose vials (MDV) also found no statistically significant differences in safety outcomes between administration formats. In healthy adults (including older adults), half-dose QIV was considered equally effective as high-dose in the two RCTs that assessed clinical effectiveness. Safety profiles were similar across groups in all 4 RCTs.

A full systematic review with meta-analysis based on the studies included in this scoping review was conducted by the NACI and the report was published in January of 2021.[3] The report found that there is some, but still insufficient, evidence that fractional doses of influenza vaccine provided via the intramuscular route are effective and immunogenic in healthy individuals. NACI concludes that since many of those at high risk of influenza (e.g., adults 65 years of age and older, individuals with specific underlying chronic health conditions) may have a lower immune response to influenza vaccination already (due to immunosenescence in older adults or a condition that alters immune function), it is important to ensure that those at high risk continue to receive the full dose of influenza vaccine.

Future research

Dose-sparing approaches such as intradermal (ID) immunisation vaccination exhibits similar, or even enhanced, immunogenicity, when using a fractional dose only, as compared to intramuscular or subcutaneous immunisation, and should be explored in future scoping reviews.[24]

CONCLUSIONS

In our scoping review, we found 13 RCTs on the efficacy and safety of fractional doses of influenza vaccine provided via the intramuscular route to healthy adults and children. These studies were used to inform a systematic review with meta-analysis which were commissioned

by the PHAC. We found that due to the low number of studies in healthy adults and the lack of studies assessing confirmed influenza and influenza-like illness, there remains a need for further evaluation of the clinical effectiveness of IM dose-sparing strategies using vaccines currently available in this population.

LIST OF ABBREVIATIONS

PHAC – Public Health Agency of Canada

CIHR – Canadian Institutes of Health Research

DSEN – Drug Safety and Effectiveness Network

MAGIC – Methods and Application Group in Indirect Comparisons

PRISMA-ScR – Preferred Reporting Items for Systematic Reviews and Meta-analysis extension to scoping reviews

ICU – Intensive Care Unit

RCT – Randomized controlled trials

NRCTs – non-randomized controlled trials

TIV – Trivalent Influenza Vaccine

AE – Adverse Events

SAE – Serious adverse events

QIV – Quadrivalent Influenza Vaccine

PFS – Pre-filled syringe

MDV – Multi-dose vial

DECLARATIONS

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

The dataset(s) supporting the conclusions of this article is(are) included within the article (and its additional file(s)).

Competing interests

The authors have no competing interests to declare.

Funding

This work was supported through the Drug Safety and Effectiveness Network funded by the Canadian Institutes of Health Research, the funders had no involvement in the design, conduct, or publication of this study. SES is funded by a Tier 1 Canada Research Chair in Knowledge Translation and the Mary Trimmer Chair in Geriatric Medicine; ACT is funded by a Tier 2 Canada Research Chair in Knowledge Synthesis.

Authors' contributions

CL wrote and revised the final manuscript. JA and PR screened citations and full-text articles, abstracted and verified data, interpreted results and wrote the first draft manuscript. CW and NR screened citations and full-text articles, abstracted data, and reviewed the manuscript. SES and ACT developed the protocol, obtained funding, interpreted results, and edited the manuscript.

Acknowledgements

The authors would like to thank Jessie McGowan for her assistance in developing literature searches, Tamara Radar for PRESS of literature search, Alissa Epworth for her assistance executing searches and retrieving articles, and Navjot Mann for her assistance in contacting author's and formatting this manuscript.

Additional files

File Format: Microsoft Word (.docx)

Title of Data: Additional File 1 (Appendices 1-7)

Description of Data: The appendices include the following additional information:

Appendix 1 – MEDLINE search strategy

Appendix 2 – EMBASE search strategy

Appendix 3 – Cochrane search strategy

Appendix 4 – List of eligible vaccines

Appendix 5 – Excluded dose-sparing studies

Appendix 6 – Study and patient data

Appendix 7 – Treatment and outcome data

FIGURE LEGEND

Figure 1. Flow chart of studies included in the review

Study flow diagram.

REFERENCES

1. PHAC. Seasonal Influenza Vaccination Coverage in Canada, 2019-2020, 2020.
2. PHAC. Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2019–2020, 2019.
3. PHAC. Recommendations on fractional influenza vaccine dosing, 2021.
4. Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. *JBI Evid Synth* 2020;18(10):2119-26. doi: 10.11124/jbies-20-00167 [published Online First: 2020/10/11]
5. World Health Organization AfHPaSR. Rapid reviews to strengthen health policy and systems: a practical guide. In: Andrea C. Tricco EVLaSES, ed., 2017:119.
6. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med* 2018;169(7):467-73. doi: 10.7326/m18-0850
7. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. *Clinical Infectious Diseases* 2013;58(3):e44-e100. doi: 10.1093/cid/cit684
8. Hervé C, Laupèze B, Del Giudice G, et al. The how's and what's of vaccine reactogenicity. *npj Vaccines* 2019;4(1):39. doi: 10.1038/s41541-019-0132-6
9. Synthesi.SR [program]. Toronto, Canada: Knowledge Translation Program, St. Michael's Hospital, 2012.
10. Della Cioppa G, Vesikari T, Sokal E, et al. Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: a dose-and schedule-finding study. *Vaccine* 2011;29(47):8696-704.
11. Skowronski DM, Hottes TS, Chong M, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. *Pediatrics* 2011;128(2):e276-89. doi: 10.1542/peds.2010-2777 [published Online First: 2011/07/20]
12. Langley JM, Vanderkooi OG, Garfield HA, et al. Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6–35 months: a randomized, controlled trial. *J Pediatric Infect Dis Soc* 2012;1(1):55-63.
13. Pavia-Ruz N, Angel Rodriguez Weber M, Lau Y-L, et al. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. *Hum Vaccin Immunother* 2013;9(9):1978-88.
14. Halasa NB, Gerber MA, Berry AA, et al. Safety and immunogenicity of full-dose trivalent inactivated influenza vaccine (TIV) compared with half-dose TIV administered to children 6 through 35 months of age. *J Pediatric Infect Dis Soc* 2015;4(3):214-24.
15. Phung A. Clinical Trial Results: A Phase IIIB, observer-blind, randomized, parallel groups, extension study to evaluate the immunogenicity and safety following a single intramuscular dose of FLUAD or Agrippal S1 influenza vaccines in healthy children previously vaccinated in the V70P5 study. . July 29, 2016 ed, 2016.
16. Jain VK, Domachowske JB, Wang L, et al. Time to change dosing of inactivated quadrivalent influenza vaccine in young children: evidence from a phase III, randomized, controlled trial. *J Pediatric Infect Dis Soc* 2017;6(1):9-19.
17. Ojeda J, Arredondo JL, Salcedo P, et al. Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial. *Hum Vaccin Immunother* 2019:1-5.

18. Robertson CA, Mercer M, Selmani A, et al. Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial. *Pediatr Infect Dis J* 2019;38(3):323-28. doi: 10.1097/inf.0000000000002227 [published Online First: 2018/11/06]
19. ClinicalTrialsRegister.eu. A Phase IIIB, observer-blind, randomized, parallel groups, extension study to evaluate the immunogenicity and safety following a single intramuscular dose of FLUAD or Agrippal S1 influenza vaccines in healthy children previously vaccinated in the V70P5 study. May 15, 2015 ed, 2015.
20. Kramer JS, Durham C, Schroeder T, et al. Effectiveness of half-dose versus full-dose influenza vaccine in health care workers. *Am J Health Syst Pharm* 2006;63(21):2111-15.
21. Engler RJ, Nelson MR, Klote MM, et al. Half-vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. *Arch Intern Med* 2008;168(22):2405-14.
22. Belshe RB, Newman FK, Wilkins K, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. *Vaccine* 2007;25(37-38):6755-63.
23. Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. *Clin Infect Dis* 2010;50(10):1331-8. doi: 10.1086/652144 [published Online First: 2010/04/10]
24. Schnyder JL, De Pijper CA, Garcia Garrido HM, et al. Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis. *Travel Med Infect Dis* 2020;37:101868. doi: 10.1016/j.tmaid.2020.101868 [published Online First: 2020/09/09]



APPENDIX 1 – MEDLINE search strategy

Database: Ovid MEDLINE(R) ALL <1946 to May 29, 2020>

Search Strategy:

---

1 influenza, human/ or exp influenza a virus/ or exp influenzavirus b/ or influenzavirus c/
2 (flu or flue or influenza* or grippe).tw,kf.
3 1 or 2
4 exp Vaccines/ or Immunization/
5 (vaccin* or immuni* or inocula* or shot or jab).tw,kf.
6 4 or 5
7 3 and 6
8 influenza vaccines/ or Adjuvants, Immunologic/
9 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).tw,kf.
10 7 or 8 or 9
11 Injections, Intramuscular/
12 (intramuscular or intra-muscular).tw,kf.
13 or/11-12
14 10 and 13
15 limit 14 to yr=2000-current
16 animals/ not humans/
17 15 not 16
18 ad.fs.
19 11 or 12 or 18
20 10 and 19
21 exp dose-response relationship, immunologic/
22 dose-Response Relationship, Drug/
23 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).tw,kf.
24 ((reduc* or lower or less) adj2 (quantity or strength or standard)).tw,kf.
25 ((dos* adj3 change) or (half adj3 dos*)).tw,kf.
26 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).tw,kf.
27 or/21-26
28 20 and 27
29 animals/ not humans/
30 28 not 29
31 limit 30 to yr=2000-current
32 17 or 31

APPENDIX 2 – EMBASE search strategy

Database: Ovid MEDLINE(R) Embase <2000 to June 11, 2020>

Search Strategy:

---

1 influenza, human/ or exp influenza a virus/ or exp influenzavirus b/ or influenzavirus c/
2 (flu or flue or influenza* or grippe).tw,kf.
3 1 or 2
4 exp Vaccines/ or Immunization/
5 (vaccin* or immuni* or inocula* or shot or jab).tw,kf.
6 4 or 5
7 3 and 6
8 influenza vaccines/ or Adjuvants, Immunologic/
9 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).tw,kf.
10 7 or 8 or 9
11 Injections, Intramuscular/
12 (intramuscular or intra-muscular).tw,kf.
13 or/11-12
14 10 and 13
15 limit 14 to yr=2009-current
16 animals/ not humans/
17 15 not 16
18 ad.fs.
19 11 or 12 or 18
20 10 and 19
21 exp dose-response relationship, immunologic/
22 dose-Response Relationship, Drug/
23 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).tw,kf.
24 ((reduc* or lower or less) adj2 (quantity or strength or standard)).tw,kf.
25 ((dos* adj3 change) or (half adj3 dos*)).tw,kf.
26 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).tw,kf.
27 or/21-26
28 20 and 27
29 animals/ not humans/
30 28 not 29
31 limit 30 to yr=2009-current
32 17 or 31
33 32 use ppez
34 exp Influenza virus/ or exp influenza/
35 (flu or flue or influenza* or grippe).tw.
36 34 or 35
37 exp vaccine/
38 exp immunization/
39 influenza vaccination/ or vaccination/
40 (vaccin* or immuni* or inocula* or shot or jab).tw.

41 or/37-40
42 36 and 41
43 influenza vaccination/
44 immunological adjuvant/
45 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).tw.
46 or/42-45
47 intramuscular drug administration/
48 (intramuscular or intra-muscular).tw.
49 47 or 48
50 46 and 49
51 limit 50 to yr="2009 -Current"
52 animals/ not humans/
53 51 not 52
54 ad.fs.
55 49 or 54
56 46 and 55
57 dose response/ or drug response/
58 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).tw.
59 ((reduc* or lower or less) adj2 (quantity or strength or standard)).tw.
60 ((dos* adj3 change) or (half adj3 dos*)).tw.
61 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).tw.
62 or/57-61
63 56 and 62
64 animals/ not humans/
65 63 not 64
66 limit 65 to yr="2009 -Current"
67 53 or 66
68 67 use emczd
69 33 or 68
70 remove duplicates from 69

APPENDIX 3 – Cochrane search strategy

Database: Database: EBM Reviews - Cochrane Database of Systematic Reviews <2005 to June 03, 2020>, EBM Reviews - ACP Journal Club <1991 to May 2020>, EBM Reviews - Database of Abstracts of Reviews of Effects <1st Quarter 2016>, EBM Reviews - Cochrane Clinical Answers <May 2020>, EBM Reviews - Cochrane Central Register of Controlled Trials <May 2020>, EBM Reviews - Cochrane Methodology Register <3rd Quarter 2012>, EBM Reviews - Health Technology Assessment <4th Quarter 2016>, EBM Reviews - NHS Economic Evaluation Database <1st Quarter 2016>
Search Strategy:

---

1 (influenza, human or influenza a virus or influenzavirus b or influenzavirus c).kw.
2 (flu or flue or influenza* or grippe).ti,ab.
3 1 or 2
4 (Vaccines or Immunization).kw.
5 (vaccin* or immuni* or inocula* or shot or jab).ti,ab.
6 4 or 5
7 3 and 6
8 (influenza vaccines or Adjuvants, Immunologic).kw.
9 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).ti,ab.
10 7 or 8 or 9
11 Injections, Intramuscular.kw.
12 (intramuscular or intra-muscular).ti,ab.
13 11 or 12
14 10 and 13
15 dose-response relationship, immunologic.kw.
16 dose-Response Relationship, Drug.kw.
17 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).ti,ab.
18 ((reduc* or lower or less) adj2 (quantity or strength or standard)).ti,ab.
19 ((dos* adj3 change) or (half adj3 dos*)).ti,ab.
20 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).ti,ab.
21 or/15-20
22 10 and 21
23 14 or 22
24 limit 23 to yr="2009 -Current" [Limit not valid in DARE; records were retained]

Database: EBM Reviews - Cochrane Database of Systematic Reviews <2005 to June 03, 2020>, EBM Reviews - ACP Journal Club <1991 to May 2020>, EBM Reviews - Database of Abstracts of Reviews of Effects <1st Quarter 2016>, EBM Reviews - Cochrane

**Clinical Answers <May 2020>, EBM Reviews - Cochrane Central Register of Controlled Trials <May 2020>, EBM Reviews -
Cochrane Methodology Register <3rd Quarter 2012>, EBM Reviews - Health Technology Assessment <4th Quarter 2016>, EBM
Reviews - NHS Economic Evaluation Database <1st Quarter 2016>
Search Strategy:**

---

1 (influenza, human or influenza a virus or influenzavirus b or influenzavirus c).kw.
2 (flu or flue or influenza* or grippe).ti,ab.
3 1 or 2
4 (Vaccines or Immunization).kw.
5 (vaccin* or immuni* or inocula* or shot or jab).ti,ab.
6 4 or 5
7 3 and 6
8 (influenza vaccines or Adjuvants, Immunologic).kw.
9 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or
FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).ti,ab.
10 7 or 8 or 9
11 Injections, Intramuscular.kw.
12 (intramuscular or intra-muscular).ti,ab.
13 11 or 12
14 10 and 13
15 dose-response relationship, immunologic.kw.
16 dose-Response Relationship, Drug.kw.
17 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or
fractional dos*).ti,ab.
18 ((reduc* or lower or less) adj2 (quantity or strength or standard)).ti,ab.
19 ((dos* adj3 change) or (half adj3 dos*)).ti,ab.
20 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3
taper*)).ti,ab.
21 or/15-20
22 10 and 21
23 14 or 22
24 limit 23 to yr="2000 - 2008" [Limit not valid in DARE; records were retained]
25 from 24 keep 1-173

APPENDIX 4 – List of eligible vaccines

Product name (manufacturer)	Vaccine Characteristic				
	Vaccine type	Route of administration	Authorized ages for use	Antigen content for each vaccine strain	Formats available
Flulaval Tetra (GSK)	IIV4-SD (split virus)	IM	6 months and older	15 µg HA /0.5 mL dose	5 mL multi-dose vial Single dose pre-filled syringe
Fluzone Quadrivalent (Sanofi Pasteur)	IIV4-SD (split virus)	IM	6 months and older	15 µg HA /0.5 mL dose	5 mL multi-dose vial Single dose vial Single dose pre-filled syringe without attached needle
Afluria Tetra (Seqirus)	IIV4-SD (split virus)	IM	5 years and older	15 µg HA /0.5 mL dose	Up to expiry date indicate on vial label
Influvac Tetra (BGP Pharma ULC, operating as Mylan)	IIV4-SD (subunit)	IM or deep subcutaneous injection	3 years and older	15 µg HA /0.5 mL dose	Single dose pre-filled syringe with or without a needle
VaxigripTetra	IIV4	IM	6 months and older	Pediatric: 7.5 µg HA /0.25 mL dose Adult: 15 µg HA /0.5 mL dose	0.5 mL pre-filled syringe
Fluarix Tetra/ Influsplit Tetra (GSK)	IIV4	IM	6 months and older	15 µg HA /0.5 mL dose	0.5 mL pre-filled syringe
Agriflu (Seqirus)	IIV3-SD (subunit)	IM	6 months and older	15 µg HA /0.5 mL dose	5 mL multi-dose vial Single dose pre-filled syringe without attached needle
Fluad Pediatric and Fluad (Seqirus)	IIV3-Adj (subunit)	IM	Pediatric: 6-23 months Adult: 65 years and older	Pediatric: 7.5 µg HA /0.25 mL dose Adult: 15 µg HA /0.5 mL dose	Single dose pre-filled syringe without a needle
Fluviral (GSK)	IIV3-SD (split virus)	IM	6 months and older	15 µg HA /0.5 mL dose	5 mL multi-dose vial
Fluzone TIV (Sanofi Pasteur)	IIV3-HD (split virus)	IM	65 years and older	Adult: 15 µg HA /0.5 mL dose	0.5 mL pre-filled syringe
Vaxigrip TIV	IIV3-SD	IM	6 months and older	Pediatric: 7.5 µg HA /0.25 mL dose Adult: 15 µg HA /0.5 mL dose	0.5 mL pre-filled syringe

Note: list of vaccines included in the review is based on feedback from PHAC and the 2020-2021 seasonal vaccine availability in Canada found here: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2020-2021.html#appA

APPENDIX 5 – Excluded dose-sparing studies

	Reference	Reason for exclusion
1	Euctr, H. U. A Randomized, Double-blind, Multi-Center Study to Evaluate Safety and Immunogenicity of One Dose of Four FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccines Containing 3.5[micro]gHA, 6[micro]gHA, 9[micro]gHA or 1. 2011. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=EUCTR2011	exclude - dose-sparing but vaccine not of interest
2	Vajo Z, Tamas F, Jankovics I. A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial. *Clin Vaccine Immunol*. 2012;19(3):313-318. doi:10.1128/CVI.05619-11	exclude - dose-sparing but vaccine not of interest
3	Treanor J, Keitel W, Belshe R, et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002;20(7-8):1099-1105. doi:10.1016/s0264-410x(01)00440-6	exclude - dose-sparing but vaccine not of interest
4	Euctr. A Randomized, Active Controlled, Double-blind, Multi-Centre Study to Evaluate Safety and Immunogenicity of One Dose of FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccine Containing 6µgHA of Seasonal A/H1N1, A/H3N2 and B Influenza Antigens in Non-elderly Adult and Elderly Subjects. 2011. Available from: http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011-003314-16-HU	exclude - dose-sparing but experimental vaccine
5	Euctr, E. S. Clinical study to compare the safety of two influenza vaccines in children and adolescents of 3 to less than 18 years of age at risk for influenza-related complications. 2013. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=EUCTR2013	exclude - dose-sparing but experimental vaccine
6	Pillet S, Aubin É, Trépanier S, et al. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol. 2016;168:72-87. doi:10.1016/j.clim.2016.03.008	exclude - dose-sparing but experimental vaccine
7	Lee JH, Cho HK, Kim KH, et al. Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months. J Korean Med Sci. 2019;34(46):e279. Published 2019 Dec 2. doi:10.3346/jkms.2019.34.e279	exclude - dose-sparing but experimental vaccine
8	Treanor JJ, Taylor DN, Tussey L, et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine. 2010;28(52):8268-8274. doi:10.1016/j.vaccine.2010.10.009	exclude - dose-sparing but experimental vaccine
9	Vajo Z, Balaton G, Vajo P, Kalabay L, Erdman A, Torzsa P. Dose sparing and the lack of a dose-response relationship with an influenza vaccine in adult and elderly patients - a randomized, double-blind clinical trial. Br J Clin Pharmacol. 2017;83(9):1912-1920. doi:10.1111/bcp.13289	exclude - dose-sparing but vaccine not of interest
10	Ctri. Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India. 2015. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=CTRI	exclude - dose-sparing but unclear vaccine (waiting for author response)
11	Euctr, F. I. Safety and Immunogenicity of the Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Children Aged 3 to 8 Years. 2011. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=EUCTR2011	exclude - dose-sparing but unclear vaccine (waiting for

		author response)
12	Euctr, C. Z. A randomized, double-blind, placebo-controlled, multi-country and multi-center, phase IV study to demonstrate the efficacy of GSK Biologicals' influenza vaccine (Fluarix[TM]) administered intramuscularly in adults. - FluarixUS-006. 2006. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=EUCTR2006	exclude - dose-sparing but unclear vaccine (waiting for author response)

APPENDIX 6 – Study and patient data

Author, Year [Study design]	Study period; Setting and Country	Objective of study	Eligibility criteria	Sample size; % Female, % previously immunized	Ethnicities
Kramer, 2006 [RCT][1]	October 2004 – November 2004; 760-bed tertiary care community teaching hospital in the USA	To compare the effectiveness of half-dose versus full dose TIV in health care workers	Age 18 years or older, hospital employee, staff member, or volunteer, and signed informed consent and authorization to use and disclose protected health information for research purposes	444; NR, NR	NR
Belshe, 2007 [RCT][2]	USA; NR	To compare the immunogenicity and safety of injection of IM and ID TIV across different dose levels (3, 6, 9, and 15µg/antigen/dose)	Healthy adults 18-49 years of age	125; 71.2%, 0%	American Indian/Alaskan Native (0%), Asian (2.4%), Black/African American (9.6%), Hawaiian/Pacific Islander (0%), Hispanic (0%), Multi-racial (0.8%), Non-Hispanic (97.6%), Other/unknown (0%), White (87.2%)
Engler, 2008 [RCT][3]	November 2004 – December 2004; Allergy-Immunology-Immunization Clinic, WRAMC, and Pentagon/DiLorenzo Health Clinic, Arlington, Virginia in the USA	To determine the effects of age, sex, and dose on the immunogenicity of intramuscular TIV	Healthy adults aged 18-64 years. Inclusion criteria were based on the remaining CDC and/or DoD priority prior to the shortage announcement which includes all children aged 6--23 months; adults aged >65 years; persons aged 2--64 years with underlying chronic medical conditions; all women who will be pregnant during the influenza season; residents of nursing homes and long-term--care facilities; children aged 2--18 years on chronic aspirin therapy; health-care workers involved in direct patient care; and out-of-home caregivers and household contacts of children aged <6 months	1316; 43.4%, 0%	African American (9%), Asian (2%), Hispanic (2%), Other/unknown (1.4%), White (85%)
	August 2007-2008; Seattle Division of the Department of	To determine pre vaccination and 4- week post-vaccination changes in antibody titer, and	Community-dwelling adults 65 years and older living in Puget Sound area in Washington State	129; 17.8%, 94.6%	African American (4.7%), Asian (1.6%), Hispanic (0.8%), Not reported

Author, Year [Study design]	Study period; Setting and Country	Objective of study	Eligibility criteria	Sample size; % Female, % previously immunized	Ethnicities
Chi, 2010 [RCT][4]	Veterans Affairs Puget Sound Health Care System in Washington State, USA.	local and systemic reactions of full-dose compared to 60% dose of TIV by IM injection			(2.3%), Other (0.8%), White (90%)
Cioppa, 2011 [RCT][5]	October 2008 – March 2009; 10 study centers in Finland and 5 centers in Belgium	To evaluate the safety, tolerability and immunogenicity of different vaccine formulations with different doses of MF59 adjuvant and/or a second B strain (QIV) when added to either high or low doses of a purified subunit influenza vaccine	Healthy children aged 6 to <36 months	126; 43.5%, NR	Asian (1.68%), Black (6.54%), White (84.2%)
Skowronski, 2011 [RCT][6]	September 2008 – December 2008; 5 sites in 3 Canadian provinces (British Columbia, Quebec, and Nova Scotia)	To determine whether giving 2 full doses of split TIV to previously unimmunized infants and toddlers can improve immunogenicity without increasing reactogenicity compared with 2 half-doses	Healthy children 6–23 months of age	267; 53.2%, 0%	Asian (7.9%), Other (14.3%), White (77.8%)
Langley, 2012 [RCT][7]	November 2008 – August 2009; 17 centers in Canada	To assess the immunogenicity and safety of a preservative-free, prefilled syringe formulation of TIV provided as the full adult dose of 0.50 mL compared with the usual children's dose of 0.25 mL in young children	Healthy children 6–35 months at the time of vaccination	390; 47.9%, 42.6%	Other (13.9%), White (86.1%)
Pavia-Ruz, 2015 [RCT][8]	October 2008 – March 2009; Hong Kong, Mexico, Taiwan, Thailand, and the USA	To evaluate Fluarix at both the standard recommended TIV dose for young children in the US (0.25 ml) and also at double this dose (0.5 ml)	Healthy children aged 6 to 35 months at the time of the first vaccination; without acute illness at the time of enrollment and who had not been vaccinated during the 2008-2009 influenza season. Administration of influenza vaccine in a previous season was not however an exclusion criteria	3318; 51%, 30.1%	African heritage/African American (3.5%), American Indian or Alaskan native (0.1%), Asian-Central/South Asian heritage (0.1%), Asian-East Asian heritage (14.5%), Asian-Japanese heritage (0.1%), Asian-South East Asian heritage

Author, Year [Study design]	Study period; Setting and Country	Objective of study	Eligibility criteria	Sample size; % Female, % previously immunized	Ethnicities
					(9.2%), Native Hawaiian or other Pacific Islander (0.2%), White - Arabic/North African heritage (0.5%), White-Caucasian/European heritage (29.9%), Hispanics and children of mixed race (42.1%)
Halasa, 2015 [RCT][9]	2010-2012; 6 study sites in USA	To determine whether a higher dose of influenza vaccine would be safe in the 6 through 35 months age group. In addition, to determine whether immunization with 0.5 mL doses of TIV (15 µg of each HA) would improve the immunogenicity without increasing the reactogenicity of TIV when administered to children 6 through 35 months of age with and without a history of previous TIV vaccination	Healthy children 6 to 35 months of age (naïve cohort) or 12 through 35 months of age (fully primed cohort) who were available for the entire study period and whose parents or guardians provided informed consent were eligible to participate. Children who were eligible in the fully primed cohort also required a history of receiving 2 doses of 2009–2010 H1N1 influenza vaccine and 2 doses of TIV at any time in the past	243; 52%, 13.2%	African (26%), Asian (1%), Multiracial (5%), other (0%); Ethnicity: Hispanic (2%), Non-Hispanic (98%), White (67%)
Phung, 2016 [RCT][10]	September 2010-January 2011; Finland	To evaluate the immunogenicity and safety following a single intramuscular dose of FLUAD or Agrippal S1 influenza vaccines in healthy children previously vaccinated	Healthy children 6–35 months at the time of vaccination	197; 55.8%, 85.7%	NR
Jain, 2017 [RCT][11]	2014-2015 influenza season; 66 study locations in USA and Mexico	To compare the safety and immunogenicity of a double-dose IIV4 manufactured by GSK Vaccines with the United States-approved standard-dose IIV4 in children 6–35 months of age	Healthy children aged 6-35 months regardless of influenza vaccination history, but could not have received any seasonal or pandemic influenza vaccine within 6 months before the first dose of study vaccine	2424; 46.9%, 57.5%	African/African American (13.9%), American Indian or Alaskan Native (2.0%), Caucasian (64.3%), Other (17.9%), South East Asian (1.8%)
Ojeda, 2019 [RCT][12]	December 2017 – January 2018; 3 study sites in Mexico	Reported the results of an open-label, randomized phase III study designed to evaluate the immunogenicity and safety	Children aged 6 months to 17 years of age	302; 46.4%, NR	NR

Author, Year [Study design]	Study period; Setting and Country	Objective of study	Eligibility criteria	Sample size; % Female, % previously immunized	Ethnicities
		of this thiomersal containing MDV format of QIV compared to the licensed thiomersal-free, single-dose PFS format in children and adolescents			
Robertson, 2019 [RCT][13]	September 2016 – March 2017; 38 sites in the USA	To compare the safety and immunogenicity of full and half doses of quadrivalent, split-virion, inactivated influenza vaccine in children 6–35 months of age	Healthy children 6–35 months of age who had not been vaccinated against influenza during the current season (2016–2017). Children 6–11 months of age had to be born at full term of pregnancy (≥37 weeks) or with a birth weight ≥2.5 kg	1950; 49.7%, 47.3%	Race: American Indian or Alaska Native (0.98%), Asian (0.46%), Black (19.2%), Native Hawaiian or Other Pacific Islander (0.46%), White (74.3%), Ethnicity: Hispanic or Latino (22%), not Hispanic or Latino (77%)

Abbreviations: CDC- Centers for Disease Control and Prevention; DoD- Department of Defense; GSK -GlaxoSmithKline; HA-hemagglutinin; IIV4 – inactivated influenza vaccine; ID - intradermal; IM - intramuscular; MDV- multi-dose vial; PFS – pre-filled syringe; QIV-quadrivalent influenza vaccine; TIV-trivalent influenza vaccine; NR – not reported

APPENDIX 7 – Treatment and outcome data

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
Kramer, 2006 [RCT][1] *Adults and Seniors (>18 years)*	Fluzone (Aventis Pasteur), **15-µg/strain** [1 x 0.5mL dose (Intramuscular into the deltoid region)] *A/Wyoming/3/2003 (H3N2), A/New Caledonia/20/99 (H1N1), and a new B strain, B/Jiangsu/10/2003*	**Effectiveness** *Lab confirmed influenza* (Laboratory confirmation of influenza diagnosis was sought in participants reporting a clinical diagnosis by their physicians): 1/222 *Influenza like illness* (Clinical diagnosis of influenza. Participants self-reported four or more symptoms consistent with influenza-like illness (i.e., headache, extreme tiredness, dry cough, fever, muscle or body aches)): 8/222	▪ There was no significant difference between the full-dose and half-dose groups in the diagnosis of influenza or in the proportion of participants self-reporting four or more symptoms consistent with influenza-like illness. ▪ No adverse events were noted by participants from either group or reported to the IRB during the course of the study
	Fluzone (Aventis Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (Intramuscular into the deltoid region)] *A/Wyoming/3/2003 (H3N2), A/New Caledonia/20/99 (H1N1), and a new B strain, B/Jiangsu/10/2004*	**Effectiveness** *Lab confirmed influenza* (Laboratory confirmation of influenza diagnosis was sought in participants reporting a clinical diagnosis by their physicians): 0/222 *Influenza like illness* (Clinical diagnosis of influenza. Participants self-reported four or more symptoms consistent with influenza-like illness (i.e., headache, extreme tiredness, dry cough, fever, muscle or body aches)): 15/222	
Belshe, 2007 [RCT][2] *Adults (18-49 years)*	Fluzone (Sanofi-Pasteur), **15-µg/strain** [1 x 0.5mL dose (Intramuscular in the non-dominant arm)]	**Reactogenicity – injection site** *Pain*[1]: 15/31 *Redness*[2]: 8/31 *Swelling*[2] :7/31 **Reactogenicity – systemic** *Fever*[3]: 1/31 *Headache*[1]: 15/31 *Malaise*[1]: 8/31 *Myalgia*[1]: 10/31	▪ Intradermal vaccine induced significantly more local inflammatory response than Intramuscular vaccine (primary comparison of this study was ID vs IM doses)
	Fluzone (Sanofi-Pasteur), **9-µg/strain** [1 x 0.3mL dose (Intramuscular in the non-dominant arm)]	**Reactogenicity – injection site** *Pain*[1]: 11/31 *Redness*[2]: 11/31 *Swelling*[2] :4/31 **Reactogenicity – systemic** *Fever*[3]: 1/31 *Headache*[1]: 6/31	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Malaise[1]: 8/31 *Myalgia*[1]: 6/31	
	Fluzone (Sanofi-Pasteur), **6-µg/strain** [1 x 0.2mL dose (Intramuscular in the non-dominant arm)]	**Reactogenicity – injection site** *Pain*[1]: 14/31 *Redness*[2]: 9/31 *Swelling*[2] :4/31 **Reactogenicity – systemic** *Fever*[3]: 0/31 *Headache*[1]: 9/31 *Malaise*[1]: 7/31 *Myalgia*[1]: 9/31	
	Fluzone (Sanofi-Pasteur), **3-µg/strain** [1 x 0.[1mL dose (Intramuscular in the non-dominant arm)]	**Reactogenicity – injection site** *Pain*[1]: 15/31 *Redness*[2]: 9/31 *Swelling*[2]:7/31 **Reactogenicity – systemic** *Fever*[3]: 3/31 *Headache*[1]: 8/31 *Malaise*[1]: 3/31 *Myalgia*[1]: 7/31	
Engler, 2008 [RCT][3] *Adults (18-64 years)*	Fluzone (Aventis Pasteur), **15-µg/strain** [1 x 0.5mL dose (Intramuscular injection)] *A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002*	**Effectiveness** *Influenza like illness* (Influenza-like illness and complications resulting in either inpatient or outpatient medical encounters were compared between dose groups (by age)): 61/632 *Hospitalization or Emergency visits*: 0.3% **Reactogenicity – local/injection site** *Any local reactions* (NR): 8.9% *Arm weakness* (NR): 8.3% *Numbness or burning* (NR): 9.7% *Pain* (NR): 5.9% *Redness or swelling* (NR): 13.4% **Reactogenicity – systemic** *Joint and/or muscle pain* (NR): 4.5%	▪ The relative risk of medical visits and hospitalizations for influenza-like illnesses were similar in the half- and full-dose group regardless of age, and there was no evidence of ILI symptom differences by sex or dose during the 21 days after immunizations. ▪ Although injection site pain was greater for full vs half dose (19.9% vs 14.4%; p=.01), when analyzed for clinically significant pain levels significant dose-dependent pain differences were not

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Adverse events *SAE*: 2/554	identified. ▪ Joint and/or muscle pain were significantly different (p=.02 and p=.03, respectively) by dose. ▪ No other adverse event differed significantly by dose
	Fluzone (Aventis Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (Intramuscular injection)] *A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2003*	**Effectiveness** *Influenza like illness* (Influenza-like illness and complications resulting in either inpatient or outpatient medical encounters were compared between dose groups (by age): 64/644 *Hospitalization or Emergency visits*: 0.2% **Reactogenicity – local/injection site** *Any local reactions* (NR): 7.5% *Arm weakness* (NR): 6.5% *Numbness or burning* (NR): 7.8% *Pain* (NR): 4.6% *Redness or swelling* (NR): 8.6% **Reactogenicity – systemic** *Joint and/or muscle pain* (NR): 2.2% **Adverse events** *SAE*: 1/556	
Chi, 2010 [RCT][4] *Seniors (>65 years)*	Fluzone (Sanofi Pasteur), **15-µg/strain** [1 x 0.5mL dose (intramuscular in deltoid of arm)] *A/Solomon Islands/3/ 2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), and B/Malaysia/2506/2004*	**Reactogenicity – injection site, N=64** *Arm motion limitation*: 1 (grade I)[4] *Itching:* 4 (grade I)[4] *Pain:* 7 (grade I)[4] *Redness or discoloration:* 9 (grade I)[4] *Swelling:* 13 (grade I)[4] **Reactogenicity - systemic, N=64** *Chills:* 1 (grade I)[4], 1 (grade II/III)[5] *Fatigue:* 4 (grade I)[4], 2 (grade II/III)[5] *Fever:* 0 *General body ache/pain:* 6 (grade I)[4], 1 (grade II/III)[5] *Headache:* 10 (grade I)[4] *Nausea:* 3 (grade I)[4], 1 (grade II/III)[5] **Adverse events**	▪ The two SAEs were acute coronary syndrome and appendicitis and neither were judged to be related to influenza vaccination

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		SAE[6]: 0/64	
	Fluzone (Sanofi Pasteur), **9-µg/strain** [1 x 0.3mL dose (intramuscular in deltoid of arm)] *A/Solomon Islands/3/ 2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), and B/Malaysia/2506/2004*	**Reactogenicity – injection site, N=64** *Arm motion limitation:* 1 (grade I)[4] *Itching:* 5 (grade I)[4] *Pain:* 11 (grade I)[4] *Redness or discoloration:* 7 (grade I)[4] *Swelling:* 4 (grade I)[4] **Reactogenicity - systemic, N=64** *Chills:* 1 (grade I)[4], 1 (grade II/III)[5] *Fatigue:* 6 (grade I)[4], 1 (grade II/III)[5] *Fever:* 1 (grade I)[4] *General body ache/pain:* 5 (grade I)[4], 2 (grade II/III)[5] *Headache:* 5 (grade I)[4], 1 (grade II/III)[5] *Nausea:* 2 (grade I)[4], 1 (grade II/III)[5] **Adverse events** *SAE*[6]*:* 2/64	
Cioppa, 2011 [RCT][5] *Infants/ Toddlers (6-36 months)*	NR - TIV, **7.5-µg/strain** [2 x 0.25mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)] *A/Brisbane/59/2007 (A/H1N1)-like virus, A/Brisbane/10/2007 (A/H3N2)-like virus, and B/Florida/4/2006-like virus (of the influenza B/Yamagata lineage)*	**Reactogenicity** *Any local reaction*[7]: 47% *Any systemic reaction*[8]: 68% **Adverse events** *AE* (solicited/spontaneously reported): 84% *SAE*: 0/25	▪ Reactogenicity of the 7.5-µg TIV/QIV formulations was slightly lower than for the corresponding 15-µg formulations. ▪ The majority of unsolicited AEs were mild or moderate in severity and none of the SAEs was considered to be related to the study vaccine.
	Agrippal - TIV, **15-µg/strain** [2 x 0.5mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)] *A/Brisbane/59/2007 (A/H1N1)-like virus, A/Brisbane/10/2007 (A/H3N2)-like virus, and B/Florida/4/2006-like virus (of the influenza B/Yamagata lineage)*	**Reactogenicity** *Any local reaction*[7]: 59% *Any systemic reaction*[8]: 50% **Adverse events** *AE* (solicited/spontaneously reported): 82% *SAE*: 0/22	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
	NR - QIV, **7.5-µg/strain** [2 x 0.25mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)] *A/Brisbane/59/2007 (A/H1N1)-like virus, A/Brisbane/10/2007 (A/H3N2)-like virus, B/Florida/4/2006-like virus (of the influenza B/Yamagata lineage), and B/Malaysia/2506/2004-like antigen virus (Victoria lineage)*	**Reactogenicity** *Any local reaction*[7]: 25% *Any systemic reaction*[8]: 50% **Adverse events** *AE* (solicited/spontaneously reported): 92% SAE: 1/25	
	NR - QIV, **15-µg/strain** [2 x 0.5mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)] *A/Brisbane/59/2007 (A/H1N1)-like virus, A/Brisbane/10/2007 (A/H3N2)-like virus, B/Florida/4/2006-like virus (of the influenza B/Yamagata lineage), and B/Malaysia/2506/2004-like antigen virus (Victoria lineage)*	**Reactogenicity** *Any local reaction*[7]: 39% *Any systemic reaction*[8]: 54% **Adverse events** *AE* (solicited/spontaneously reported): 71% *SAE*: 1/28	
	Vaxigrip pediatric - TIV (Sanofi Pasteur), **7.5-µg/strain** [2 x 0.25mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)]	**Reactogenicity** *Any local reaction*[7]: 50% *Any systemic reaction*[8]: 46% **Adverse events** *AE* (solicited/spontaneously reported): 73% *SAE*: 1/26	
Skowronski, 2011 [RCT][6] *Infants/ Toddlers (6-23 months)*	Vaxigrip (Sanofi-Pasteur), 15-µg/strain **[2 x 0.5mL dose** (Intramuscular injection)] *A/Brisbane/10/07 (H3N2); A/Brisbane/59/07 (H1N1); and B/Florida/4/06 (Yamagata lineage)*	**Reactogenicity – injection site** *Induration* (NR): 13.7% *Redness* (NR): 22.6% *Swelling* (NR): 15.3% *Tenderness* (NR): 22.6% **Reactogenicity – systemic** *Fever* (>37.5°C): 8.06% *Irritability* (NR): 59.7% *Decreased appetite* (NR): 38.7%	▪ Local reactions generally were less common in infants than toddlers and more common with full doses versus half doses, but none of these differences were significant. ▪ One serious adverse event was reported: a toddler in the half dose group was

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Drowsiness (NR): 39.5% *Sleep disturbance* (NR): 54.8% **Adverse events** *SAE:* NR	hospitalized with pneumonia 28 days after the first vaccination. The event was deemed unlikely related to the vaccine.
	Vaxigrip (Sanofi-Pasteur), 15-µg/strain **[2 x 0.25mL dose** (Intramuscular injection)] *A/Brisbane/10/07 (H3N2); A/Brisbane/59/07 (H1N1); and B/Florida/4/06 (Yamagata lineage)*	**Reactogenicity – injection site** *Induration* (NR): 6.3% *Redness* (NR): 20.3% *Swelling* (NR): 8.6% *Tenderness* (NR): 25.8% **Reactogenicity – systemic** *Fever* (>37.5°C): 11.7% *Irritability* (NR): 60.2% *Decreased appetite* (NR): 43% *Drowsiness* (NR): 41.4% *Sleep disturbance* (NR): 50% **Adverse events** *SAE:* 1/128	▪ All of the rate differences were significantly below the allowed 10% increase in reactogenicity for the full dose ($p< 0.001$ for infant and combined analyses, $p<.005$ for toddlers). ▪ This randomized controlled trial in infants and toddlers shows that compared with 0.25-mL half-dosing, administration of 2 full 0.5-mL doses of trivalent inactivated influenza vaccine can increase antibody response without increasing reactogenicity in previously unimmunized infants aged 6 to 11 months.
Langley, 2012 [RCT][7] *Infants/ Toddlers (6-35 months)*	Fluviral F1 (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (Intramuscularly in the anterolateral part of the thigh (if the participant was less than 12 months) or in the deltoid region of the arm)] *A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (an A/Brisbane/10/2007 [H3N2]–like virus), and B/Florida/4/2006*	**Reactogenicity – injection site** *Pain* (NR): 45/164 *Redness* (NR): 49/164 *Swelling* (NR): 22/164 **Reactogenicity – systemic** *Drowsiness* (NR) – 44/164 *Fever* (NR) – 10/164 *Irritability* (NR) – 62/164 *Loss of appetite* (NR) – 37/164 **Adverse events** *SAE:* 1/164	▪ Fluviral F1 group had 1 case of pneumonia resolved ▪ Fluviral F2 group had 1 case of bronchial hyper-reactivity in resolving stage ▪ The 0.5-mL dose of the study vaccine, when administered to children aged 6–35 months, resulted in a modest but not statistically significant improvement in

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Unsolicited adverse events (NR): 108/164 *Medically attended events* (NR): 52/164	immunogenicity with clinically similar safety and reactogenicity compared with the 0.25-mL dose.
	Fluviral F2 (Sanofi-Pasteur), **15-µg/strain** [1 x 0.5mL dose (Intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm)] *A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (an A/Brisbane/10/2007 [H3N2]–like virus), and B/Florida/4/2006*	**Reactogenicity – injection site** *Pain* (NR): 55/167 *Redness* (NR): 54/167 *Swelling* (NR): 24/167 **Reactogenicity – systemic** *Drowsiness* (NR) – 52/167 *Fever* (NR) – 6/167 *Irritability* (NR) – 69/167 *Loss of appetite* (NR) – 43/167 **Adverse events** *SAE*: 1/167 *Unsolicited adverse events* (NR): 112/167 *Medically attended events* (NR): 40/167	
	Vaxigrip (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (Intramuscularly in the anterolateral part of the thigh (if the participant was less than 12 months) or in the deltoid region of the arm)] A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (an A/Brisbane/10/2007 [H3N2]–like virus), and B/Florida/4/2006	**Reactogenicity – injection site** *Pain* (NR): 17/43 *Redness* (NR): 13/43 *Swelling* (NR): 5/43 **Reactogenicity – systemic** *Drowsiness* (NR) – 11/43 *Fever* (NR) – 2/43 *Irritability* (NR) – 15/43 *Loss of appetite* (NR) – 9/43 **Adverse events** *SAE:* NR/43 *Unsolicited adverse events* (NR): 24/43 *Medically attended events* (NR): 9/43	
Pavia-Ruz, 2013 [RCT][8] *Infants/ Toddlers*	Fluarix (GSK), **15-µg/strain** [1 x 0.5mL dose (intramuscular injection into the right deltoid muscle or anterolateral thigh)]	**Reactogenicity – injection site** *Any injection site reactions*[9]: 514/1086 *Pain:* 406/1086 *Redness*: 249/1086 *Swelling:* 170/1086	▪ The reactogenicity and safety profile of the study vaccine did not appear to be affected by doubling the dose. ▪ One subject in the Flu-15µg

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
(6-35 months)	*A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) and B/Brisbane/3/2007*	**Reactogenicity – systemic** *Any general reactions*[10]: 575/1086 *Drowsiness:* 317/1086 *Fever:* 69/1086 *Irritability:* 387/1086 *Loss of appetite:* 273/1086 **Adverse events** *Any AE*: 729/1086 *SAE*: 29/1086	group had two SAEs, (apnea and cyanosis) which were considered by the investigator to be possibly related to vaccination. The participant was hospitalized and the events resolved on the same day as they occurred.
	Fluarix (GSK), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular injection into the right deltoid muscle or anterolateral thigh)] *A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) and B/Brisbane/3/2007*	**Reactogenicity – injection site** *Any injection site reactions*[9]: 492/1081 *Pain:* 403/1081 *Redness*: 259/1081 *Swelling:* 152/1081 **Reactogenicity – systemic** *Any general reactions*[10]*:* 598/1081 *Drowsiness:* 293/1081 *Fever:* 67/1081 *Irritability:* 386/1081 *Loss of appetite:* 281/1081 **Adverse events** *Any AE*: 724/1081 *SAE*: 35/1081	
	Fluzone (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular injection into the right deltoid muscle or anterolateral thigh)] *A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) and B/Florida/4/2006*	**Reactogenicity – injection site** *Any injection site reactions*[9]*:* 467/1090 *Pain:* 363/1090 *Redness:* 253/1090 *Swelling:* 129/1090 **Reactogenicity – systemic** *Any general reactions*[10]: 592/1090 *Drowsiness:* 298/1090 *Irritability:* 375/1090 *Fever:* 72/1090 *Loss of appetite:* 270/1090	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Adverse events *Any AE:* 722/1090 *SAE:* 31/1090	
Halasa, 2015 [RCT][9] *Infants/ Toddlers (6-35 months)*	Fluzone (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular)] *A/California/7/09 (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/ 60/2008-like virus*	**Reactogenicity** *Redness at injection site*: 8/48 *Fever* (temperature >39°C after the first dose): 7/80	▪ No significant differences between the full-dose or half-dose groups for either the fully primed or naive cohorts for systemic reactions or local reactions when both seasons were combined. ▪ The only significant difference in the 2011–2012 season was that 8 of 48 (16.7%) participants in the half-dose group compared with 32 of 96 (33.3%) in the full-dose group had increased redness at the injection site (P < .05). ▪ No significant differences between the groups in unsolicited AEs, serious adverse events (SAEs), or onset of chronic medical conditions between the dose groups in either the naive or fully primed cohorts, and none of the SAEs were deemed related to the vaccine.
	Fluzone (Sanofi Pasteur), **15-µg/strain** [1 x 0.5 mL dose (intramuscular)] *A/California/7/09 (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/ 60/2008-like virus*	**Reactogenicity** *Redness at injection site*: 32/96 *Fever* (temperature >39°C after the first dose): 19/161	
Phung, 2016 [RCT][10] *Infants/ Toddlers (6-35 months)*	FLUAD (NR), NR [**1 x 0.5mL dose** (Intramuscular injection)] *A/H1N1, A/H3N2, Strain B*	**Reactogenicity** *Any local reaction*[11]: 45/61 *Any systemic reaction*[12]: 36/61 **Adverse events** *SAE* (based on MedDRA v 17.1 definition): 2/61	
	FLUAD (NR), NR [**1 x 0.25 mL dose** (Intramuscular injection)]	**Reactogenicity** *Any local reaction*[11]: 63/75	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
	A/H1N1, A/H3N2, Strain B	*Any systemic reaction*[12]: 42/75 **Adverse events** *SAE* (based on MedDRA v 17.1 definition): 2/75	
	Agrippal S1 (NR), NR [**1 x 0.5mL dose** (Intramuscular injection)] *A/H1N1, A/H3N2, Strain B*	**Reactogenicity** *Any local reaction*[11]: 42/51 *Any systemic reaction*[12]: 24/51 **Adverse events** *SAE* (based on MedDRA v 17.1 definition): 0/51	
	Agrippal S1 (NR), NR [**1 x 0.25mL dose** (Intramuscular injection)] *A/H1N1, A/H3N2, Strain B*	**Reactogenicity** *Any local reaction*[11]: 6/10 *Any systemic reaction*[12]: 5/10 **Adverse events** *SAE* (based on MedDRA v 17.1): 0/10	
Jain, 2017 [RCT][11] *Infants/ Toddlers (6-35 months)*	Flulaval Quadrivalent (GSK), **15-µg/strain** [1 x 0.5mL dose (intramuscular in deltoid region)] *A/California/7/2009 (A/H1N1), A/Texas/50/2012 (A/H3N2), B/Brisbane/60/2008 (B/Victoria), and B/Massachusetts/2/2012 (B/Yamagata)*	**Reactogenicity – injection site (within 7 days)** *Pain*: 44.0% *Redness*: 1.4% *Swelling*: 1.0% **Reactogenicity – systemic (within 7 days)** *Drowsiness:* 40.6% *Fever (>=38.0C):* 7.9% *Irritability/fussiness:* 54.4% *Loss of appetite:* 33.7% **Adverse events** *Any AE*: 45.5% *Vaccine-related AE*: 5.9% *Any SAE*[13]: 1.8% *Febrile seizures*: 0.4% *Medically attended event*[14]: 60.2%	▪ None of the febrile seizures or the SAEs were considered by the investigator to be related to vaccination ▪ Double-dose IIV4 may improve protection against influenza B in some young children and simplifies annual influenza vaccination by allowing the same vaccine dose to be used for all eligible children and adults.
	Fluzone Quadrivalent (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular in deltoid region)]	**Reactogenicity – injection site (within 7 days)** *Pain*: 40.1% *Redness:* 1.4% *Swelling*: 0.4% **Reactogenicity – systemic (within 7 days)**	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
	A/California/7/2009 (A/H1N1), A/Texas/50/2012 (A/H3N2), B/Brisbane/60/2008 (B/Victoria), and B/Massachusetts/2/2012 (B/Yamagata)	*Drowsiness:* 40.9% *Fever (>=38.0C):* 7.5% *Irritability/fussiness:* 50.5% *Loss of appetite:* 33.4% **Adverse events** *Any AE:* 44.1% *Vaccine-related AE:* 5.8% *Any SAE*[13]*:* 1.7% *Febrile seizures*: 0.3% *Medically attended event*[14]: 59.1%	
Ojeda. 2019 [RCT][12] *Infants/ Toddlers and Children (6 months – 17 years)*	Vaxigrip Tetra (Sanofi Pasteur) – **PFS**, 15-µg/strain [1 x 0.5mL dose (intramuscular or deep subcutaneous injection)] *A/Michigan/45/2015 (H1N1)pdm09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, /Brisbane/60/2008-like virus (B/Victoria lineage), and B/Phuket/3073/2013 (B/Yamagata lineage)*	**Reactogenicity, N=142** *Any injection-site reaction* (solicited within 7 days)*:* 26 (6-35mo), 16 (3-8yr), 42 (9-7yr) *Any systemic reaction* (solicited within 7 days): 25 (6-35mo), 15 (3-8yr), 35 (9-7yr) **Adverse events, N=147** *AE* (immediate unsolicited): 1 (9-17 years) *Non-serious AE:* 25 (6-35mo), 9 (3-8yr), 8 (9-7yr) *Vaccine-related non-serious AE*: 1 (9-17 years) *AE leading to study discontinuation*: 0 *SAE*: 0	▪ Solicited reactions were mostly grade 1 (mild) in intensity and resolved within 3 days. ▪ Solicited systemic reactions were reported in more infants aged 6 − 35 months in the MDV group than in the PFS group however, because the 95% CIs were overlapping, this was not thought clinically significant. ▪ None of these unsolicited AEs were considered related to a study vaccine by the investigators. ▪ There were no differences in reactogenicity or safety between the two vaccine formats. These results showed that the MDV format of QIV was as safe and immunogenic as the PFS format in infants, children, and adolescents. These findings support the use of MDV QIV
	Vaxigrip Tetra (Sanofi Pasteur) - **MDV,** 15-µg/strain [1 x 0.5mL dose (intramuscular or deep subcutaneous injection)] *A/Michigan/45/2015 (H1N1)pdm09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, /Brisbane/60/2008-like virus (B/Victoria lineage), and B/Phuket/3073/2013 (B/Yamagata lineage)*	**Reactogenicity, N=139** *Any injection-site reaction*(solicited within 7 days)*:* 27 (6-35mo), 16 (3-8yr), 26 (9-7yr) *Any systemic reaction*(solicited within 7 days): 33 (6-35mo), 13 (3-8yr), 30 (9-7yr) **Adverse events, N=150** *AE* (immediate unsolicited): 0 *Non-serious AE:* 31 (6-35mo), 14 (3-8yr), 5 (9-7yr) *Vaccine-related non-serious AE*: 0 *AE leading to study discontinuation*: 0 *SAE:* 0	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
			as a resource-saving alternative for seasonal influenza vaccination.
Robertson, 2019 [RCT][13] *Infants/ Toddlers (6-35 months)*	Fluzone Quadrivalent (Sanofi Pasteur), **15-µg/strain** [1 x 0.5mL dose (intramuscular single-dose syringes in deltoid of arm)] *A/California/07/2009 X-179A (H1N1), A/Hong Kong/4801/2014 X-263B (H3N2), B/Brisbane/60/2008 (Victoria lineage), B/Phuket/3073/2013 (Yamagata lineage)*	**Reactogenicity** *Any injection-site reaction*[15]: 533/939 *Any systemic reaction*[16]: 561/941 **Adverse events** *Vaccine-related AE* (immediate within 30 mins): 0/992 *Vaccine-related AE* (within 28 days): 30/992 *AE leading to study discontinuation*: 0/992 *SAE*: 5/992	▪ Proportions of participants reporting solicited injection-site reactions, solicited systemic reactions, vaccine-related unsolicited AEs were similar for the full- and half-dose groups ▪ None of the AEs leading to study discontinuation or the SAEs were considered related to vaccination ▪ A single AE of special interest (chronic urticaria first appearing 3 days post-vaccination and continuing for >6 weeks) was considered by the investigator to be related to vaccination ▪ In children 6–35 months of age, a full dose of IIV4 was immunogenic and had a safety profile comparable to that of a half dose with no new safety concerns observed.
	Fluzone Quadrivalent (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular single-dose syringes in deltoid of arm)] *A/California/07/2009 X-179A (H1N1), A/Hong Kong/4801/2014 X-263B (H3N2), B/Brisbane/60/2008 (Victoria lineage), B/Phuket/3073/2013 (Yamagata lineage)*	**Reactogenicity** *Any injection-site reaction*[15]: 480/909 *Any systemic reaction*[16]: 533/909 **Adverse events** *Vaccine-related AE* (unsolicited within 30 mins): 1/949 *Vaccine-related AE* (unsolicited within 28 days): 29/949 *AE leading to study discontinuation*: 3/949 *SAE*: 5/949	

Abbreviations: AE – adverse events, ID – intradermal; ILI – influenza-like illness; IM – intramuscular; MDV – multi-dose vials, n – number of people with condition, N – sample size of treatment arm, NR – not reported, PFS – prefilled syringe, SAE – serious adverse events

[1] Defined as mild (easily tolerated), moderate (interferes with normal behaviour or activities), severe (incapacitating, unable to perform usual activities, may require medical attention)
[2] Present at or near the approximate point of needle entry; small <2.5cm, medium >2.5cm to <5cm, large >5cm
[3] Oral temperature >37.5 C; mild >37.5 to 38 C, moderate >38.1 to 39 C, severe >39.1 C
[4] Grade I reactions defined as “present but easily tolerated” for fatigue, muscle ache, headache, itching or pain at injection site; oral temperature >/=38 and <39 degrees Celsius; some limitation to arm motion due to stiffness or discomfort but easily tolerated; redness or swelling >/= 8cm

[5] Grade II/III reactions defined as “interferes with normal activity” to “severe and incapacitating” for fatigue, muscle ache, headache, itching or pain at injection site; oral temperature >/=39 degrees Celsius; limitation to arm motion due to stiffness or discomfort that interferes with normal activity; redness or swelling > 8cm
[6] Defined as serious adverse events resulting in hospitalization
[7] Solicited local reactions included ecchymosis, erythema, induration, swelling, and tenderness at injection site
[8] Solicited systemic reactions included sleepiness, diarrhea, vomiting, irritability, change in eating habits, shivering, and unusual crying
[9] Included injection site reactions of Grade 1, “minor reaction to touch”, Grade 2, “cries/protests on touch”, and Grade 3, “cries when limb moved/spontaneously painful”
[10] Included systemic reactions of Grade 1, “no effect on normal activity”, Grade 2, “interferes with normal activity”, and Grade 3, “prevents normal activity”
[11] Included injection site ecchymosis, injection sit erythema, injection site induration, injection site swelling, tenderness, injection site pain
[12] Included change in eating habits, sleepiness, unusual crying, irritability, vomiting, diarrhea, chills/shivering, malaise, myalgia, arthralgia, headache, fatigue, fever (>37.3 C)
[13] Defined serious adverse events as any untoward medical occurrence that results in death, is life-threatening, requires/prolongs hospitalization, or results in disability or incapacity during entire study period
[14] Defined as hospitalization, emergency room visit, and/or medical practitioner visit during entire study period
[15] Included tenderness, redness and/or swelling solicited within 7 days
[16] Included fever, vomiting, abnormal crying, drowsiness, loss of appetite, and/or irritability solicited within 7 days

PRISMA ScR checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	Click here to enter text.
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	Click here to enter text.
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	Click here to enter text.
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	Click here to enter text.
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	Click here to enter text.
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	Click here to enter text.
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	Click here to enter text.
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Click here to enter text.
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	Click here to enter text.
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	Click here to enter text.

Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	Click here to enter text.
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	Click here to enter text.
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	Click here to enter text.
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	Click here to enter text.
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	Click here to enter text.
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Click here to enter text.
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	Click here to enter text.
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	Click here to enter text.
DISCUSSION			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	Click here to enter text.
Limitations	20	Discuss the limitations of the scoping review process.	Click here to enter text.
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	
FUNDING			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	Click here to enter text.

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with information sources (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic

reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

BMJ Open

Safety and effectiveness of dose-sparing strategies for intramuscular seasonal influenza vaccine: A rapid scoping review

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2021-050596.R1
Article Type:	Original research
Date Submitted by the Author:	03-Aug-2021
Complete List of Authors:	Lunny, Carole; UBC, DAPT; St Michael's Hospital Li Ka Shing Knowledge Institute, Knowledge Translation Program Antony, Jesmin; St Michael's Hospital Li Ka Shing Knowledge Institute Rios, Patricia; Independent Researcher Williams, Chantal ; Independent Researcher Ramkissoon, Naveeta; St Michael's Hospital Li Ka Shing Knowledge Institute, Knowledge Translation Straus, Sharon; St Michael's Hospital Li Ka Shing Knowledge Institute; University of Toronto, Geriatric Medicine Tricco, Andrea; St Michael's Hospital Li Ka Shing Knowledge Institute, Knowledge Translation Program
Primary Subject Heading:	Immunology (including allergy)
Secondary Subject Heading:	Immunology (including allergy)
Keywords:	VIROLOGY, IMMUNOLOGY, PUBLIC HEALTH

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Safety and effectiveness of dose-sparing strategies for intramuscular seasonal influenza vaccine:

A rapid scoping review

Carole Lunny[1,2*†] Email: carole.lunny@ubc.ca

Jesmin Antony[2*] Email: jesmin.antony@unityhealth.to

Patricia Rios[3] Email: patricia.rios@wchospital.ca

Chantal Williams[3] Email: chantal.williams@uhn.ca

Naveeta Ramkissoon[2] Email: naveeta.ramkissoon@unityhealth.to

Sharon E. Straus[2,4,5] Email: sharon.straus@unityhealth.to

Andrea C. Tricco[2,6] Email: andrea.tricco@unityhealth.to

[1]Cochrane Hypertension Review Group and the Therapeutics Initiative, University of British Columbia, Vancouver, BC

[2]Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada

[3]Independent Researcher

[4]Department of Medicine, University of Toronto, Toronto, Ontario, Canada

[5] Department of Geriatric Medicine, University of Toronto, Toronto, Ontario, Canada

[6] Epidemiology Division, Dalla Lana School of Public Health and Institute for Health, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada

*These authors contributed equally.

†Corresponding Author

Carole Lunny, MPH, PhD, Postdoctoral Fellow, Methodology and Research Synthesis SPOR Evidence Alliance, Unity Health, University of Toronto

24 Word count: 3370

ABSTRACT

Background: The objective of this rapid scoping review was to identify studies of dose-sparing strategies for administration of intramuscular seasonal influenza vaccines in healthy individuals of all ages.

Methods: Comprehensive literature searches were executed in MEDLINE, EMBASE, and the Cochrane library. The grey literature was searched via international clinical trial registries for relevant studies published in English in the last 20 years. We included studies in healthy humans of any age that used any dose-sparing strategy to administer intramuscular seasonal influenza vaccines. Title/abstract and full-text screening were carried out by pairs of reviewers independently. Data extraction was conducted by a single reviewer and verified by a second reviewer. Our outcomes of interest were influenza infections, ICU admission, pneumonia, hospitalizations, adverse events, and mortality. Results were summarized descriptively.

Results: A total of 13 studies with 10,351 participants were included in the review and all studies were randomized control trials (RCTs) conducted between 2006 and 2019. The most common interventions were the trivalent influenza vaccine (n=10), followed by the quadrivalent influenza vaccine (n=4). Nine studies included infants/toddlers 6-36 months old and one of these studies also included children and adolescents. In these nine studies, no clinical effectiveness outcomes were reported. Of the four adult studies (≥ 18 years), two studies reported on effectiveness outcomes.

Conclusions: Due to the low number of studies in healthy adults and the lack of studies assessing confirmed influenza and influenza-like illness, there remains a need for further evaluation.

Keywords:

STRENGTHS AND LIMITATIONS OF THIS STUDY

Strengths:

- This rapid scoping review was conducted within a 6-week timeline and the methods were tailored to provide results to the stakeholders within 4 weeks.
- We did not restrict the search dates and study screening was completed in independently by two reviewers.

Limitations:

- We limited the selection of studies to those published in the English language, and data extraction was conducted by one abstractor and one verifier.
- Twelve dose-sparing RCTs were not included in the review because they did not include vaccine interventions that were deemed of interest to the stakeholders, and/or did not provide sufficient data.

BACKGROUND

The symptoms of novel coronavirus disease (COVID-19) closely mimic those of seasonal influenza vaccine and health officials recommend vaccination against the flu to limit confounding of flu symptoms with COVID-19 symptoms. An anticipated shortage in influenza vaccine supplies was of concern.[1] This anticipated shortage did not happen however, and in the 2019-2020 flu season, influenza vaccination coverage among adults (42%) was similar to the previous season (42%). This question of vaccine shortage remains relevant in Canada and other jurisdictions for future COVID-19 and flue seasons. As a potential solution, health officials were interested in assessing the effectiveness of fractional dosing (e.g., half-doses) of currently available intramuscular influenza vaccines.

Fractional dosing, or dose-sparing, strategies are those where less than the standard dose of hemagglutinin (HA) antigen, and thus less volume of vaccine, is administered, increasing the overall number of influenza vaccine doses available. In Canada, influenza vaccines are currently authorized for intramuscular administration only, apart from the live-attenuated influenza vaccine, which is administered intranasally.[2] Standard dose influenza vaccines contain 15 mcg of HA per strain and are delivered in 0.5 mL volume. Therefore, the total amount of HA in standard dose trivalent vaccines is 45 mcg, and the total amount of HA in standard dose quadrivalent vaccines is 60 mcg.

A scoping review of all the available dose-sparing strategies for intramuscular administration of seasonal influenza vaccines currently approved in Canada for healthy populations had not been systematically conducted. With the resource-constraints for the influenza season due to COVID-19, there was a need to scope the evidence on the safety and effectiveness of dose-sparing strategies for intramuscular administration of seasonal influenza vaccines. The objective of this

rapid scoping review was to identify studies of dose-sparing strategies for administration of intramuscular seasonal influenza vaccines in healthy individuals of all ages. The results of this scoping review were used to inform a systematic review with meta-analysis by National Advisory Committee on Immunization (NACI) on the same topic [3].

METHODS

The Centre for Immunization and Respiratory Infectious Diseases of the Public Health Agency of Canada (PHAC) commissioned a rapid scoping review on the available methods for fractional dosing of seasonal influenza vaccines through the Canadian Institutes of Health Research (CIHR) Drug Safety and Effectiveness Network (DSEN) with a 6-week timeline for preliminary results.

Protocol

The methods for this review were guided by the updated reviewer manual for scoping reviews published by JBI and the World Health Organization's guide to rapid reviews.[4, 5] Results are reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis extension to scoping reviews (PRISMA-ScR).[6] A protocol for this rapid scoping review was disseminated through the Open Science Framework registry (https://osf.io/8mwz2/).

Patient and Public Involvement statement

No patients or the public were involved in this rapid scoping review.

Literature search

Comprehensive literature searches were developed and executed by an experienced librarian in Ovid MEDLINE (**Appendix 1**), EMBASE using the OVID interface (**Appendix 2**), and the Cochrane library between 1946 and May 2020 (**Appendix 3**). The literature search was peer reviewed by a second librarian using the PRESS checklist

(https://www.cadth.ca/resources/finding-evidence/press). The grey (i.e., difficult to locate or unpublished) literature was searched via international clinical trial registries (i.e. clinicaltrials.gov, EU clinical trial register). References of relevant systematic reviews and included studies were also scanned.

Eligibility criteria

The eligibility criteria followed the Population, Intervention, Comparators, Outcome, Study design (PICOS) framework as follows:

- Population: Healthy humans of any age. Immunocompromised populations and animal studies were excluded. Examples of persons with weakened immune systems include those with HIV/AIDS; cancer and transplant patients who are taking certain immunosuppressive drugs; and those with inherited diseases that affect the immune system (e.g., congenital agammaglobulinemia, congenital IgA deficiency)[7].
- Intervention: Any dose-sparing strategy used to administer intramuscular seasonal influenza vaccines (eligible vaccines listed in **Appendix 4**). Eligible strategies included, but were not limited to, administrating less than the standard 15 ug HA antigen using multi-dose vials, half dosing, or pre-formulated products with reduced antigen quantity, or with revised vaccine dose schedules. Any studies examining monovalent pandemic vaccines, specialty/experimental vaccines (e.g., high dose), whole virus vaccines, or other routes of administration (e.g. intranasal, intradermal) were not eligible. Only vaccine products approved for use in Canada or equivalent formulations approved for use in other countries were eligible for inclusion. Concomitant administration with other vaccine products were included only if administered to both the intervention and the comparator groups.
- Comparator: Any of the interventions listed above, no intervention, or placebo.

- Outcomes: Lab-confirmed influenza infection (primary outcome), influenza-like illness or clinical/symptomatic diagnosis of influenza, hospitalization, intensive care unit (ICU) admission, pneumonia, mortality, and adverse events (local/systemic reactogenicity, vascular-related, serious). Reactogenicity represents the physical manifestation of the inflammatory response to vaccination, and can include injection-site pain, redness, swelling or induration at the injection site, as well as systemic symptoms, such as fever, myalgia, or headache.[8]
- Study designs: Randomized controlled trials (RCTs), non-randomised studies (e.g., quasi-RCTs, non-randomized trials, interrupted time series, controlled before after), and observational studies (e.g., cohort, case control) were included. Studies must have had a control or comparator group in order to be eligible for inclusion and as such, cross-sectional, case series, case reports, and qualitative studies were excluded.
- Publication status: We included full text and abstracts if they included data on safety or effectiveness.

Inclusion was also limited to studies written in the English language due to the short timelines for the conduct of this review.

Study selection

A screening form based on the eligibility criteria was prepared and pilot-tested with 30 studies with all members of the review team until sufficient agreement (>75%) was reached prior to both title/abstract (level 1) and full-text (level 2) screening. Subsequent screening at level 1 and level 2 were completed by two reviewers working independently using the Knowledge Translation Program's proprietary screening software (synthesi.SR)[9]. Any discrepancies between reviewers were consistently resolved by a third independent reviewer.

Data extraction

Items for data collection included study characteristics (study design, year of publication, country of conduct, multi-center vs. single site), patient characteristics (mean age, age range, sex, vaccination history), intervention details (type of vaccine, vaccine manufacturer, dose, timing and administration of treatment), comparator details (comparator intervention, dose), and outcome results (influenza infections, ICU admission, pneumonia, hospitalizations, adverse events, mortality) at the longest duration of follow-up.

A standardized form for data extraction was developed and pilot tested by the entire review team using two pre-selected full-text RCTs to ensure understanding of the data items to be extracted, and congruence among reviewers. All included studies were extracted by one reviewer independently and then verified by a second reviewer.

Risk of bias assessment

As this was a scoping review, the risk of bias of studies was not assessed.[4]

Synthesis

The synthesis involved providing a descriptive summary of included studies with summary tables and detailed tables of study results. Study results were organized and tabulated according to patients (children vs adults), interventions, and outcomes and where available information on relevant subgroups.

RESULTS

Literature search

We screened 2,378 titles and abstracts from our database search and an additional 13 citations located through searching the grey literature and scanning references. Of these, 144 potentially relevant full-text articles were screened for eligibility (**Figure 1**). Twelve studies that assessed

dose-sparing strategies were excluded during full-text screening because the vaccine under study was not of interest or unclearly reported. We contacted authors of these 12 unclear studies and received 1 response confirming the vaccine was not of interest (see list of excluded studies in **Appendix 5**). Subsequently, 13 RCTs were included; five trial protocols were found and were denoted as duplicate/companion reports. No non-randomised or observational studies were found that fulfilled the eligibility criteria.

Study characteristics

Table 1 summarizes the characteristics of the 13 RCTs published between 2006 and 2019; and conducted mainly in the US, followed by Mexico, Canada and Finland. The majority of the studies evaluated trivalent vaccines (10/13 [77%]) and most were conducted in the 6-36 month-old pediatric population (9/13 [69%]). Almost all studies reported on reactogenicity and/or other adverse events, but only two studies reported on the effectiveness of our outcomes of interest (i.e., lab-confirmed influenza and influenza-like illness).

Full study and patient characteristic details for each study are reported in **Appendix 6** and treatment and outcome details in **Appendix 7**.

Table 1: Characteristics of included studies (n=13)

Characteristics	**Category**	**Frequency (%)**
Date of publication	2006-2010	4 (30.8)
	2011-2015	5 (38.4)
	2016-2020	4 (30.8)
Multi-center or single site	Multi-centre	8 (61.5)
	Single centre	2 (15.4)
Countries of conduct[a]	USA	8 (61.5)
	Mexico	3 (23.1)
	Canada	2 (15.4)
	Finland	2 (15.4)
	Belgium	1 (7.7)
	Hong Kong	1 (7.7)
	Taiwan	1 (7.7)
	Thailand	1 (7.7)

Populations[a,b]	Infants/Toddlers (6-36 months)	9 (69.2)
	Children (37 months – 17 years)	1 (7.7)
	Adults (18-64 years)	3 (23.1)
	Older adults (≥65)	1 (7.7)
Treatments[a,c]	Trivalent influenza vaccine (TIV)	10 (76.9)
	Quadrivalent influenza vaccine (QIV)	4 (30.8)
Outcomes[a]	Effectiveness	2 (15.4)
	Local and Systemic Reactogenicity	12 (92.3)
	Adverse events	10 (76.9)

[a]Each study can fit into more than one category so the total percentage will not add up to 100%
[b]One study includes both infants/toddlers and children, and another includes both adults and seniors
[c]One study includes both TIV and QIV arms

RCTs in healthy children (<18 years old)

Nine studies included infants/toddlers 6-36 months old and one study also included children and adolescents (**Table 2**). None of these studies reported results on the effectiveness outcomes that were relevant to our review and established *a priori*, however all of them reported on safety outcomes.

199 ***Table 2: Nine RCTs conducted in children (6 months – 17 years)***

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
TRIVALENT AND QUADRIVALENT INFLUENZA VACCINES (TIV/QIV)									
Cioppa, 2011[10]	October 2008 – March 2009 Belgium	NR - TIV, **7.5-µg/strain** [2 x 0.25mL dose]	20.0 months (7.0)	6- <36 months	43.5	NR	25	Local and Systemic reactogenicity Adverse events	Reactogenicity of the 7.5-µg TIV/QIV formulations was slightly lower than for the corresponding 15-µg formulations. The majority of unsolicited AEs were mild or moderate in severity and none of the SAEs was considered to be related to the study vaccine.
		Agrippal - TIV, **15-µg/strain** [2 x 0.5mL dose]	15.0 months (8.8)	6- <36 months	43.5	NR	22		
		NR - QIV, **7.5-µg/strain** [2 x 0.25mL dose]	18.0 months (8.9)	6- <36 months	43.5	NR	25		
		NR - QIV, **15-µg/strain** [2 x 0.5mL dose]	15.2 months (7.8)	6- <36 months	43.5	NR	28		
		Vaxigrip (Sanofi Pasteur), **7.5-µg/strain** [2 x 0.25mL dose]	16.1 months (8.5)	6- <36 months	43.5	NR	26		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
Skowronski, 2011[11]	September 2008 – December 2008 Canada	Vaxigrip (Sanofi-Pasteur), 15-µg/strain **[2 x 0.5mL dose**]	13.2 months (5.1)	6-23 months	53.2	0	124	Local and Systemic reactogenicity Adverse events	Local reactions generally were less common in infants than toddlers and more common with full doses versus half doses, but none of these differences were significant. One serious adverse event was reported: a toddler in the half dose group was hospitalized with pneumonia 28 days after the first vaccination. The event was deemed unlikely related to the vaccine.
		Vaxigrip (Sanofi-Pasteur), 15-µg/strain **[2 x 0.25mL dose]**	12.8 months (5.0)	6-23 months	53.2	0	128		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
									Compared with 0.25-mL half-dosing, administration of 2 full 0.5-mL doses of trivalent inactivated influenza vaccine can increase antibody response without increasing reactogenicity in previously unimmunized infants aged 6 to 11 months.
Langley, 2012[12]	November 2008 – August 2009 Canada	Fluviral F1 (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	18.2 months (9.06)	6-35 months	47.9	42.6	164	Local and Systemic reactogenicity Adverse events	Fluviral F1 group had 1 case of pneumonia resolved. Fluviral F2 group had 1 case of
		Fluviral F2 (Sanofi-Pasteur), **15-µg/strain** [1 x 0.5mL dose]	17.5 months (8.27)	6-35 months	47.9	42.6	167		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
		Vaxigrip (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	17.0 months (8.33)	6-35 months	47.9	42.6	43		bronchial hyper-reactivity in resolving stage. The 0.5-mL dose of the study vaccine, when administered to children aged 6–35 months, resulted in a modest but not statistically significant improvement in immunogenicity with clinically similar safety and reactogenicity compared with the 0.25-mL dose.
Pavia-Ruz, 2013[13]	October 2008-March 2009	Fluarix (GSK), **15-µg/strain** [1 x 0.5mL dose]	21.2 months (8.37)	6-35 months	51	30.1	1018	Local and Systemic reactogenicity	The reactogenicity and safety

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
	Hong Kong, Mexico, Taiwan, Thailand, and the USA	Fluarix (GSK), **7.5-µg/strain** [1 x 0.25 mL dose]	21.2 months (8.03)	6-35 months	51	30.1	1018	Adverse events	profile of the study vaccine did not appear to be affected by doubling the dose. One participant in the Flu-15µg group had two SAEs, (apnea and cyanosis) which were considered by the investigator to be possibly related to vaccination. The subject was hospitalized and the events resolved on the same day as they occurred.
		Fluzone (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	21.1 months (8.20)	6-35 months	51	30.1	1031		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
Halasa, 2015[14]	2010-2012 USA	Fluzone (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	13.5	6-35 months, 12-35 months	52	13.2	80	Local and Systemic reactogenicity	No significant differences between the full-dose or half-dose groups for either the fully primed or naive cohorts for systemic reactions or local reactions when both seasons were combined. The only significant difference in the 2011–2012 season was that 8 of 48 (16.7%) participants in the half-dose group compared with 32 of 96 (33.3%) in the full-dose group had increased
		Fluzone (Sanofi Pasteur), **15-µg/strain** [1 x 0.5 mL dose]	14.5				163		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
									redness at the injection site (P < .05). No significant differences between the groups in AE, SAE, or onset of chronic medical conditions between the dose groups in either the naive or fully primed cohorts, and none of the SAEs were deemed related to the vaccine.
Phung, 2016[15]	September 2010-January 2011 Finland	FLUAD (NR), NR [**1 x 0.5mL dose**]	68.7 months (18)	6-35 months	55.8	85.7	60	Local and Systemic reactogenicity Adverse events	*Trial protocol with no author conclusions.*
		FLUAD (NR), NR [**1 x 0.25 mL dose]**	60.4 months (23.2)	6-35 months	55.8	85.7	75		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
		Agrippal S1 (NR), NR [**1 x 0.5mL dose**]	68 months (17.1)	6-35 months	55.8	85.7	51		
		Agrippal S1 (NR), NR [**1 x 0.25mL dose**]	32.4 months (1.9)	6-35 months	55.8	85.7	11		
Jain, 2017[16]	2014-2015 Influenza Season USA and New Mexico	Flulaval (GSK), **15-µg/strain** [1 x 0.5mL dose]	19.7 months (8.7)	6-35 months	46.9	57.5	1013	Local and Systemic reactogenicity Adverse events	None of the febrile seizures or the SAEs were considered by the investigator to be related to vaccination. Double-dose vaccines may improve protection against influenza B in some young children and simplifies annual influenza vaccination by
		Fluzone (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	19.9 months (8.9)	6-35 months	46.9	57.5	1028		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
									allowing the same vaccine dose to be used for all eligible children and adults.
Ojeda, 2019[17]	December 2017-January 2018 Mexico	Vaxigrip Tetra (Sanofi Pasteur) **PFS 15-µg/strain** [1 x 0.5mL dose]	NR (6 months – 17 years)	6 months – 17 years	46.4	NR	149	Local and Systemic reactogenicity Adverse events	Solicited systemic reactions were reported in more infants aged 6 − 35 months in the MDV group than in the PFS group however this was not clinically significant. AE not considered related to a study vaccine. There were no differences in reactogenicity or safety
		Vaxigrip Tetra (Sanofi Pasteur) **MDV 15-µg/strain** [1 x 0.5mL dose]	NR (6 months – 17 years)	6 months – 17 years	46.4	NR	153		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
									between the two vaccine formats. These results showed that the MDV format of QIV was as safe and immunogenic as the PFS format in infants, children, and adolescents. These findings support the use of MDV QIV as a resource-saving alternative for seasonal influenza vaccination.
Robertson, 2019[18]	September 2016 – March 2017	Fluzone (Sanofi Pasteur) **15-µg/strain** [1x0.5mL dose]	20.5 months (8.55)	6-35 months	49.7	47.25	992	Local and Systemic reactogenicity	No significant differences between full- and half-dose

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcomes	Author reported conclusions
	USA	Fluzone (Sanofi Pasteur) **7.5-µg/strain** [1x0.25 dose]	20.4 months (8.75)	6-35 months	49.7	47.25	949	Adverse events	groups. AE leading to study discontinuation/ SAE not considered vaccine-related. A full dose vaccine was immunogenic and had a safety profile comparable to that of a half dose, with no new safety concerns observed.

Abbreviations: AE – adverse events; GMR - geometric mean ratio; GMFR – geometric mean fold rise; GMT - geometric mean antibody titer; HA - hemagglutinin; HAI - hemagglutination inhibition; ID – intradermal; IM – intramuscular; ITT – intent-to-treat; MDV – multi-dose vials, n – number of people with condition, N – sample size of treatment arm, NR – not reported, PFS – prefilled dose, SAEs – serious adverse events

Safety outcomes

Trivalent influenza vaccines

Six of the included RCTs assessed trivalent influenza vaccines (TIV) in young children (6-36 months) and reported on local and systemic reactogenicity outcomes and other adverse events.[10-14, 19] Two RCTs compared the administration of full (0.5mL) and half (0.25mL) doses of the same standard 15µg/strain vaccine.[11, 19] The first RCT compared two full versus two half doses of TIV in previously unimmunized infants (6-11 months) and toddlers (12-23 months) using Vaxigrip (15µg/strain).[11] The study found that in the infants group, two full 0.5-mL doses of vaccine did not increase reactogenicity. Local reactions were less common in infants than toddlers and more common with full doses versus half doses, but the differences were not statistically significant. An identified clinical trial registry compared a single intramuscular injection of 0.5mL to 0.25mL of FLUAD or Agrippal and showed comparable numbers of children with reactogenicity outcomes and other adverse events across the groups, but no significance levels or conclusions were provided by the investigators upon contact.[19] The objective of three of the included RCTs was to examine the impact of administering the full adult dose of 15µg/strain vaccines compared with the usual children's dose of 7.5µg/strain in infants and toddlers.[12-14] A multicenter RCT was conducted in Canada assessing the safety of full-dose Fluviral TIV (15µg/strain) compared with the half-dose (7.5µg/strain) and an active comparator Vaxigrip (7.5µg/strain).[12] Compared with the half-dose, the full-dose vaccine resulted in clinically similar reactogenicity and safety. A similar three-arm RCT to assess the use of Fluarix at two different dose levels (7.5µg/strain and 15µg/strain) compared to an established control vaccine Fluzone (7.5µg/strain) also found the reactogenicity and safety profile of Fluarix did not appear to be affected by doubling the dose, but one participant in the 15µg group had two

serious adverse events (apnea and cyanosis) that were considered by the investigator to be possibly related to vaccination.[13] A third multicenter RCT compared the 15 µg/strain formulation to the 7.5µg/strain formulation of Fluzone (Sanofi Pasteur) administered to young children across multiple influenza seasons.[14] This study also found no statistically significant differences between the full-dose or half-dose groups for systemic reactions, local reactions or adverse events when both seasons were combined; however, in the 2011–2012 season, 8 of 48 (16.7%) participants in the half-dose group compared with 32 of 96 (33.3%) in the full-dose group had increased redness at the injection site ($P < .05$).

Cioppa et al. (2009) was the only trial that compared the safety and tolerability of both TIV and QIV vaccine formulations.[10] The vaccine arms of interest were a QIV 15-µg/strain, TIV 15-µg/strain, QIV 7.5-µg/strain, TIV 7.5-µg/strain, and a control Vaxigrip TIV 7.5-µg/strain vaccine. Reactogenicity of the 7.5-µg TIV/QIV formulations was slightly lower than for the corresponding 15-µg formulations, but there was no difference in reactogenicity between TIV and QIV vaccines.

Quadrivalent influenza vaccines

Four of the included RCTs evaluated quadrivalent influenza vaccines (QIV) in children.[10, 16-18] All of the studies reported reactogenicity outcomes and other adverse events. The Cioppa et al. (2009) RCT reported both TIV and QIV vaccines and the results are reported above.[10] Two studies compared full-dose QIV to pediatric 7.5µg/strain Fluzone. In the first RCT, full dose Fluzone had a similar safety profile to half-dose Fluzone with a single adverse event being attributed to the study vaccine.[18] Similarly, the second study found that full-dose Flulaval may improve protection against influenza in some young children when compared to low-dose Fluzone, and in this RCT, none of the adverse events were considered to be study-related as

reported by the investigator.[16] The final trial evaluated Vaxigrip Tetra (15µg/strain) administered to children and adolescents in two different formats.[17] Vaxigrip administered as a single dose using a pre-filled syringe (PFS) was compared to a 10-dose multi-dose vial (MDV). Systemic reactions were reported in more infants aged 6 − 35 months in the MDV group than in the PFS group; however this difference was not clinically significant. The authors concluded that there was no difference in reactogenicity or safety between the two vaccine formats in infants, children, and adolescents.

RCTs in healthy adults (≥18 years old)

One RCT included healthy adults over 18 years, two studies included healthy adults from 18-45 and 18-65 years old, and one study included older healthy adults (≥ 65 years) (**Table 3**). Two studies reported on effectiveness outcomes and three on reactogenicity and other adverse events. All four RCTs evaluated Fluzone QIV.

261 ***Table 3: Four RCTs conducted in adults (≥18 years old)***

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Relevant Outcomes	Author reported conclusions
QUADRIVALENT INFLUENZA VACCINES (QIV)									
Kramer, 2006 [20]	October 2004 – November 2004 USA	Fluzone (Aventis Pasteur), **15-µg/strain** [1 x 0.5mL dose]	NR (>18 years)	>18 years	NR	NR	222	Lab-confirmed influenza Influenza-like illness Adverse events	There was no significant difference between the full-dose and half-dose groups in the diagnosis of influenza or in the proportion of participants self-reporting four or more symptoms consistent with influenza-like illness. No adverse events were noted by participants from either group or reported to the IRB during the course of the study
		Fluzone (Aventis Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	NR (>18 years)	>18 years	NR	NR	222		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Relevant Outcomes	Author reported conclusions
Engler, 2008 [21]	November 2004 – December 2004 USA	Fluzone (Aventis Pasteur), **15-µg/strain** [1 x 0.5mL dose]	NR (18 – 64 years)	18-64 years	43.4	0	554	Influenza-like illness Hospital/ER visits Local and Systemic reactogenicity Adverse events	The relative risk of medical visits and hospitalizations for influenza-like illnesses were similar in the half- and full-dose group regardless of age, and there was no evidence of ILI symptom differences by sex or dose during the 21 days after immunizations. Although injection site pain was greater for full- vs half-dose (19.9% vs 14.4%; p=.01), when analyzed for clinically significant pain levels significant
		Fluzone (Aventis Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	NR (18 – 64 years)	18-64 years	43.4	0	556		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Relevant Outcomes	Author reported conclusions
									dose-dependent pain differences were not identified. Joint and/or muscle pain were significantly different (p=.02 and p=.03, respectively) by dose. No other adverse event differed significantly by dose.
Belshe, 2007 [22]	NR USA	Fluzone (Sanofi-Pasteur), **15-µg/strain** [1 x 0.5mL dose]	31.5 years (9.6)	18-49 years	71.2	0	31	Local and Systemic reactogenicity	Intradermal (ID) vaccine induced significantly more local inflammatory response than Intramuscular (IM) vaccine but this did not translate into an
		Fluzone (Sanofi-Pasteur), **9-µg/strain** [1 x 0.3mL dose]	31.2 years (9.4)	18-49 years	71.2	0	32		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Relevant Outcomes	Author reported conclusions
		Fluzone (Sanofi-Pasteur), **6-µg/strain** [1 x 0.2mL dose]	30.1 years (10.3)	18-49 years	71.2	0	31		increased immune response for ID vaccines compared to IM (primary comparison of this study was ID vs IM doses)
		Fluzone (Sanofi-Pasteur), **3-µg/strain** [1 x 0.1mL dose]	31.9 years (10.3)	18-49 years	71.2	0	31		
Chi, 2010[23]	August 2007-2008 USA	Fluzone (Sanofi Pasteur), **15-µg/strain** [1 x 0.5mL dose]	75.6 years (6.8)	>65 years	17.8	94.6	65	Local and Systemic reactogenicity Adverse events	The two SAEs were acute coronary syndrome and appendicitis and neither were judged to be related to influenza vaccination
		Fluzone (Sanofi Pasteur), **9-µg/strain** [1 x 0.3mL dose]	75.2 years (7.7)	>65 years	17.8	94.6	64		

Abbreviations: AE – adverse events, GMT - geometric mean antibody titer; HA - hemagglutinin; ID – intradermal; ILI – influenza-like illness; IM – intramuscular; MDV – multi-dose vials, n – number of people with condition, N – sample size of treatment arm, NR – not reported, PFS – prefilled syringe, SAE – serious adverse events

Effectiveness outcomes

Two of the included RCTs that examined the same vaccine (Fluzone manufactured by Aventis Pasteur) in healthy adult populations reported effectiveness outcomes including lab-confirmed influenza infections, influenza like illness, and/or hospitalizations or emergency room visits after vaccination.[20, 21] The RCT by Kramer et al. (2006) found that 3.6% of participants receiving a 15-µg/strain dose of vaccine reported influenza like illness compared to 6.8% of participants that received a 7.5-µg/strain dose.[20] However, only one participant in the RCT that received the 15-µg/strain dose was confirmed via laboratory analysis to have influenza. The authors concluded that half-dose and full-dose vaccinations appear to be similarly effective based on the low rate of influenza infections and similar symptom surveys between both groups but acknowledge that further studies examining immunogenicity are needed to confirm.

A similar RCT by Engler et al. (2008) that compared a 15-µg/strain dose of Fluzone vaccine to a 7.5-µg/strain dose found equal proportions of participants reporting influenza like illness (9.7% vs 9.9%) and hospitalizations or emergency room visits (0.3% v 0.2%).[21] The authors found the relative risk of medical visits or hospitalizations between both groups was the same even when adjusting for age and that age, sex, nor dose had an influence on the severity of influenza like illness symptoms.

Safety outcomes

Three of the included studies in adult populations reported adverse events that occurred during the trial while one RCT indicated that no adverse events were recorded for the duration of their trial.[20-23] All three studies reporting adverse events compared different doses of Fluzone vaccine including 3-µg, 6-µg, 7.5-µg, 9-µg, and 15-µg per strain doses.

Two of the studies were carried out in healthy adult populations and one RCT was conducted in older healthy adults (>60 years of age).[21-23] One RCT found that joint or muscle pain following vaccination was statistically significantly higher in the full dose (15-µg) group compared to the half-dose (7.5-µg) group and that while injection site pain initially appeared to be statistically significantly higher in the full dose group, when adjusted to include only clinically significant pain levels (>3 out of 5 on a visual analogue scale) the difference was no longer statistically significant.[21] The RCT found no differences in occurrence or severity of any other adverse effects. Similarly, one RCT comparing four different doses of Fluzone (3-µg, 6-µg, 9-µg, and 15-µg per strain) did not report any differences between the IM vaccination groups.[22] Finally, the RCT in older adults also found no difference in the occurrence or severity of adverse events in the low dose (9-µg) versus high dose (15-µg) group and found no serious adverse events that were considered related to the vaccine.[23]

DISCUSSION

PHAC commissioned this rapid scoping review to identify the evidence for efficacy and safety of fractional influenza vaccine dosing for intramuscular administration of seasonal influenza vaccines in healthy individuals of all ages that have been evaluated in human trials. Thirteen RCTs published between 2006 and 2019 comparing standard/full-dose and half/low-dose vaccines were included in this scoping review after a comprehensive search of three electronic databases, trial registries and references of relevant systematic reviews. The majority of the included RCTs were conducted in children and evaluated trivalent influenza vaccines (TIV). In young, healthy children, there were no effectiveness outcomes of interest reported. However, local reactogenicity, systemic reactogenicity and adverse events were comparable across the full-dose and half-dose TIV and QIV vaccine arms. In addition, the authors of one RCT in children

and adolescents that compared full-dose QIV using pre-filled syringes (PFS) versus multi-dose vials (MDV) also found no statistically significant differences in safety outcomes between administration formats. In healthy adults (including older adults), half-dose QIV was considered equally effective as high-dose in the two RCTs that assessed clinical effectiveness. Safety profiles were similar across groups in all 4 RCTs.

A full systematic review with meta-analysis based on the studies and results of this scoping review was conducted by the NACI and the report was published in January of 2021.[3] The report found that there is some, but still insufficient, evidence that fractional doses of influenza vaccine provided via the intramuscular route are effective and immunogenic in healthy individuals. NACI concludes that since many of those at high risk of influenza (e.g., adults 65 years of age and older, individuals with specific underlying chronic health conditions) may have a lower immune response to influenza vaccination already (due to immunosenescence in older adults or a condition that alters immune function), it is important to ensure that those at high risk continue to receive the full dose of influenza vaccine.

Strengths and limitations

A strength of this rapid scoping review was that it was conducted within a 6-week timeline and the methods were tailored to provide results to the stakeholders within 4 weeks. We also did not restrict the search dates and study screening was completed independently by two reviewers. We developed a comprehensive search using three major databases, and searched the grey literature. We engaged with the NACI stakeholder group, who provided input on the PICO criteria, and funded this rapid scoping review.

We were limited by the lack of studies providing objective outcome data. Only one RCT by Kramer et al. reported the objective outcome “lab confirmed influenza”, and the other RCT by

Engler only reported the outcome "influenza like illness" [20, 21]. Since a 2014 review found that less than 25% of cases diagnosed by physicians as influenza like illness were later laboratory proven influenza cases [24], we are lacking RCTs examining fractional dosing of IM influenza immunization. Further, twelve dose-sparing RCTs were not included because they did not provide sufficient data, and did not include vaccines that were deemed of interest to the stakeholders. Another limitation was that only studies published in the English language were included, and data extraction was conducted by one abstractor and one verifier. Since this was a scoping review, we did not appraise the methodological quality of the included studies.[25]

Future research

Dose-sparing approaches such as intradermal (ID) immunisation vaccination exhibits similar, or even enhanced, immunogenicity, when using a fractional dose only, as compared to intramuscular or subcutaneous immunisation, and should be explored in future scoping reviews.[26]

CONCLUSIONS

In our scoping review, we found 13 RCTs on the efficacy and safety of fractional doses of influenza vaccine provided via the intramuscular route to healthy adults and children. These studies were used to inform a systematic review with meta-analysis which were commissioned by the PHAC. We found that due to the low number of studies in healthy adults and the lack of studies assessing confirmed influenza and influenza-like illness, there remains a need for further evaluation of the clinical effectiveness of IM dose-sparing strategies using vaccines currently available in this population.

LIST OF ABBREVIATIONS

PHAC – Public Health Agency of Canada

CIHR – Canadian Institutes of Health Research

DSEN – Drug Safety and Effectiveness Network

MAGIC – Methods and Application Group in Indirect Comparisons

PRISMA-ScR – Preferred Reporting Items for Systematic Reviews and Meta-analysis extension to scoping reviews

ICU – Intensive Care Unit

RCT – Randomized controlled trials

NRCTs – non-randomized controlled trials

TIV – Trivalent Influenza Vaccine

AE – Adverse Events

SAE – Serious adverse events

QIV – Quadrivalent Influenza Vaccine

PFS – Pre-filled syringe

MDV – Multi-dose vial

DECLARATIONS

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

The dataset(s) supporting the conclusions of this article is(are) included within the article (and its additional file(s)).

Competing interests

The authors have no competing interests to declare.

Funding

This work was supported through the Drug Safety and Effectiveness Network funded by the Canadian Institutes of Health Research, the funders had no involvement in the design, conduct, or publication of this study. SES is funded by a Tier 1 Canada Research Chair in Knowledge Translation and the Mary Trimmer Chair in Geriatric Medicine; ACT is funded by a Tier 2 Canada Research Chair in Knowledge Synthesis.

Authors' contributions

CL wrote and revised the final manuscript. JA and PR screened citations and full-text articles, abstracted and verified data, interpreted results and wrote the first draft manuscript. CW and NR screened citations and full-text articles, abstracted data, and reviewed the manuscript. SES and ACT developed the protocol, obtained funding, interpreted results, and edited the manuscript.

Acknowledgements

The authors would like to thank Jessie McGowan for her assistance in developing literature searches, Tamara Radar for PRESS of literature search, Alissa Epworth for her assistance executing searches and retrieving articles, and Navjot Mann for her assistance in contacting author's and formatting this manuscript.

Additional files

File Format: Microsoft Word (.docx)

Title of Data: Additional File 1 (Appendices 1-7)

Description of Data: The appendices include the following additional information:

Appendix 1 – MEDLINE search strategy

Appendix 2 – EMBASE search strategy

Appendix 3 – Cochrane search strategy

Appendix 4 – List of eligible vaccines

Appendix 5 – Excluded dose-sparing studies

Appendix 6 – Study and patient data

Appendix 7 – Treatment and outcome data

FIGURE LEGEND

Figure 1. Flow chart of studies included in the review

Study flow diagram.

REFERENCES

1. PHAC. Seasonal Influenza Vaccination Coverage in Canada, 2019-2020. 2020.

2. PHAC. Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2019–2020. 2019.

3. PHAC. Recommendations on fractional influenza vaccine dosing. 2021. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-fractional-influenza-vaccine-dosing.html

4. Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. *JBI Evid Synth*. 2020;18(10):2119-26.

5. World Health Organization AfHPaSR. Rapid reviews to strengthen health policy and systems: a practical guide 2017. Available from: https://www.who.int/alliance-hpsr/resources/publications/rapid-review-guide/en/.

6. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018;169(7):467-73.

7. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. *Clin Infect Dis*. 2013;58(3):e44-e100.

8. Hervé C, Laupèze B, Del Giudice G, et al. The how's and what's of vaccine reactogenicity. *npj Vaccines*. 2019;4(1):39.

9. Synthesi.SR. Toronto, Canada: Knowledge Translation Program, St. Michael's Hospital; 2012.

10. Della Cioppa G, Vesikari T, Sokal E, et al. Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: a dose-and schedule-finding study. *Vaccine*. 2011;29(47):8696-704.

11. Skowronski DM, Hottes TS, Chong M, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. *Pediatrics*. 2011;128(2):e276-89.

12. Langley JM, Vanderkooi OG, Garfield HA, et al. Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6–35 months: a randomized, controlled trial. *J Pediatric Infect Dis Soc*. 2012;1(1):55-63.

13. Pavia-Ruz N, Angel Rodriguez Weber M, Lau Y-L, et al. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. *Hum Vaccin Immunother*. 2013;9(9):1978-88.

14. Halasa NB, Gerber MA, Berry AA, et al. Safety and immunogenicity of full-dose trivalent inactivated influenza vaccine (TIV) compared with half-dose TIV administered to children 6 through 35 months of age. *J Pediatric Infect Dis Soc*. 2015;4(3):214-24.

15. Clinical Trial Results: A Phase IIIB, observer-blind, randomized, parallel groups, extension study to evaluate the immunogenicity and safety following a single intramuscular dose of FLUAD or Agrippal S1 influenza vaccines in healthy children previously vaccinated in the V70P5 study. [Internet]. 2016 [cited July 6, 2020]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021644-18/results.

16. Jain VK, Domachowske JB, Wang L, et al. Time to change dosing of inactivated quadrivalent influenza vaccine in young children: evidence from a phase III, randomized, controlled trial. *J Pediatric Infect Dis Soc*. 2017;6(1):9-19.

17. Ojeda J, Arredondo JL, Salcedo P, et al. Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial. *Hum Vaccin Immunother*. 2019:1-5.

18. Robertson CA, Mercer M, Selmani A, et al. Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial. *Pediatr Infect Dis J*. 2019;38(3):323-8.

19. A Phase IIIB, observer-blind, randomized, parallel groups, extension study to evaluate the immunogenicity and safety following a single intramuscular dose of FLUAD or Agrippal S1 influenza vaccines in healthy children previously vaccinated in the V70P5 study. [Internet]. 2015 [cited July 14, 2020]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021644-18/results.

20. Kramer JS, Durham C, Schroeder T, et al. Effectiveness of half-dose versus full-dose influenza vaccine in health care workers. *Am J Health Syst Pharm*. 2006;63(21):2111-5.

21. Engler RJ, Nelson MR, Klote MM, et al. Half-vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. *Arch Intern Med*. 2008;168(22):2405-14.

22. Belshe RB, Newman FK, Wilkins K, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. *Vaccine*. 2007;25(37-38):6755-63.

23. Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. *Clin Infect Dis*. 2010;50(10):1331-8.

24. Thomas RE. Is influenza-like illness a useful concept and an appropriate test of influenza vaccine effectiveness? *Vaccine*. 2014;32(19):2143-9.

25. Peters MD, Godfrey C, McInerney P, et al. Chapter 11: scoping reviews (2020 version). *JBI manual for evidence synthesis, JBI*. 2020;2020.

26. Schnyder JL, De Pijper CA, Garcia Garrido HM, et al. Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis. *Travel Med Infect Dis*. 2020;37:101868.



PRISMA ScR checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	4
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	4
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	4
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	5-6
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	5
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Appendix 1-3
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	6
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	6

Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	N/A
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	6
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	6
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	7, Appendix 6-7
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	N/A
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	8-25
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	25
DISCUSSION			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	25-27
Limitations	20	Discuss the limitations of the scoping review process.	26
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	27
FUNDING			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	28

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with information sources (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

APPENDIX 1 – MEDLINE search strategy

Database: Ovid MEDLINE(R) ALL <1946 to May 29, 2020>

Search Strategy:

---

1 influenza, human/ or exp influenza a virus/ or exp influenzavirus b/ or influenzavirus c/
2 (flu or flue or influenza* or grippe).tw,kf.
3 1 or 2
4 exp Vaccines/ or Immunization/
5 (vaccin* or immuni* or inocula* or shot or jab).tw,kf.
6 4 or 5
7 3 and 6
8 influenza vaccines/ or Adjuvants, Immunologic/
9 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).tw,kf.
10 7 or 8 or 9
11 Injections, Intramuscular/
12 (intramuscular or intra-muscular).tw,kf.
13 or/11-12
14 10 and 13
15 limit 14 to yr=2000-current
16 animals/ not humans/
17 15 not 16
18 ad.fs.
19 11 or 12 or 18
20 10 and 19
21 exp dose-response relationship, immunologic/
22 dose-Response Relationship, Drug/
23 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).tw,kf.
24 ((reduc* or lower or less) adj2 (quantity or strength or standard)).tw,kf.
25 ((dos* adj3 change) or (half adj3 dos*)).tw,kf.
26 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).tw,kf.
27 or/21-26
28 20 and 27
29 animals/ not humans/
30 28 not 29
31 limit 30 to yr=2000-current
32 17 or 31

APPENDIX 2 – EMBASE search strategy

Database: Ovid MEDLINE(R) Embase <2000 to June 11, 2020>

Search Strategy:

---

1 influenza, human/ or exp influenza a virus/ or exp influenzavirus b/ or influenzavirus c/
2 (flu or flue or influenza* or grippe).tw,kf.
3 1 or 2
4 exp Vaccines/ or Immunization/
5 (vaccin* or immuni* or inocula* or shot or jab).tw,kf.
6 4 or 5
7 3 and 6
8 influenza vaccines/ or Adjuvants, Immunologic/
9 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).tw,kf.
10 7 or 8 or 9
11 Injections, Intramuscular/
12 (intramuscular or intra-muscular).tw,kf.
13 or/11-12
14 10 and 13
15 limit 14 to yr=2009-current
16 animals/ not humans/
17 15 not 16
18 ad.fs.
19 11 or 12 or 18
20 10 and 19
21 exp dose-response relationship, immunologic/
22 dose-Response Relationship, Drug/
23 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).tw,kf.
24 ((reduc* or lower or less) adj2 (quantity or strength or standard)).tw,kf.
25 ((dos* adj3 change) or (half adj3 dos*)).tw,kf.
26 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).tw,kf.
27 or/21-26
28 20 and 27
29 animals/ not humans/
30 28 not 29
31 limit 30 to yr=2009-current
32 17 or 31
33 32 use ppez
34 exp Influenza virus/ or exp influenza/
35 (flu or flue or influenza* or grippe).tw.
36 34 or 35
37 exp vaccine/
38 exp immunization/
39 influenza vaccination/ or vaccination/
40 (vaccin* or immuni* or inocula* or shot or jab).tw.
41 or/37-40
42 36 and 41
43 influenza vaccination/

44 immunological adjuvant/
45 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).tw.
46 or/42-45
47 intramuscular drug administration/
48 (intramuscular or intra-muscular).tw.
49 47 or 48
50 46 and 49
51 limit 50 to yr="2009 -Current"
52 animals/ not humans/
53 51 not 52
54 ad.fs.
55 49 or 54
56 46 and 55
57 dose response/ or drug response/
58 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).tw.
59 ((reduc* or lower or less) adj2 (quantity or strength or standard)).tw.
60 ((dos* adj3 change) or (half adj3 dos*)).tw.
61 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).tw.
62 or/57-61
63 56 and 62
64 animals/ not humans/
65 63 not 64
66 limit 65 to yr="2009 -Current"
67 53 or 66
68 67 use emczd
69 33 or 68
70 remove duplicates from 69

APPENDIX 3 – Cochrane search strategy

Database: Database: EBM Reviews - Cochrane Database of Systematic Reviews <2005 to June 03, 2020>, EBM Reviews - ACP Journal Club <1991 to May 2020>, EBM Reviews - Database of Abstracts of Reviews of Effects <1st Quarter 2016>, EBM Reviews - Cochrane Clinical Answers <May 2020>, EBM Reviews - Cochrane Central Register of Controlled Trials <May 2020>, EBM Reviews - Cochrane Methodology Register <3rd Quarter 2012>, EBM Reviews - Health Technology Assessment <4th Quarter 2016>, EBM Reviews - NHS Economic Evaluation Database <1st Quarter 2016>
Search Strategy:
----

1 (influenza, human or influenza a virus or influenzavirus b or influenzavirus c).kw.
2 (flu or flue or influenza* or grippe).ti,ab.
3 1 or 2
4 (Vaccines or Immunization).kw.
5 (vaccin* or immuni* or inocula* or shot or jab).ti,ab.
6 4 or 5
7 3 and 6
8 (influenza vaccines or Adjuvants, Immunologic).kw.
9 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).ti,ab.
10 7 or 8 or 9
11 Injections, Intramuscular.kw.
12 (intramuscular or intra-muscular).ti,ab.
13 11 or 12
14 10 and 13
15 dose-response relationship, immunologic.kw.
16 dose-Response Relationship, Drug.kw.
17 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).ti,ab.
18 ((reduc* or lower or less) adj2 (quantity or strength or standard)).ti,ab.
19 ((dos* adj3 change) or (half adj3 dos*)).ti,ab.
20 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).ti,ab.
21 or/15-20
22 10 and 21
23 14 or 22
24 limit 23 to yr="2009 -Current" [Limit not valid in DARE; records were retained]

Database: EBM Reviews - Cochrane Database of Systematic Reviews <2005 to June 03, 2020>, EBM Reviews - ACP Journal Club <1991 to May 2020>, EBM Reviews - Database of Abstracts of Reviews of Effects <1st Quarter 2016>, EBM Reviews - Cochrane Clinical Answers <May 2020>, EBM Reviews - Cochrane Central Register of Controlled Trials <May 2020>, EBM Reviews -

Cochrane Methodology Register <3rd Quarter 2012>, EBM Reviews - Health Technology Assessment <4th Quarter 2016>, EBM Reviews - NHS Economic Evaluation Database <1st Quarter 2016>
Search Strategy:

---

1 (influenza, human or influenza a virus or influenzavirus b or influenzavirus c).kw.
2 (flu or flue or influenza* or grippe).ti,ab.
3 1 or 2
4 (Vaccines or Immunization).kw.
5 (vaccin* or immuni* or inocula* or shot or jab).ti,ab.
6 4 or 5
7 3 and 6
8 (influenza vaccines or Adjuvants, Immunologic).kw.
9 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).ti,ab.
10 7 or 8 or 9
11 Injections, Intramuscular.kw.
12 (intramuscular or intra-muscular).ti,ab.
13 11 or 12
14 10 and 13
15 dose-response relationship, immunologic.kw.
16 dose-Response Relationship, Drug.kw.
17 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).ti,ab.
18 ((reduc* or lower or less) adj2 (quantity or strength or standard)).ti,ab.
19 ((dos* adj3 change) or (half adj3 dos*)).ti,ab.
20 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).ti,ab.
21 or/15-20
22 10 and 21
23 14 or 22
24 limit 23 to yr="2000 - 2008" [Limit not valid in DARE; records were retained]
25 from 24 keep 1-173

APPENDIX 4 – List of eligible vaccines

Product name (manufacturer)	Vaccine Characteristic				
	Vaccine type	Route of administration	Authorized ages for use	Antigen content for each vaccine strain	Formats available
Flulaval Tetra (GSK)	IIV4-SD (split virus)	IM	6 months and older	15 µg HA /0.5 mL dose	5 mL multi-dose vial Single dose pre-filled syringe
Fluzone Quadrivalent (Sanofi Pasteur)	IIV4-SD (split virus)	IM	6 months and older	15 µg HA /0.5 mL dose	5 mL multi-dose vial Single dose vial Single dose pre-filled syringe without attached needle
Afluria Tetra (Seqirus)	IIV4-SD (split virus)	IM	5 years and older	15 µg HA /0.5 mL dose	Up to expiry date indicate on vial label
Influvac Tetra (BGP Pharma ULC, operating as Mylan)	IIV4-SD (subunit)	IM or deep subcutaneous injection	3 years and older	15 µg HA /0.5 mL dose	Single dose pre-filled syringe with or without a needle
VaxigripTetra	IIV4	IM	6 months and older	Pediatric: 7.5 µg HA /0.25 mL dose Adult: 15 µg HA /0.5 mL dose	0.5 mL pre-filled syringe
Fluarix Tetra/ Influsplit Tetra (GSK)	IIV4	IM	6 months and older	15 µg HA /0.5 mL dose	0.5 mL pre-filled syringe
Agriflu (Seqirus)	IIV3-SD (subunit)	IM	6 months and older	15 µg HA /0.5 mL dose	5 mL multi-dose vial Single dose pre-filled syringe without attached needle
Fluad Pediatric and Fluad (Seqirus)	IIV3-Adj (subunit)	IM	Pediatric: 6-23 months Adult: 65 years and older	Pediatric: 7.5 µg HA /0.25 mL dose Adult: 15 µg HA /0.5 mL dose	Single dose pre-filled syringe without a needle
Fluviral (GSK)	IIV3-SD (split virus)	IM	6 months and older	15 µg HA /0.5 mL dose	5 mL multi-dose vial
Fluzone TIV (Sanofi Pasteur)	IIV3-HD (split virus)	IM	65 years and older	Adult: 15 µg HA /0.5 mL dose	0.5 mL pre-filled syringe
Vaxigrip TIV	IIV3-SD	IM	6 months and older	Pediatric: 7.5 µg HA /0.25 mL dose Adult: 15 µg HA /0.5 mL dose	0.5 mL pre-filled syringe

Note: list of vaccines included in the review is based on feedback from PHAC and the 2020-2021 seasonal vaccine availability in Canada found here: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2020-2021.html#appA

APPENDIX 5 – Excluded dose-sparing studies

	Reference	Reason for exclusion
1	Euctr, H. U. A Randomized, Double-blind, Multi-Center Study to Evaluate Safety and Immunogenicity of One Dose of Four FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccines Containing 3.5[micro]gHA, 6[micro]gHA, 9[micro]gHA or 1. 2011. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=EUCTR2011	exclude - dose-sparing but vaccine not of interest
2	Vajo Z, Tamas F, Jankovics I. A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial. *Clin Vaccine Immunol*. 2012;19(3):313-318. doi:10.1128/CVI.05619-11	exclude - dose-sparing but vaccine not of interest
3	Treanor J, Keitel W, Belshe R, et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002;20(7-8):1099-1105. doi:10.1016/s0264-410x(01)00440-6	exclude - dose-sparing but vaccine not of interest
4	Euctr. A Randomized, Active Controlled, Double-blind, Multi-Centre Study to Evaluate Safety and Immunogenicity of One Dose of FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccine Containing 6µgHA of Seasonal A/H1N1, A/H3N2 and B Influenza Antigens in Non-elderly Adult and Elderly Subjects. 2011. Available from: http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011-003314-16-HU	exclude - dose-sparing but experimental vaccine
5	Euctr, E. S. Clinical study to compare the safety of two influenza vaccines in children and adolescents of 3 to less than 18 years of age at risk for influenza-related complications. 2013. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=EUCTR2013	exclude - dose-sparing but experimental vaccine
6	Pillet S, Aubin É, Trépanier S, et al. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol. 2016;168:72-87. doi:10.1016/j.clim.2016.03.008	exclude - dose-sparing but experimental vaccine
7	Lee JH, Cho HK, Kim KH, et al. Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months. J Korean Med Sci. 2019;34(46):e279. Published 2019 Dec 2. doi:10.3346/jkms.2019.34.e279	exclude - dose-sparing but experimental vaccine
8	Treanor JJ, Taylor DN, Tussey L, et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine. 2010;28(52):8268-8274. doi:10.1016/j.vaccine.2010.10.009	exclude - dose-sparing but experimental vaccine
9	Vajo Z, Balaton G, Vajo P, Kalabay L, Erdman A, Torzsa P. Dose sparing and the lack of a dose-response relationship with an influenza vaccine in adult and elderly patients - a randomized, double-blind clinical trial. Br J Clin Pharmacol. 2017;83(9):1912-1920. doi:10.1111/bcp.13289	exclude - dose-sparing but vaccine not of interest
10	Ctri. Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India. 2015. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=CTRI	exclude - dose-sparing but unclear vaccine (waiting for author response)
11	Euctr, F. I. Safety and Immunogenicity of the Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Children Aged 3 to 8 Years. 2011. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=EUCTR2011	exclude - dose-sparing but unclear vaccine (waiting for author response)
12	Euctr, C. Z. A randomized, double-blind, placebo-controlled, multi-country and multi-center, phase IV study to demonstrate the efficacy of GSK Biologicals' influenza vaccine (Fluarix[TM])	exclude - dose-sparing but unclear vaccine (waiting for author response)

	administered intramuscularly in adults. - FluarixUS-006. 2006. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=EUCTR2006	

APPENDIX 6 – Study and patient data

Author, Year [Study design]	Study period; Setting and Country	Objective of study	Eligibility criteria	Sample size; % Female, % previously immunized	Ethnicities
Kramer, 2006 [RCT][1]	October 2004 – November 2004; 760-bed tertiary care community teaching hospital in the USA	To compare the effectiveness of half-dose versus full dose TIV in health care workers	Age 18 years or older, hospital employee, staff member, or volunteer, and signed informed consent and authorization to use and disclose protected health information for research purposes	444; NR, NR	NR
Belshe, 2007 [RCT][2]	USA; NR	To compare the immunogenicity and safety of injection of IM and ID TIV across different dose levels (3, 6, 9, and 15µg/antigen/dose)	Healthy adults 18-49 years of age	125; 71.2%, 0%	American Indian/Alaskan Native (0%), Asian (2.4%), Black/African American (9.6%), Hawaiian/Pacific Islander (0%), Hispanic (0%), Multi-racial (0.8%), Non-Hispanic (97.6%), Other/unknown (0%), White (87.2%)
Engler, 2008 [RCT][3]	November 2004 – December 2004; Allergy-Immunology-Immunization Clinic, WRAMC, and Pentagon/DiLorenzo Health Clinic, Arlington, Virginia in the USA	To determine the effects of age, sex, and dose on the immunogenicity of intramuscular TIV	Healthy adults aged 18-64 years. Inclusion criteria were based on the remaining CDC and/or DoD priority prior to the shortage announcement which includes all children aged 6--23 months; adults aged >65 years; persons aged 2--64 years with underlying chronic medical conditions; all women who will be pregnant during the influenza season; residents of nursing homes and long-term--care facilities; children aged 2--18 years on chronic aspirin therapy; health-care workers involved in direct patient care; and out-of-home caregivers and household contacts of children aged <6 months	1316; 43.4%, 0%	African American (9%), Asian (2%), Hispanic (2%), Other/unknown (1.4%), White (85%)
	August 2007-2008; Seattle Division of the Department of	To determine pre vaccination and 4- week post-vaccination changes in antibody titer, and	Community-dwelling adults 65 years and older living in Puget Sound area in Washington State	129; 17.8%, 94.6%	African American (4.7%), Asian (1.6%), Hispanic (0.8%), Not reported

Author, Year [Study design]	Study period; Setting and Country	Objective of study	Eligibility criteria	Sample size; % Female, % previously immunized	Ethnicities
Chi, 2010 [RCT][4]	Veterans Affairs Puget Sound Health Care System in Washington State, USA.	local and systemic reactions of full-dose compared to 60% dose of TIV by IM injection			(2.3%), Other (0.8%), White (90%)
Cioppa, 2011 [RCT][5]	October 2008 – March 2009; 10 study centers in Finland and 5 centers in Belgium	To evaluate the safety, tolerability and immunogenicity of different vaccine formulations with different doses of MF59 adjuvant and/or a second B strain (QIV) when added to either high or low doses of a purified subunit influenza vaccine	Healthy children aged 6 to <36 months	126; 43.5%, NR	Asian (1.68%), Black (6.54%), White (84.2%)
Skowronski, 2011 [RCT][6]	September 2008 – December 2008; 5 sites in 3 Canadian provinces (British Columbia, Quebec, and Nova Scotia)	To determine whether giving 2 full doses of split TIV to previously unimmunized infants and toddlers can improve immunogenicity without increasing reactogenicity compared with 2 half-doses	Healthy children 6–23 months of age	267; 53.2%, 0%	Asian (7.9%), Other (14.3%), White (77.8%)
Langley, 2012 [RCT][7]	November 2008 – August 2009; 17 centers in Canada	To assess the immunogenicity and safety of a preservative-free, prefilled syringe formulation of TIV provided as the full adult dose of 0.50 mL compared with the usual children's dose of 0.25 mL in young children	Healthy children 6–35 months at the time of vaccination	390; 47.9%, 42.6%	Other (13.9%), White (86.1%)
Pavia-Ruz, 2015 [RCT][8]	October 2008 – March 2009; Hong Kong, Mexico, Taiwan, Thailand, and the USA	To evaluate Fluarix at both the standard recommended TIV dose for young children in the US (0.25 ml) and also at double this dose (0.5 ml)	Healthy children aged 6 to 35 months at the time of the first vaccination; without acute illness at the time of enrollment and who had not been vaccinated during the 2008-2009 influenza season. Administration of influenza vaccine in a previous season was not however an exclusion criteria	3318; 51%, 30.1%	African heritage/African American (3.5%), American Indian or Alaskan native (0.1%), Asian-Central/South Asian heritage (0.1%), Asian-East Asian heritage (14.5%), Asian-Japanese heritage (0.1%), Asian-South East Asian heritage

Author, Year [Study design]	Study period; Setting and Country	Objective of study	Eligibility criteria	Sample size; % Female, % previously immunized	Ethnicities
					(9.2%), Native Hawaiian or other Pacific Islander (0.2%), White - Arabic/North African heritage (0.5%), White-Caucasian/European heritage (29.9%), Hispanics and children of mixed race (42.1%)
Halasa, 2015 [RCT][9]	2010-2012; 6 study sites in USA	To determine whether a higher dose of influenza vaccine would be safe in the 6 through 35 months age group. In addition, to determine whether immunization with 0.5 mL doses of TIV (15 µg of each HA) would improve the immunogenicity without increasing the reactogenicity of TIV when administered to children 6 through 35 months of age with and without a history of previous TIV vaccination	Healthy children 6 to 35 months of age (naïve cohort) or 12 through 35 months of age (fully primed cohort) who were available for the entire study period and whose parents or guardians provided informed consent were eligible to participate. Children who were eligible in the fully primed cohort also required a history of receiving 2 doses of 2009–2010 H1N1 influenza vaccine and 2 doses of TIV at any time in the past	243; 52%, 13.2%	African (26%), Asian (1%), Multiracial (5%), other (0%); Ethnicity: Hispanic (2%), Non-Hispanic (98%), White (67%)
Phung, 2016 [RCT][10]	September 2010-January 2011; Finland	To evaluate the immunogenicity and safety following a single intramuscular dose of FLUAD or Agrippal S1 influenza vaccines in healthy children previously vaccinated	Healthy children 6–35 months at the time of vaccination	197; 55.8%, 85.7%	NR
Jain, 2017 [RCT][11]	2014-2015 influenza season; 66 study locations in USA and Mexico	To compare the safety and immunogenicity of a double-dose IIV4 manufactured by GSK Vaccines with the United States-approved standard-dose IIV4 in children 6–35 months of age	Healthy children aged 6-35 months regardless of influenza vaccination history, but could not have received any seasonal or pandemic influenza vaccine within 6 months before the first dose of study vaccine	2424; 46.9%, 57.5%	African/African American (13.9%), American Indian or Alaskan Native (2.0%), Caucasian (64.3%), Other (17.9%), South East Asian (1.8%)
Ojeda, 2019 [RCT][12]	December 2017 – January 2018; 3 study sites in Mexico	Reported the results of an open-label, randomized phase III study designed to evaluate the immunogenicity and safety	Children aged 6 months to 17 years of age	302; 46.4%, NR	NR

Author, Year [Study design]	Study period; Setting and Country	Objective of study	Eligibility criteria	Sample size; % Female, % previously immunized	Ethnicities
		of this thiomersal containing MDV format of QIV compared to the licensed thiomersal-free, single-dose PFS format in children and adolescents			
Robertson, 2019 [RCT][13]	September 2016 – March 2017; 38 sites in the USA	To compare the safety and immunogenicity of full and half doses of quadrivalent, split-virion, inactivated influenza vaccine in children 6–35 months of age	Healthy children 6–35 months of age who had not been vaccinated against influenza during the current season (2016–2017). Children 6–11 months of age had to be born at full term of pregnancy (≥37 weeks) or with a birth weight ≥2.5 kg	1950; 49.7%, 47.3%	Race: American Indian or Alaska Native (0.98%), Asian (0.46%), Black (19.2%), Native Hawaiian or Other Pacific Islander (0.46%), White (74.3%), Ethnicity: Hispanic or Latino (22%), not Hispanic or Latino (77%)

Abbreviations: CDC- Centers for Disease Control and Prevention; DoD- Department of Defense; GSK -GlaxoSmithKline; HA-hemagglutinin; IIV4 – inactivated influenza vaccine; ID - intradermal; IM - intramuscular; MDV- multi-dose vial; PFS – pre-filled syringe; QIV-quadrivalent influenza vaccine; TIV-trivalent influenza vaccine; NR – not reported

APPENDIX 7 – Treatment and outcome data

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
Kramer, 2006 [RCT][1] *Adults and Seniors (>18 years)*	Fluzone (Aventis Pasteur), **15-µg/strain** [1 x 0.5mL dose (Intramuscular into the deltoid region)] *A/Wyoming/3/2003 (H3N2), A/New Caledonia/20/99 (H1N1), and a new B strain, B/Jiangsu/10/2003*	**Effectiveness** *Lab confirmed influenza* (Laboratory confirmation of influenza diagnosis was sought in participants reporting a clinical diagnosis by their physicians): 1/222 *Influenza like illness* (Clinical diagnosis of influenza. Participants self-reported four or more symptoms consistent with influenza-like illness (i.e., headache, extreme tiredness, dry cough, fever, muscle or body aches)): 8/222	▪ There was no significant difference between the full-dose and half-dose groups in the diagnosis of influenza or in the proportion of participants self-reporting four or more symptoms consistent with influenza-like illness. ▪ No adverse events were noted by participants from either group or reported to the IRB during the course of the study
	Fluzone (Aventis Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (Intramuscular into the deltoid region)] *A/Wyoming/3/2003 (H3N2), A/New Caledonia/20/99 (H1N1), and a new B strain, B/Jiangsu/10/2004*	**Effectiveness** *Lab confirmed influenza* (Laboratory confirmation of influenza diagnosis was sought in participants reporting a clinical diagnosis by their physicians): 0/222 *Influenza like illness* (Clinical diagnosis of influenza. Participants self-reported four or more symptoms consistent with influenza-like illness (i.e., headache, extreme tiredness, dry cough, fever, muscle or body aches)): 15/222	
Belshe, 2007 [RCT][2] *Adults (18-49 years)*	Fluzone (Sanofi-Pasteur), **15-µg/strain** [1 x 0.5mL dose (Intramuscular in the non-dominant arm)]	**Reactogenicity – injection site** *Pain*[1]: 15/31 *Redness*[2]: 8/31 *Swelling*[2] :7/31 **Reactogenicity – systemic** *Fever*[3]: 1/31 *Headache*[1]: 15/31 *Malaise*[1]: 8/31 *Myalgia*[1]: 10/31	▪ Intradermal vaccine induced significantly more local inflammatory response than Intramuscular vaccine (primary comparison of this study was ID vs IM doses)
	Fluzone (Sanofi-Pasteur), **9-µg/strain** [1 x 0.3mL dose (Intramuscular in the non-dominant arm)]	**Reactogenicity – injection site** *Pain*[1]: 11/31 *Redness*[2]: 11/31 *Swelling*[2] :4/31 **Reactogenicity – systemic** *Fever*[3]: 1/31 *Headache*[1]: 6/31	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Malaise[1]: 8/31 *Myalgia*[1]: 6/31	
	Fluzone (Sanofi-Pasteur), **6-µg/strain** [1 x 0.2mL dose (Intramuscular in the non-dominant arm)]	**Reactogenicity – injection site** *Pain*[1]: 14/31 *Redness*[2]: 9/31 *Swelling*[2] :4/31 **Reactogenicity – systemic** *Fever*[3]: 0/31 *Headache*[1]: 9/31 *Malaise*[1]: 7/31 *Myalgia*[1]: 9/31	
	Fluzone (Sanofi-Pasteur), **3-µg/strain** [1 x 0.[1mL dose (Intramuscular in the non-dominant arm)]	**Reactogenicity – injection site** *Pain*[1]: 15/31 *Redness*[2]: 9/31 *Swelling*[2]:7/31 **Reactogenicity – systemic** *Fever*[3]: 3/31 *Headache*[1]: 8/31 *Malaise*[1]: 3/31 *Myalgia*[1]: 7/31	
Engler, 2008 [RCT][3] *Adults (18-64 years)*	Fluzone (Aventis Pasteur), **15-µg/strain** [1 x 0.5mL dose (Intramuscular injection)] *A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002*	**Effectiveness** *Influenza like illness* (Influenza-like illness and complications resulting in either inpatient or outpatient medical encounters were compared between dose groups (by age)): 61/632 *Hospitalization or Emergency visits*: 0.3% **Reactogenicity – local/injection site** *Any local reactions* (NR): 8.9% *Arm weakness* (NR): 8.3% *Numbness or burning* (NR): 9.7% *Pain* (NR): 5.9% *Redness or swelling* (NR): 13.4% **Reactogenicity – systemic** *Joint and/or muscle pain* (NR): 4.5%	▪ The relative risk of medical visits and hospitalizations for influenza-like illnesses were similar in the half- and full-dose group regardless of age, and there was no evidence of ILI symptom differences by sex or dose during the 21 days after immunizations. ▪ Although injection site pain was greater for full vs half dose (19.9% vs 14.4%; p=.01), when analyzed for clinically significant pain levels significant dose-dependent

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Adverse events *SAE*: 2/554	pain differences were not identified. ▪ Joint and/or muscle pain were significantly different (p=.02 and p=.03, respectively) by dose. ▪ No other adverse event differed significantly by dose
	Fluzone (Aventis Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (Intramuscular injection)] *A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2003*	**Effectiveness** *Influenza like illness* (Influenza-like illness and complications resulting in either inpatient or outpatient medical encounters were compared between dose groups (by age): 64/644 *Hospitalization or Emergency visits*: 0.2% **Reactogenicity – local/injection site** *Any local reactions* (NR): 7.5% *Arm weakness* (NR): 6.5% *Numbness or burning* (NR): 7.8% *Pain* (NR): 4.6% *Redness or swelling* (NR): 8.6% **Reactogenicity – systemic** *Joint and/or muscle pain* (NR): 2.2% **Adverse events** *SAE*: 1/556	
Chi, 2010 [RCT][4] *Seniors (>65 years)*	Fluzone (Sanofi Pasteur), **15-µg/strain** [1 x 0.5mL dose (intramuscular in deltoid of arm)] *A/Solomon Islands/3/ 2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), and B/Malaysia/2506/2004*	**Reactogenicity – injection site, N=64** *Arm motion limitation*: 1 (grade I)[4] *Itching:* 4 (grade I)[4] *Pain:* 7 (grade I)[4] *Redness or discoloration:* 9 (grade I)[4] *Swelling:* 13 (grade I)[4] **Reactogenicity - systemic, N=64** *Chills:* 1 (grade I)[4], 1 (grade II/III)[5] *Fatigue:* 4 (grade I)[4], 2 (grade II/III)[5] *Fever:* 0 *General body ache/pain:* 6 (grade I)[4], 1 (grade II/III)[5] *Headache:* 10 (grade I)[4] *Nausea:* 3 (grade I)[4], 1 (grade II/III)[5] **Adverse events**	▪ The two SAEs were acute coronary syndrome and appendicitis and neither were judged to be related to influenza vaccination

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		SAE[6]: 0/64	
	Fluzone (Sanofi Pasteur), **9-µg/strain** [1 x 0.3mL dose (intramuscular in deltoid of arm)] *A/Solomon Islands/3/ 2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), and B/Malaysia/2506/2004*	**Reactogenicity – injection site, N=64** *Arm motion limitation:* 1 (grade I)[4] *Itching:* 5 (grade I)[4] *Pain:* 11 (grade I)[4] *Redness or discoloration:* 7 (grade I)[4] *Swelling:* 4 (grade I)[4] **Reactogenicity - systemic, N=64** *Chills:* 1 (grade I)[4], 1 (grade II/III)[5] *Fatigue:* 6 (grade I)[4], 1 (grade II/III)[5] *Fever:* 1 (grade I)[4] *General body ache/pain:* 5 (grade I)[4], 2 (grade II/III)[5] *Headache:* 5 (grade I)[4], 1 (grade II/III)[5] *Nausea:* 2 (grade I)[4], 1 (grade II/III)[5] **Adverse events** *SAE*[6]*:* 2/64	
Cioppa, 2011 [RCT][5] *Infants/ Toddlers (6-36 months)*	NR - TIV, **7.5-µg/strain** [2 x 0.25mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)] *A/Brisbane/59/2007 (A/H1N1)-like virus, A/Brisbane/10/2007 (A/H3N2)-like virus, and B/Florida/4/2006-like virus (of the influenza B/Yamagata lineage)*	**Reactogenicity** *Any local reaction*[7]: 47% *Any systemic reaction*[8]: 68% **Adverse events** *AE* (solicited/spontaneously reported): 84% *SAE*: 0/25	▪ Reactogenicity of the 7.5-µg TIV/QIV formulations was slightly lower than for the corresponding 15-µg formulations. ▪ The majority of unsolicited AEs were mild or moderate in severity and none of the SAEs was considered to be related to the study vaccine.
	Agrippal - TIV, **15-µg/strain** [2 x 0.5mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)] *A/Brisbane/59/2007 (A/H1N1)-like virus, A/Brisbane/10/2007 (A/H3N2)-like virus, and B/Florida/4/2006-like virus (of the influenza B/Yamagata lineage)*	**Reactogenicity** *Any local reaction*[7]: 59% *Any systemic reaction*[8]: 50% **Adverse events** *AE* (solicited/spontaneously reported): 82% *SAE*: 0/22	

Author, Year; [Study design] *Population*	Treatment arms Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	Effectiveness and Safety *Outcome* (definition): n/N (unless otherwise indicated)	Conclusions
	NR - QIV, **7.5-µg/strain** [2 x 0.25mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)] *A/Brisbane/59/2007 (A/H1N1)-like virus, A/Brisbane/10/2007 (A/H3N2)-like virus, B/Florida/4/2006-like virus (of the influenza B/Yamagata lineage), and B/Malaysia/2506/2004-like antigen virus (Victoria lineage)*	**Reactogenicity** *Any local reaction*[7]: 25% *Any systemic reaction*[8]: 50% **Adverse events** *AE* (solicited/spontaneously reported): 92% SAE: 1/25	
	NR - QIV, **15-µg/strain** [2 x 0.5mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)] *A/Brisbane/59/2007 (A/H1N1)-like virus, A/Brisbane/10/2007 (A/H3N2)-like virus, B/Florida/4/2006-like virus (of the influenza B/Yamagata lineage), and B/Malaysia/2506/2004-like antigen virus (Victoria lineage)*	**Reactogenicity** *Any local reaction*[7]: 39% *Any systemic reaction*[8]: 54% **Adverse events** *AE* (solicited/spontaneously reported): 71% *SAE*: 1/28	
	Vaxigrip pediatric - TIV (Sanofi Pasteur), **7.5-µg/strain** [2 x 0.25mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)]	**Reactogenicity** *Any local reaction*[7]: 50% *Any systemic reaction*[8]: 46% **Adverse events** *AE* (solicited/spontaneously reported): 73% *SAE*: 1/26	
Skowronski, 2011 [RCT][6] *Infants/ Toddlers (6-23 months)*	Vaxigrip (Sanofi-Pasteur), 15-µg/strain **[2 x 0.5mL dose** (Intramuscular injection)] *A/Brisbane/10/07 (H3N2); A/Brisbane/59/07 (H1N1); and B/Florida/4/06 (Yamagata lineage)*	**Reactogenicity – injection site** *Induration* (NR): 13.7% *Redness* (NR): 22.6% *Swelling* (NR): 15.3% *Tenderness* (NR): 22.6% **Reactogenicity – systemic** *Fever* (>37.5°C): 8.06% *Irritability* (NR): 59.7% *Decreased appetite* (NR): 38.7%	▪ Local reactions generally were less common in infants than toddlers and more common with full doses versus half doses, but none of these differences were significant. ▪ One serious adverse event was reported: a toddler in the half dose group was

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Drowsiness (NR): 39.5% *Sleep disturbance* (NR): 54.8% **Adverse events** *SAE:* NR	hospitalized with pneumonia 28 days after the first vaccination. The event was deemed unlikely related to the vaccine. ▪ All of the rate differences were significantly below the allowed 10% increase in reactogenicity for the full dose ($p< 0.001$ for infant and combined analyses, $p<.005$ for toddlers). ▪ This randomized controlled trial in infants and toddlers shows that compared with 0.25-mL half-dosing, administration of 2 full 0.5-mL doses of trivalent inactivated influenza vaccine can increase antibody response without increasing reactogenicity in previously unimmunized infants aged 6 to 11 months.
	Vaxigrip (Sanofi-Pasteur), 15-µg/strain **[2 x 0.25mL dose** (Intramuscular injection)] *A/Brisbane/10/07 (H3N2); A/Brisbane/59/07 (H1N1); and B/Florida/4/06 (Yamagata lineage)*	**Reactogenicity – injection site** *Induration* (NR): 6.3% *Redness* (NR): 20.3% *Swelling* (NR): 8.6% *Tenderness* (NR): 25.8% **Reactogenicity – systemic** *Fever* (>37.5°C): 11.7% *Irritability* (NR): 60.2% *Decreased appetite* (NR): 43% *Drowsiness* (NR): 41.4% *Sleep disturbance* (NR): 50% **Adverse events** *SAE:* 1/128	
Langley, 2012 [RCT][7] *Infants/ Toddlers (6-35 months)*	Fluviral F1 (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (Intramuscularly in the anterolateral part of the thigh (if the participant was less than 12 months) or in the deltoid region of the arm)] *A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (an A/Brisbane/10/2007 [H3N2]–like virus), and B/Florida/4/2006*	**Reactogenicity – injection site** *Pain* (NR): 45/164 *Redness* (NR): 49/164 *Swelling* (NR): 22/164 **Reactogenicity – systemic** *Drowsiness* (NR) – 44/164 *Fever* (NR) – 10/164 *Irritability* (NR) – 62/164 *Loss of appetite* (NR) – 37/164 **Adverse events** *SAE:* 1/164	▪ Fluviral F1 group had 1 case of pneumonia resolved ▪ Fluviral F2 group had 1 case of bronchial hyper-reactivity in resolving stage ▪ The 0.5-mL dose of the study vaccine, when administered to children aged 6–35 months, resulted in a modest but not statistically significant improvement in

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Unsolicited adverse events (NR): 108/164 *Medically attended events* (NR): 52/164	immunogenicity with clinically similar safety and reactogenicity compared with the 0.25-mL dose.
	Fluviral F2 (Sanofi-Pasteur), **15-µg/strain** [1 x 0.5mL dose (Intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm)] *A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (an A/Brisbane/10/2007 [H3N2]–like virus), and B/Florida/4/2006*	**Reactogenicity – injection site** *Pain* (NR): 55/167 *Redness* (NR): 54/167 *Swelling* (NR): 24/167 **Reactogenicity – systemic** *Drowsiness* (NR) – 52/167 *Fever* (NR) – 6/167 *Irritability* (NR) – 69/167 *Loss of appetite* (NR) – 43/167 **Adverse events** *SAE*: 1/167 *Unsolicited adverse events* (NR): 112/167 *Medically attended events* (NR): 40/167	
	Vaxigrip (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (Intramuscularly in the anterolateral part of the thigh (if the participant was less than 12 months) or in the deltoid region of the arm)] A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (an A/Brisbane/10/2007 [H3N2]–like virus), and B/Florida/4/2006	**Reactogenicity – injection site** *Pain* (NR): 17/43 *Redness* (NR): 13/43 *Swelling* (NR): 5/43 **Reactogenicity – systemic** *Drowsiness* (NR) – 11/43 *Fever* (NR) – 2/43 *Irritability* (NR) – 15/43 *Loss of appetite* (NR) – 9/43 **Adverse events** *SAE:* NR/43 *Unsolicited adverse events* (NR): 24/43 *Medically attended events* (NR): 9/43	
Pavia-Ruz, 2013 [RCT][8] *Infants/ Toddlers*	Fluarix (GSK), **15-µg/strain** [1 x 0.5mL dose (intramuscular injection into the right deltoid muscle or anterolateral thigh)]	**Reactogenicity – injection site** *Any injection site reactions*[9]: 514/1086 *Pain:* 406/1086 *Redness*: 249/1086 *Swelling:* 170/1086	▪ The reactogenicity and safety profile of the study vaccine did not appear to be affected by doubling the dose.

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
(6-35 months)	*A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) and B/Brisbane/3/2007*	**Reactogenicity – systemic** *Any general reactions*[10]: 575/1086 *Drowsiness:* 317/1086 *Fever:* 69/1086 *Irritability:* 387/1086 *Loss of appetite:* 273/1086 **Adverse events** *Any AE*: 729/1086 *SAE*: 29/1086	▪ One subject in the Flu-15µg group had two SAEs, (apnea and cyanosis) which were considered by the investigator to be possibly related to vaccination. The participant was hospitalized and the events resolved on the same day as they occurred.
	Fluarix (GSK), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular injection into the right deltoid muscle or anterolateral thigh)] *A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) and B/Brisbane/3/2007*	**Reactogenicity – injection site** *Any injection site reactions*[9]: 492/1081 *Pain:* 403/1081 *Redness*: 259/1081 *Swelling:* 152/1081 **Reactogenicity – systemic** *Any general reactions*[10]*:* 598/1081 *Drowsiness:* 293/1081 *Fever:* 67/1081 *Irritability:* 386/1081 *Loss of appetite:* 281/1081 **Adverse events** *Any AE*: 724/1081 *SAE*: 35/1081	
	Fluzone (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular injection into the right deltoid muscle or anterolateral thigh)] *A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) and B/Florida/4/2006*	**Reactogenicity – injection site** *Any injection site reactions*[9]*:* 467/1090 *Pain:* 363/1090 *Redness:* 253/1090 *Swelling:* 129/1090 **Reactogenicity – systemic** *Any general reactions*[10]: 592/1090 *Drowsiness:* 298/1090 *Irritability:* 375/1090 *Fever:* 72/1090 *Loss of appetite:* 270/1090	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Adverse events *Any AE:* 722/1090 *SAE:* 31/1090	
Halasa, 2015 [RCT][9] *Infants/ Toddlers (6-35 months)*	Fluzone (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular)] *A/California/7/09 (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/ 60/2008-like virus*	**Reactogenicity** *Redness at injection site*: 8/48 *Fever* (temperature >39°C after the first dose): 7/80	▪ No significant differences between the full-dose or half-dose groups for either the fully primed or naive cohorts for systemic reactions or local reactions when both seasons were combined. ▪ The only significant difference in the 2011–2012 season was that 8 of 48 (16.7%) participants in the half-dose group compared with 32 of 96 (33.3%) in the full-dose group had increased redness at the injection site (P < .05). ▪ No significant differences between the groups in unsolicited AEs, serious adverse events (SAEs), or onset of chronic medical conditions between the dose groups in either the naive or fully primed cohorts, and none of the SAEs were deemed related to the vaccine.
	Fluzone (Sanofi Pasteur), **15-µg/strain** [1 x 0.5 mL dose (intramuscular)] *A/California/7/09 (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/ 60/2008-like virus*	**Reactogenicity** *Redness at injection site*: 32/96 *Fever* (temperature >39°C after the first dose): 19/161	
Phung, 2016 [RCT][10] *Infants/ Toddlers (6-35 months)*	FLUAD (NR), NR [**1 x 0.5mL dose** (Intramuscular injection)] *A/H1N1, A/H3N2, Strain B*	**Reactogenicity** *Any local reaction*[11]: 45/61 *Any systemic reaction*[12]: 36/61 **Adverse events** *SAE* (based on MedDRA v 17.1 definition): 2/61	
	FLUAD (NR), NR [**1 x 0.25 mL dose** (Intramuscular injection)]	**Reactogenicity** *Any local reaction*[11]: 63/75	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
	A/H1N1, A/H3N2, Strain B	*Any systemic reaction*[12]: 42/75 **Adverse events** *SAE* (based on MedDRA v 17.1 definition): 2/75	
	Agrippal S1 (NR), NR [**1 x 0.5mL dose** (Intramuscular injection)] *A/H1N1, A/H3N2, Strain B*	**Reactogenicity** *Any local reaction*[11]: 42/51 *Any systemic reaction*[12]: 24/51 **Adverse events** *SAE* (based on MedDRA v 17.1 definition): 0/51	
	Agrippal S1 (NR), NR [**1 x 0.25mL dose** (Intramuscular injection)] *A/H1N1, A/H3N2, Strain B*	**Reactogenicity** *Any local reaction*[11]: 6/10 *Any systemic reaction*[12]: 5/10 **Adverse events** *SAE* (based on MedDRA v 17.1): 0/10	
Jain, 2017 [RCT][11] *Infants/ Toddlers (6-35 months)*	Flulaval Quadrivalent (GSK), **15-µg/strain** [1 x 0.5mL dose (intramuscular in deltoid region)] *A/California/7/2009 (A/H1N1), A/Texas/50/2012 (A/H3N2), B/Brisbane/60/2008 (B/Victoria), and B/Massachusetts/2/2012 (B/Yamagata)*	**Reactogenicity – injection site (within 7 days)** *Pain*: 44.0% *Redness*: 1.4% *Swelling*: 1.0% **Reactogenicity – systemic (within 7 days)** *Drowsiness:* 40.6% *Fever (>=38.0C):* 7.9% *Irritability/fussiness:* 54.4% *Loss of appetite:* 33.7% **Adverse events** *Any AE*: 45.5% *Vaccine-related AE*: 5.9% *Any SAE*[13]: 1.8% *Febrile seizures*: 0.4% *Medically attended event*[14]: 60.2%	▪ None of the febrile seizures or the SAEs were considered by the investigator to be related to vaccination ▪ Double-dose IIV4 may improve protection against influenza B in some young children and simplifies annual influenza vaccination by allowing the same vaccine dose to be used for all eligible children and adults.
	Fluzone Quadrivalent (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular in deltoid region)]	**Reactogenicity – injection site (within 7 days)** *Pain*: 40.1% *Redness:* 1.4% *Swelling*: 0.4% **Reactogenicity – systemic (within 7 days)**	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
	A/California/7/2009 (A/H1N1), A/Texas/50/2012 (A/H3N2), B/Brisbane/60/2008 (B/Victoria), and B/Massachusetts/2/2012 (B/Yamagata)	*Drowsiness:* 40.9% *Fever (>=38.0C):* 7.5% *Irritability/fussiness:* 50.5% *Loss of appetite:* 33.4% **Adverse events** *Any AE:* 44.1% *Vaccine-related AE:* 5.8% *Any SAE*[13]*:* 1.7% *Febrile seizures*: 0.3% *Medically attended event*[14]: 59.1%	
Ojeda. 2019 [RCT][12] *Infants/ Toddlers and Children (6 months – 17 years)*	Vaxigrip Tetra (Sanofi Pasteur) – **PFS**, 15-µg/strain [1 x 0.5mL dose (intramuscular or deep subcutaneous injection)] *A/Michigan/45/2015 (H1N1)pdm09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, /Brisbane/60/2008-like virus (B/Victoria lineage), and B/Phuket/3073/2013 (B/Yamagata lineage)*	**Reactogenicity, N=142** *Any injection-site reaction* (solicited within 7 days)*:* 26 (6-35mo), 16 (3-8yr), 42 (9-7yr) *Any systemic reaction* (solicited within 7 days): 25 (6-35mo), 15 (3-8yr), 35 (9-7yr) **Adverse events, N=147** *AE* (immediate unsolicited): 1 (9-17 years) *Non-serious AE:* 25 (6-35mo), 9 (3-8yr), 8 (9-7yr) *Vaccine-related non-serious AE*: 1 (9-17 years) *AE leading to study discontinuation*: 0 *SAE*: 0	▪ Solicited reactions were mostly grade 1 (mild) in intensity and resolved within 3 days. ▪ Solicited systemic reactions were reported in more infants aged 6 − 35 months in the MDV group than in the PFS group however, because the 95% CIs were overlapping, this was not thought clinically significant. ▪ None of these unsolicited AEs were considered related to a study vaccine by the investigators. ▪ There were no differences in reactogenicity or safety between the two vaccine formats. These results showed that the MDV format of QIV was as safe and immunogenic as the PFS format in infants, children, and adolescents. These findings support the use of MDV QIV
	Vaxigrip Tetra (Sanofi Pasteur) - **MDV,** 15-µg/strain [1 x 0.5mL dose (intramuscular or deep subcutaneous injection)] *A/Michigan/45/2015 (H1N1)pdm09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, /Brisbane/60/2008-like virus (B/Victoria lineage), and B/Phuket/3073/2013 (B/Yamagata lineage)*	**Reactogenicity, N=139** *Any injection-site reaction*(solicited within 7 days)*:* 27 (6-35mo), 16 (3-8yr), 26 (9-7yr) *Any systemic reaction*(solicited within 7 days): 33 (6-35mo), 13 (3-8yr), 30 (9-7yr) **Adverse events, N=150** *AE* (immediate unsolicited): 0 *Non-serious AE:* 31 (6-35mo), 14 (3-8yr), 5 (9-7yr) *Vaccine-related non-serious AE*: 0 *AE leading to study discontinuation*: 0 *SAE:* 0	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
			as a resource-saving alternative for seasonal influenza vaccination.
Robertson, 2019 [RCT][13] *Infants/ Toddlers (6-35 months)*	Fluzone Quadrivalent (Sanofi Pasteur), **15-µg/strain** [1 x 0.5mL dose (intramuscular single-dose syringes in deltoid of arm)] *A/California/07/2009 X-179A (H1N1), A/Hong Kong/4801/2014 X-263B (H3N2), B/Brisbane/60/2008 (Victoria lineage), B/Phuket/3073/2013 (Yamagata lineage)*	**Reactogenicity** *Any injection-site reaction*[15]: 533/939 *Any systemic reaction*[16]: 561/941 **Adverse events** *Vaccine-related AE* (immediate within 30 mins): 0/992 *Vaccine-related AE* (within 28 days): 30/992 *AE leading to study discontinuation*: 0/992 *SAE*: 5/992	▪ Proportions of participants reporting solicited injection-site reactions, solicited systemic reactions, vaccine-related unsolicited AEs were similar for the full- and half-dose groups ▪ None of the AEs leading to study discontinuation or the SAEs were considered related to vaccination ▪ A single AE of special interest (chronic urticaria first appearing 3 days post-vaccination and continuing for >6 weeks) was considered by the investigator to be related to vaccination ▪ In children 6–35 months of age, a full dose of IIV4 was immunogenic and had a safety profile comparable to that of a half dose with no new safety concerns observed.
	Fluzone Quadrivalent (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular single-dose syringes in deltoid of arm)] *A/California/07/2009 X-179A (H1N1), A/Hong Kong/4801/2014 X-263B (H3N2), B/Brisbane/60/2008 (Victoria lineage), B/Phuket/3073/2013 (Yamagata lineage)*	**Reactogenicity** *Any injection-site reaction*[15]: 480/909 *Any systemic reaction*[16]: 533/909 **Adverse events** *Vaccine-related AE* (unsolicited within 30 mins): 1/949 *Vaccine-related AE* (unsolicited within 28 days): 29/949 *AE leading to study discontinuation*: 3/949 *SAE*: 5/949	

Abbreviations: AE – adverse events, ID – intradermal; ILI – influenza-like illness; IM – intramuscular; MDV – multi-dose vials, n – number of people with condition, N – sample size of treatment arm, NR – not reported, PFS – prefilled syringe, SAE – serious adverse events

[1] Defined as mild (easily tolerated), moderate (interferes with normal behaviour or activities), severe (incapacitating, unable to perform usual activities, may require medical attention)
[2] Present at or near the approximate point of needle entry; small <2.5cm, medium >2.5cm to <5cm, large >5cm
[3] Oral temperature >37.5 C; mild >37.5 to 38 C, moderate >38.1 to 39 C, severe >39.1 C
[4] Grade I reactions defined as “present but easily tolerated” for fatigue, muscle ache, headache, itching or pain at injection site; oral temperature >/=38 and <39 degrees Celsius; some limitation to arm motion due to stiffness or discomfort but easily tolerated; redness or swelling >/= 8cm

[5] Grade II/III reactions defined as “interferes with normal activity” to “severe and incapacitating” for fatigue, muscle ache, headache, itching or pain at injection site; oral temperature >/=39 degrees Celsius; limitation to arm motion due to stiffness or discomfort that interferes with normal activity; redness or swelling > 8cm

[6] Defined as serious adverse events resulting in hospitalization

[7] Solicited local reactions included ecchymosis, erythema, induration, swelling, and tenderness at injection site

[8] Solicited systemic reactions included sleepiness, diarrhea, vomiting, irritability, change in eating habits, shivering, and unusual crying

[9] Included injection site reactions of Grade 1, “minor reaction to touch”, Grade 2, “cries/protests on touch”, and Grade 3, “cries when limb moved/spontaneously painful”

[10] Included systemic reactions of Grade 1, “no effect on normal activity”, Grade 2, “interferes with normal activity”, and Grade 3, “prevents normal activity”

[11] Included injection site ecchymosis, injection sit erythema, injection site induration, injection site swelling, tenderness, injection site pain

[12] Included change in eating habits, sleepiness, unusual crying, irritability, vomiting, diarrhea, chills/shivering, malaise, myalgia, arthralgia, headache, fatigue, fever (>37.3 C)

[13] Defined serious adverse events as any untoward medical occurrence that results in death, is life-threatening, requires/prolongs hospitalization, or results in disability or incapacity during entire study period

[14] Defined as hospitalization, emergency room visit, and/or medical practitioner visit during entire study period

[15] Included tenderness, redness and/or swelling solicited within 7 days

[16] Included fever, vomiting, abnormal crying, drowsiness, loss of appetite, and/or irritability solicited within 7 days

BMJ Open

Safety and effectiveness of dose-sparing strategies for intramuscular seasonal influenza vaccine: A rapid scoping review

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2021-050596.R2
Article Type:	Original research
Date Submitted by the Author:	29-Aug-2021
Complete List of Authors:	Lunny, Carole; UBC, DAPT; St Michael's Hospital Li Ka Shing Knowledge Institute, Knowledge Translation Program Antony, Jesmin; St Michael's Hospital Li Ka Shing Knowledge Institute Rios, Patricia; Independent Researcher Williams, Chantal ; Independent Researcher Ramkissoon, Naveeta; St Michael's Hospital Li Ka Shing Knowledge Institute, Knowledge Translation Straus, Sharon; St Michael's Hospital Li Ka Shing Knowledge Institute; University of Toronto, Geriatric Medicine Tricco, Andrea; St Michael's Hospital Li Ka Shing Knowledge Institute, Knowledge Translation Program
Primary Subject Heading:	Immunology (including allergy)
Secondary Subject Heading:	Immunology (including allergy)
Keywords:	VIROLOGY, IMMUNOLOGY, PUBLIC HEALTH

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Safety and effectiveness of dose-sparing strategies for intramuscular seasonal influenza vaccine:
A rapid scoping review

Carole Lunny[1,2]*† Email: carole.lunny@ubc.ca
Jesmin Antony[2]* Email: jesmin.antony@unityhealth.to
Patricia Rios[3] Email: patricia.rios@wchospital.ca
Chantal Williams[3] Email: chantal.williams@uhn.ca
Naveeta Ramkissoon[2] Email: naveeta.ramkissoon@unityhealth.to
Sharon E. Straus[2,4,5] Email: sharon.straus@unityhealth.to
Andrea C. Tricco[2,6] Email: andrea.tricco@unityhealth.to

[1]Cochrane Hypertension Review Group and the Therapeutics Initiative, University of British Columbia, Vancouver, BC
[2]Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
[3]Independent Researcher
[4]Department of Medicine, University of Toronto, Toronto, Ontario, Canada
[5] Department of Geriatric Medicine, University of Toronto, Toronto, Ontario, Canada
[6] Epidemiology Division, Dalla Lana School of Public Health and Institute for Health, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada

*These authors contributed equally.

†Corresponding Author : Carole Lunny, MPH, PhD, Postdoctoral Fellow, Methodology and Research Synthesis
SPOR Evidence Alliance, Unity Health, University of Toronto

Word count: 3559

ABSTRACT

Background: The objective of this rapid scoping review was to identify studies of dose-sparing strategies for administration of intramuscular seasonal influenza vaccines in healthy individuals of all ages.

Methods: Comprehensive literature searches were executed in MEDLINE, Embase, and the Cochrane library. The grey literature was searched via international clinical trial registries for relevant studies published in English in the last 20 years. We included studies in healthy humans of any age that used any dose-sparing strategy to administer intramuscular seasonal influenza vaccines. Title/abstract and full-text screening were carried out by pairs of reviewers independently. Data extraction was conducted by a single reviewer and verified by a second reviewer. Our outcomes were influenza infections, ICU admission, pneumonia, hospitalizations, adverse events, and mortality. Results were summarized descriptively.

Results: A total of 13 studies with 10,351 participants were included in the review and all studies were randomized control trials (RCTs) conducted between 2006 and 2019. The most common interventions were the trivalent influenza vaccine (n=10), followed by the quadrivalent influenza vaccine (n=4). Nine studies included infants/toddlers 6-36 months old and one of these studies also included children and adolescents. In these nine studies, no clinical effectiveness outcomes were reported. Of the four adult studies (≥ 18 years), two studies reported on effectiveness outcomes, however only one RCT reported on laboratory confirmed influenza.

Conclusions: Due to the low number of studies in healthy adults and the lack of studies assessing confirmed influenza and influenza-like illness, there remains a need for further evaluation.

Keywords:

STRENGTHS AND LIMITATIONS OF THIS STUDY

Strengths:

- This rapid scoping review was conducted within a 6-week timeline and the methods were tailored to provide results to the stakeholders within 4 weeks.
- We did not restrict the search dates and study screening was completed in independently by two reviewers.

Limitations:

- We limited the selection of studies to those published in the English language, and data extraction was conducted by one abstractor and one verifier.
- Twelve dose-sparing RCTs were not included in the review because they did not include vaccine interventions that were deemed of interest to the stakeholders, and/or did not provide sufficient data.

BACKGROUND

The symptoms of novel coronavirus disease (COVID-19) closely mimic those of seasonal influenza vaccine and health officials recommend vaccination against the flu to limit confounding of flu symptoms with COVID-19 symptoms. An anticipated shortage in influenza vaccine supplies was of concern.[1] This anticipated shortage did not happen however, and in the 2019-2020 flu season, influenza vaccination coverage among adults (42%) was similar to the previous season (42%). This question of vaccine shortage remains relevant in Canada and other jurisdictions for future COVID-19 and flue seasons. As a potential solution, health officials were interested in assessing the effectiveness of fractional dosing (e.g., half-doses) of currently available intramuscular influenza vaccines.

Fractional dosing, or dose-sparing, strategies are those where less than the standard dose of hemagglutinin (HA) antigen, and thus less volume of vaccine, is administered, increasing the overall number of influenza vaccine doses available. In Canada, influenza vaccines are currently authorized for intramuscular administration only, apart from the live-attenuated influenza vaccine, which is administered intranasally.[2] Standard dose influenza vaccines contain 15 mcg of HA per strain and are delivered in 0.5 mL volume. Therefore, the total amount of HA in standard dose trivalent vaccines is 45 mcg, and the total amount of HA in standard dose quadrivalent vaccines is 60 mcg.

A scoping review of all the available dose-sparing strategies for intramuscular administration of seasonal influenza vaccines currently approved in Canada for healthy populations had not been systematically conducted. With the resource-constraints for the influenza season due to COVID-19, there was a need to scope the evidence on the safety and effectiveness of dose-sparing strategies for intramuscular administration of seasonal influenza vaccines. The objective of this rapid scoping review was to identify studies of dose-sparing strategies for administration of intramuscular seasonal influenza vaccines in healthy individuals of all ages. The results of this scoping review were used to inform a systematic review with meta-analysis by National Advisory Committee on Immunization (NACI) on the same topic [3].

METHODS

The Centre for Immunization and Respiratory Infectious Diseases of the Public Health Agency of Canada (PHAC) commissioned a rapid scoping review on the available methods for fractional dosing of seasonal influenza vaccines through the Canadian Institutes of Health Research (CIHR) Drug Safety and Effectiveness Network (DSEN) with a 6-week timeline for preliminary results.

Protocol

The methods for this review were guided by the updated reviewer manual for scoping reviews published by JBI and the World Health Organization's guide to rapid reviews.[4, 5] Results are reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis extension to scoping reviews (PRISMA-ScR).[6] A protocol for this rapid scoping review was disseminated through the Open Science Framework registry (https://osf.io/8mwz2/).

Patient and Public Involvement statement

No patients or the public were involved in this rapid scoping review.

Literature search

Comprehensive literature searches were developed and executed by an experienced librarian in Ovid MEDLINE (**Appendix 1**), EMBASE using the OVID interface (**Appendix 2**), and the Cochrane library between 1946 and May 2020 (**Appendix 3**). The literature search was peer reviewed by a second librarian using the PRESS checklist (https://www.cadth.ca/resources/finding-evidence/press). The grey (i.e., difficult to locate or unpublished) literature was searched via international clinical trial registries (i.e. clinicaltrials.gov, EU clinical trial register). References of relevant systematic reviews and included studies were also scanned.

Eligibility criteria

The eligibility criteria followed the Population, Intervention, Comparators, Outcome, Study design (PICOS) framework as follows:

- Population: Healthy humans of any age. Immunocompromised populations and animal studies were excluded. Examples of persons with weakened immune systems include those with HIV/AIDS; cancer and transplant patients who are taking certain immunosuppressive drugs; and those with inherited diseases that affect the immune system (e.g., congenital agammaglobulinemia, congenital IgA deficiency)[7].
- Intervention: Any dose-sparing strategy used to administer intramuscular seasonal influenza vaccines (eligible vaccines listed in **Appendix 4**). Eligible strategies included, but were not limited to, administrating less than the standard 15 ug HA antigen using multi-dose vials, half dosing, or pre-formulated products with reduced antigen quantity, or with revised vaccine dose schedules. Any studies examining monovalent pandemic vaccines, specialty/experimental vaccines (e.g., high dose), whole virus vaccines, or other routes of administration (e.g. intranasal, intradermal) were not eligible. Only vaccine products approved for use in Canada or equivalent formulations approved for use in other countries were eligible for inclusion. Concomitant administration with other vaccine products were included only if administered to both the intervention and the comparator groups.
- Comparator: Any of the interventions listed above, no intervention, or placebo.
- Outcomes: Lab-confirmed influenza infection (primary outcome), influenza-like illness or clinical/symptomatic diagnosis of influenza, hospitalization, intensive care unit (ICU) admission, pneumonia, mortality, and adverse events (local/systemic reactogenicity, vascular-related, serious). Reactogenicity represents the physical manifestation of the inflammatory response to vaccination, and can include injection-site pain, redness, swelling or induration at the injection site, as well as systemic symptoms, such as fever, myalgia, or headache.[8] Immunogenicity outcomes were not abstracted, but these studies were flagged for NACI.
- Study designs: Randomized controlled trials (RCTs), non-randomised studies (e.g., quasi-RCTs, non-randomized trials, interrupted time series, controlled before after), and observational studies (e.g., cohort, case control) were included. Studies must have had a control or comparator group in order to be eligible for inclusion and as such, cross-sectional, case series, case reports, and qualitative studies were excluded.

- Publication status: We included full text and abstracts if they included data on safety or effectiveness.

Inclusion was also limited to studies written in the English language due to the short timelines for the conduct of this review.

Study selection

A screening form based on the eligibility criteria was prepared and pilot-tested with 30 studies with all members of the review team until sufficient agreement (>75%) was reached prior to both title/abstract (level 1) and full-text (level 2) screening. Subsequent screening at level 1 and level 2 were completed by two reviewers working independently using the Knowledge Translation Program's proprietary screening software (synthesi.SR)[9]. Any discrepancies between reviewers were consistently resolved by a third independent reviewer.

Data extraction

Items for data collection included study characteristics (study design, year of publication, country of conduct, multi-center vs. single site), patient characteristics (mean age, age range, sex, vaccination history), intervention details (type of vaccine, vaccine manufacturer, dose, timing and administration of treatment), comparator details (comparator intervention, dose), and outcome results (influenza infections, ICU admission, pneumonia, hospitalizations, adverse events, mortality) at the longest duration of follow-up.

A standardized form for data extraction was developed and pilot tested by the entire review team using two pre-selected full-text RCTs to ensure understanding of the data items to be extracted, and congruence among reviewers. All included studies were extracted by one reviewer independently and then verified by a second reviewer.

Risk of bias assessment

As this was a scoping review, the risk of bias of studies was not assessed.[4]

Synthesis

The synthesis involved providing a descriptive summary of included studies with summary tables and detailed tables of study results. Study results were organized and tabulated according to patients (children vs adults), interventions, and outcomes and where available information on relevant subgroups.

RESULTS

Literature search

We screened 2,378 titles and abstracts from our database search and an additional 13 citations located through searching the grey literature and scanning references. Of these, 144 potentially relevant full-text articles were screened for eligibility (**Figure 1**). Twelve studies that assessed dose-sparing strategies were excluded during full-text screening because the vaccine under study was not of interest or unclearly reported. We contacted authors of these 12 unclear studies and received 1 response confirming the vaccine was not of interest (see list of excluded studies in **Appendix 5**). Subsequently, 13 RCTs were included; five trial protocols were found and were denoted as duplicate/companion reports. No non-randomised or observational studies were found that fulfilled the eligibility criteria.

Study characteristics

Table 1 summarizes the characteristics of the 13 RCTs published between 2006 and 2019; and conducted mainly in the US, followed by Mexico, Canada and Finland. The majority of the studies evaluated trivalent vaccines (10/13 [77%]) and most were conducted in the 6-36 month-old pediatric population (9/13 [69%]). Almost all studies reported on reactogenicity and/or other adverse events, but only two studies reported on the effectiveness of our outcomes of interest (i.e., lab-confirmed influenza and influenza-like illness).

Full study and patient characteristic details for each study are reported in **Appendix 6** and treatment and outcome details in **Appendix 7**.

Table 1: Characteristics of included studies (n=13)

Characteristics	Category	Frequency (%)
Date of publication	2006-2010	4 (30.8)
	2011-2015	5 (38.4)
	2016-2020	4 (30.8)
Multi-center or single site	Multi-centre	8 (61.5)
	Single centre	2 (15.4)
Countries of conduct[a]	USA	8 (61.5)
	Mexico	3 (23.1)
	Canada	2 (15.4)
	Finland	2 (15.4)
	Belgium	1 (7.7)
	Hong Kong	1 (7.7)
	Taiwan	1 (7.7)
	Thailand	1 (7.7)
Populations[a,b]	Infants/Toddlers (6-36 months)	9 (69.2)
	Children (37 months – 17 years)	1 (7.7)
	Adults (18-64 years)	3 (23.1)
	Older adults (≥65)	1 (7.7)
Treatments[a,c]	Trivalent influenza vaccine (TIV)	10 (76.9)
	Quadrivalent influenza vaccine (QIV)	4 (30.8)
Outcomes[a]	Effectiveness	2 (15.4)
	Local and Systemic Reactogenicity	12 (92.3)
	Adverse events	10 (76.9)

[a]Each study can fit into more than one category so the total percentage will not add up to 100%
[b]One study includes both infants/toddlers and children, and another includes both adults and seniors
[c]One study includes both TIV and QIV arms

RCTs in healthy children (<18 years old)

Nine studies included infants/toddlers 6-36 months old and one study also included children and adolescents (**Table 2**). None of these studies reported results on the effectiveness outcomes that were relevant to our review and established *a priori*, however all of them reported on safety outcomes.

222 ***Table 2: Nine RCTs conducted in children (6 months – 17 years)***

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcome	Author reported conclusions
TRIVALENT AND QUADRIVALENT INFLUENZA VACCINES (TIV/QIV)									
Cioppa, 2011[10]	October 2008 – March 2009 Belgium	NR - TIV, **7.5-µg/strain** [2 x 0.25mL dose]	20.0 months (7.0)	6- <36 months	43.5	NR	25	Local and Systemic reactogenicity Adverse events	Reactogenicity of the 7.5-µg TIV/QIV formulations was slightly lower than for the corresponding 15-µg formulations. The majority of unsolicited AEs were mild or moderate in severity and none of the SAEs was considered to be related to the study vaccine.
		Agrippal - TIV, **15-µg/strain** [2 x 0.5mL dose]	15.0 months (8.8)	6- <36 months	43.5	NR	22		
		NR - QIV, **7.5-µg/strain** [2 x 0.25mL dose]	18.0 months (8.9)	6- <36 months	43.5	NR	25		
		NR - QIV, **15-µg/strain** [2 x 0.5mL dose]	15.2 months (7.8)	6- <36 months	43.5	NR	28		
		Vaxigrip (Sanofi Pasteur), **7.5-µg/strain** [2 x 0.25mL dose]	16.1 months (8.5)	6- <36 months	43.5	NR	26		
Skowronski, 2011[11]	September 2008 – December 2008 Canada	Vaxigrip (Sanofi-Pasteur), 15-µg/strain **[2 x 0.5mL dose]**	13.2 months (5.1)	6-23 months	53.2	0	124	Local and Systemic reactogenicity Adverse	Local reactions generally were less common in infants than toddlers and more common with full

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcome	Author reported conclusions
		Vaxigrip (Sanofi-Pasteur), 15-µg/strain **[2 x 0.25mL dose]**	12.8 months (5.0)	6-23 months	53.2	0	128	events	doses versus half doses, but none of these differences were significant. One serious adverse event was reported: a toddler in the half dose group was hospitalized with pneumonia 28 days after the first vaccination. The event was deemed unlikely related to the vaccine. Compared with 0.25-mL half-dosing, administration of 2 full 0.5-mL doses of trivalent inactivated influenza vaccine can increase antibody response

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcome	Author reported conclusions
									without increasing reactogenicity in previously unimmunized infants aged 6 to 11 months.
Langley, 2012[12]	November 2008 – August 2009 Canada	Fluviral F1 (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	18.2 months (9.06)	6-35 months	47.9	42.6	164	Local and Systemic reactogenicity Adverse events	Fluviral F1 group had 1 case of pneumonia resolved. Fluviral F2 group had 1 case of bronchial hyper-reactivity in resolving stage. The 0.5-mL dose of the study vaccine, when administered to children aged 6–35 months, resulted in a modest but not statistically significant improvement in immunogenicity
		Fluviral F2 (Sanofi-Pasteur), **15-µg/strain** [1 x 0.5mL dose]	17.5 months (8.27)	6-35 months	47.9	42.6	167		
		Vaxigrip (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	17.0 months (8.33)	6-35 months	47.9	42.6	43		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcome	Author reported conclusions
									with clinically similar safety and reactogenicity compared with the 0.25-mL dose.
Pavia-Ruz, 2013[13]	October 2008-March 2009 Hong Kong, Mexico, Taiwan, Thailand, and the USA	Fluarix (GSK), **15-µg/strain** [1 x 0.5mL dose]	21.2 months (8.37)	6-35 months	51	30.1	1018	Local and Systemic reactogenicity Adverse events	The reactogenicity and safety profile of the study vaccine did not appear to be affected by doubling the dose. One participant in the Flu-15µg group had two SAEs, (apnea and cyanosis) which were considered by the investigator to be possibly related to vaccination. The subject was hospitalized and the events resolved on the same day as they
		Fluarix (GSK), **7.5-µg/strain** [1 x 0.25 mL dose]	21.2 months (8.03)	6-35 months	51	30.1	1018		
		Fluzone (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	21.1 months (8.20)	6-35 months	51	30.1	1031		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcome	Author reported conclusions
									occurred.
Halasa, 2015[14]	2010-2012 USA	Fluzone (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	13.5	6-35 months, 12-35 months	52	13.2	80	Local and Systemic reactogenicity	No significant differences between the full-dose or half-dose groups for either the fully primed or naive cohorts for systemic reactions or local reactions when both seasons were combined. The only significant difference in the 2011–2012 season was that 8 of 48 (16.7%) participants in the half-dose group compared with 32 of 96 (33.3%) in the full-dose group had
		Fluzone (Sanofi Pasteur), **15-µg/strain** [1 x 0.5 mL dose]	14.5				163		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcome	Author reported conclusions
									increased redness at the injection site (P < .05). No significant differences between the groups in AE, SAE, or onset of chronic medical conditions between the dose groups in either the naive or fully primed cohorts, and none of the SAEs were deemed related to the vaccine.
Phung, 2016[15]	September 2010-January 2011 Finland	FLUAD (NR), NR [**1 x 0.5mL dose**]	68.7 months (18)	6-35 months	55.8	85.7	60	Local and Systemic reactogenicity Adverse events	*Trial protocol with no author conclusions.*
		FLUAD (NR), NR [**1 x 0.25 mL dose**]	60.4 months (23.2)	6-35 months	55.8	85.7	75		
		Agrippal S1 (NR),	68 months (17.1)	6-35 months	55.8	85.7	51		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcome	Author reported conclusions
		NR [**1 x 0.5mL dose**]							
		Agrippal S1 (NR), NR [**1 x 0.25mL dose**]	32.4 months (1.9)	6-35 months	55.8	85.7	11		
Jain, 2017[16]	2014-2015 Influenza Season USA and New Mexico	Flulaval (GSK), **15-µg/strain** [1 x 0.5mL dose]	19.7 months (8.7)	6-35 months	46.9	57.5	1013	Local and Systemic reactogenicity Adverse events	None of the febrile seizures or the SAEs were considered by the investigator to be related to vaccination. Double-dose vaccines may improve protection against influenza B in some young children and simplifies annual influenza vaccination by allowing the same vaccine dose to be used for all eligible children
		Fluzone (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	19.9 months (8.9)	6-35 months	46.9	57.5	1028		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcome	Author reported conclusions
									and adults.
Ojeda, 2019[17]	December 2017-January 2018 Mexico	Vaxigrip Tetra (Sanofi Pasteur) **PFS 15-µg/strain** [1 x 0.5mL dose]	NR (6 months – 17 years)	6 months – 17 years	46.4	NR	149	Local and Systemic reactogenicity Adverse events	Solicited systemic reactions were reported in more infants aged 6 − 35 months in the MDV group than in the PFS group however this was not clinically significant. AE not considered related to a study vaccine. There were no differences in reactogenicity or safety between the two vaccine formats. These results showed that the MDV
		Vaxigrip Tetra (Sanofi Pasteur) **MDV 15-µg/strain** [1 x 0.5mL dose]	NR (6 months – 17 years)	6 months – 17 years	46.4	NR	153		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcome	Author reported conclusions
									format of QIV was as safe and immunogenic as the PFS format in infants, children, and adolescents. These findings support the use of MDV QIV as a resource-saving alternative for seasonal influenza vaccination.
Robertson, 2019[18]	September 2016 – March 2017 USA	Fluzone (Sanofi Pasteur) **15-µg/strain** [1x0.5mL dose]	20.5 months (8.55)	6-35 months	49.7	47.25	992	Local and Systemic reactogenicity Adverse events	No significant differences between full- and half-dose groups. AE leading to study discontinuation/SAE not considered vaccine-related. A full dose vaccine was immunogenic and
		Fluzone (Sanofi Pasteur) **7.5-µg/strain** [1x0.25 dose]	20.4 months (8.75)	6-35 months	49.7	47.25	949		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Outcome	Author reported conclusions
									had a safety profile comparable to that of a half dose, with no new safety concerns observed.

Abbreviations: AE – adverse events; GMR - geometric mean ratio; GMFR – geometric mean fold rise; GMT - geometric mean antibody titer; HA - hemagglutinin; HAI - hemagglutination inhibition; ID – intradermal; IM – intramuscular; ITT – intent-to-treat; MDV – multi-dose vials, n – number of people with condition, N – sample size of treatment arm, NR – not reported, PFS – prefilled dose, SAEs – serious adverse events

Safety outcomes

Trivalent influenza vaccines

Six of the included RCTs assessed trivalent influenza vaccines (TIV) in young children (6-36 months) and reported on local and systemic reactogenicity outcomes and other adverse events.[10-14, 19] Two RCTs compared the administration of full (0.5mL) and half (0.25mL) doses of the same standard 15µg/strain vaccine.[11, 19] The first RCT compared two full versus two half doses of TIV in previously unimmunized infants (6-11 months) and toddlers (12-23 months) using Vaxigrip (15µg/strain).[11] The study found that in the infants group, two full 0.5-mL doses of vaccine did not increase reactogenicity. Local reactions were less common in infants than toddlers and more common with full doses versus half doses, but the differences were not statistically significant. An identified clinical trial registry compared a single intramuscular injection of 0.5mL to 0.25mL of FLUAD or Agrippal and showed comparable numbers of children with reactogenicity outcomes and other adverse events across the groups, but no significance levels or conclusions were provided by the investigators upon contact.[19]

The objective of three of the included RCTs was to examine the impact of administering the full adult dose of 15µg/strain vaccines compared with the usual children's dose of 7.5µg/strain in infants and toddlers.[12-14] A multicenter RCT was conducted in Canada assessing the safety of full-dose Fluviral TIV (15µg/strain) compared with the half-dose (7.5µg/strain) and an active comparator Vaxigrip (7.5µg/strain).[12] Compared with the half-dose, the full-dose vaccine resulted in clinically similar reactogenicity and safety. A similar three-arm RCT to assess the use of Fluarix at two different dose levels (7.5µg/strain and 15µg/strain) compared to an established control vaccine Fluzone (7.5µg/strain) also found the reactogenicity and safety profile of Fluarix did not appear to be affected by doubling the dose, but one participant in the 15µg group had two serious adverse events (apnea and cyanosis) that were considered by the investigator to be possibly related to vaccination.[13] A third multicenter RCT compared the 15 µg/strain formulation to the 7.5µg/strain formulation of Fluzone (Sanofi Pasteur) administered to young children across multiple influenza seasons.[14] This study also found no statistically significant differences between the full-dose or half-dose groups for systemic reactions, local reactions or adverse events when both seasons were combined; however, in the 2011–2012 season, 8 of 48 (16.7%) participants in the half-dose group compared with 32 of 96 (33.3%) in the full-dose group had increased redness at the injection site ($P < .05$).

Cioppa et al. (2009) was the only trial that compared the safety and tolerability of both TIV and QIV vaccine formulations.[10] The vaccine arms of interest were a QIV 15-µg/strain, TIV 15-µg/strain, QIV 7.5-µg/strain, TIV 7.5-µg/strain, and a control Vaxigrip TIV 7.5-µg/strain vaccine. Reactogenicity of the 7.5-µg TIV/QIV formulations was slightly lower than for the corresponding 15-µg formulations, but there was no difference in reactogenicity between TIV and QIV vaccines.

Quadrivalent influenza vaccines

Four of the included RCTs evaluated quadrivalent influenza vaccines (QIV) in children.[10, 16-18] All of the studies reported reactogenicity outcomes and other adverse events. The Cioppa et al. (2009) RCT reported both TIV and QIV vaccines and the results are reported above.[10] Two studies compared full-dose QIV to pediatric 7.5µg/strain Fluzone. In the first RCT, full dose Fluzone had a similar safety profile to half-dose Fluzone with a single adverse event being

attributed to the study vaccine.[18] Similarly, the second study found that full-dose Flulaval may improve protection against influenza in some young children when compared to low-dose Fluzone, and in this RCT, none of the adverse events were considered to be study-related as reported by the investigator.[16] The final trial evaluated Vaxigrip Tetra (15µg/strain) administered to children and adolescents in two different formats.[17] Vaxigrip administered as a single dose using a pre-filled syringe (PFS) was compared to a 10-dose multi-dose vial (MDV). Systemic reactions were reported in more infants aged 6 − 35 months in the MDV group than in the PFS group; however this difference was not clinically significant. The authors concluded that there was no difference in reactogenicity or safety between the two vaccine formats in infants, children, and adolescents.

RCTs in healthy adults (≥18 years old)

One RCT included healthy adults over 18 years, two studies included healthy adults from 18-45 and 18-65 years old, and one study included older healthy adults (≥ 65 years) (**Table 3**). Two studies reported on effectiveness outcomes and three on reactogenicity and other adverse events. All four RCTs evaluated Fluzone QIV.

288 ***Table 3: Four RCTs conducted in adults (≥18 years old)***

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Relevant Outcomes	Author reported conclusions
QUADRIVALENT INFLUENZA VACCINES (QIV)									
Kramer, 2006 [20]	October 2004 – November 2004 USA	Fluzone (Aventis Pasteur), **15-µg/strain** [1 x 0.5mL dose]	NR (>18 years)	>18 years	NR	NR	222	Lab-confirmed influenza (one patient receiving the full dose) Influenza-like illness Adverse events	There was no significant difference between the full-dose and half-dose groups in the diagnosis of influenza or in the proportion of participants self-reporting four or more symptoms consistent with influenza-like illness. No adverse events were noted by participants from either group or reported to the IRB during the course of the study
		Fluzone (Aventis Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	NR (>18 years)	>18 years	NR	NR	222		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Relevant Outcomes	Author reported conclusions
Engler, 2008 [21]	November 2004 – December 2004 USA	Fluzone (Aventis Pasteur), **15-µg/strain** [1 x 0.5mL dose]	NR (18 – 64 years)	18-64 years	43.4	0	554	Influenza-like illness Hospital/ER visits Local and Systemic reactogenicity Adverse events	The relative risk of medical visits and hospitalizations for influenza-like illnesses were similar in the half- and full-dose group regardless of age, and there was no evidence of ILI symptom differences by sex or dose during the 21 days after immunizations. Although injection site pain was greater for full- vs half-dose (19.9% vs 14.4%; p=.01), when analyzed for clinically significant pain
		Fluzone (Aventis Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose]	NR (18 – 64 years)	18-64 years	43.4	0	556		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Relevant Outcomes	Author reported conclusions
									levels significant dose-dependent pain differences were not identified. Joint and/or muscle pain were significantly different (p=.02 and p=.03, respectively) by dose. No other adverse event differed significantly by dose.
Belshe, 2007 [22]	NR USA	Fluzone (Sanofi-Pasteur), **15-µg/strain** [1 x 0.5mL dose]	31.5 years (9.6)	18-49 years	71.2	0	31	Local and Systemic reactogenicity	Intradermal (ID) vaccine induced significantly more local inflammatory response than Intramuscular (IM) vaccine but
		Fluzone (Sanofi-Pasteur),	31.2 years (9.4)	18-49 years	71.2	0	32		

Author, Year	Study period and countr(ies)	Treatment arms Brand name (manufacturer) HA/strain [dosing]	Mean age (SD)	Age range	Sex (overall % female)	Vaccination history (overall % previously immunized)	ITT sample size	Relevant Outcomes	Author reported conclusions
		9-µg/strain [1 x 0.3mL dose]							this did not translate into an increased immune response for ID vaccines compared to IM (primary comparison of this study was ID vs IM doses)
		Fluzone (Sanofi-Pasteur), **6-µg/strain** [1 x 0.2mL dose]	30.1 years (10.3)	18-49 years	71.2	0	31		
		Fluzone (Sanofi-Pasteur), **3-µg/strain** [1 x 0.1mL dose]	31.9 years (10.3)	18-49 years	71.2	0	31		
Chi, 2010[23]	August 2007-2008 USA	Fluzone (Sanofi Pasteur), **15-µg/strain** [1 x 0.5mL dose]	75.6 years (6.8)	>65 years	17.8	94.6	65	Local and Systemic reactogenicity Adverse events	The two SAEs were acute coronary syndrome and appendicitis and neither were judged to be related to influenza vaccination
		Fluzone (Sanofi Pasteur), **9-µg/strain** [1 x 0.3mL dose]	75.2 years (7.7)	>65 years	17.8	94.6	64		

Abbreviations: AE – adverse events, GMT - geometric mean antibody titer; HA - hemagglutinin; ID – intradermal; ILI – influenza-like illness; IM – intramuscular; MDV – multi-dose vials, n – number of people with condition, N – sample size of treatment arm, NR – not reported, PFS – prefilled syringe, SAE – serious adverse events

Effectiveness outcomes

Two of the included RCTs that examined the same vaccine (Fluzone manufactured by Aventis Pasteur) in healthy adult populations reported effectiveness outcomes. Only one study by Kramer et al. included lab-confirmed influenza infection [20], two reported influenza like illness, [20, 21] and one reported hospitalizations or emergency room visits after vaccination [21]. The RCT by Kramer et al. (2006) found that 3.6% of participants receiving a 15-µg/strain dose of vaccine reported influenza like illness compared to 6.8% of participants that received a 7.5-µg/strain dose.[20] However, only one participant that received the full dose 15-µg/strain was confirmed via laboratory analysis to have influenza, and no patients in the half dose arm got lab confirmation. The authors concluded that half-dose and full-dose vaccinations appear to be similarly effective for influenza like illness and similar symptom surveys between both groups but acknowledge that further studies examining immunogenicity are needed to confirm.

A similar RCT by Engler et al. (2008) that compared a 15-µg/strain dose of Fluzone vaccine to a 7.5-µg/strain dose found equal proportions of participants reporting influenza like illness (9.7% vs 9.9%) and hospitalizations or emergency room visits (0.3% v 0.2%).[21] The authors found the relative risk of medical visits or hospitalizations between both groups was the same even when adjusting for age and that age, sex, nor dose had an influence on the severity of influenza like illness symptoms.

Safety outcomes

Three of the included studies in adult populations reported adverse events that occurred during the trial while one RCT indicated that no adverse events were recorded for the duration of their trial.[20-23] All three studies reporting adverse events compared different doses of Fluzone vaccine including 3-µg, 6-µg, 7.5-µg, 9-µg, and 15-µg per strain doses.

Two of the studies were carried out in healthy adult populations and one RCT was conducted in older healthy adults (>60 years of age).[21-23] One RCT found that joint or muscle pain following vaccination was statistically significantly higher in the full dose (15-µg) group compared to the half-dose (7.5-µg) group and that while injection site pain initially appeared to be statistically significantly higher in the full dose group, when adjusted to include only clinically significant pain levels (>3 out of 5 on a visual analogue scale) the difference was no longer statistically significant.[21] The RCT found no differences in occurrence or severity of any other adverse effects. Similarly, one RCT comparing four different doses of Fluzone (3-µg, 6-µg, 9-µg, and 15-µg per strain) did not report any differences between the IM vaccination groups.[22] Finally, the RCT in older adults also found no difference in the occurrence or severity of adverse events in the low dose (9-µg) versus high dose (15-µg) group and found no serious adverse events that were considered related to the vaccine.[23]

DISCUSSION

PHAC commissioned this rapid scoping review to identify the evidence for efficacy and safety of fractional influenza vaccine dosing for intramuscular administration of seasonal influenza vaccines in healthy individuals of all ages that have been evaluated in human trials. Thirteen RCTs published between 2006 and 2019 comparing standard/full-dose and half/low-dose vaccines were included in this scoping review after a comprehensive search of three electronic

databases, trial registries and references of relevant systematic reviews. The majority of the included RCTs were conducted in children and evaluated trivalent influenza vaccines (TIV). In young, healthy children, there were no effectiveness outcomes of interest reported. However, local reactogenicity, systemic reactogenicity and adverse events were comparable across the full-dose and half-dose TIV and QIV vaccine arms. In addition, the authors of one RCT in children and adolescents that compared full-dose QIV using pre-filled syringes (PFS) versus multi-dose vials (MDV) also found no statistically significant differences in safety outcomes between administration formats. In healthy adults (including older adults), half-dose QIV was considered equally effective as high-dose in the two RCTs that assessed clinical effectiveness. Safety profiles were similar across groups in all 4 RCTs.

A full systematic review with meta-analysis based on the studies and results of this scoping review was conducted by the NACI and the report was published in January of 2021.[3] Briefly, the report found that there is some, but still insufficient, evidence that fractional doses of influenza vaccine provided via the intramuscular route are effective and immunogenic in healthy individuals. NACI concludes that since many of those at high risk of influenza (e.g., adults 65 years of age and older, individuals with specific underlying chronic health conditions) may have a lower immune response to influenza vaccination already (due to immunosenescence in older adults or a condition that alters immune function), it is important to ensure that those at high risk continue to receive the full dose of influenza vaccine. With regard to the safety of intramuscular seasonal fractional doses of influenza vaccines, there is fair evidence that fractional doses do not result in significant differences compared to full dose with regard to severe adverse effects post-influenza vaccination. Readers are encouraged to reference the full NACI report on the Health Canada website [3].

Strengths and limitations

A strength of this rapid scoping review was that it was conducted within a 6-week timeline and the methods were tailored to provide results to the stakeholders within 4 weeks. We also did not restrict the search dates and study screening was completed independently by two reviewers. We developed a comprehensive search using three major databases, and searched the grey literature. We engaged with the NACI stakeholder group, who provided input on the PICO criteria, and funded this rapid scoping review.

We were limited by the lack of studies providing objective outcome data. Only one RCT by Kramer et al. reported the objective outcome “lab confirmed influenza”, and the other RCT by Engler only reported the outcome “influenza like illness” [20, 21]. Since a 2014 narrative review found that less than 25% of cases diagnosed by physicians as influenza like illness were later laboratory proven influenza cases [24], we are lacking RCTs examining fractional dosing of IM influenza immunization. Further, twelve dose-sparing RCTs were not included because they did not provide sufficient data, and did not include vaccines that were deemed of interest to the stakeholders. Another limitation was that only studies published in the English language were included, and data extraction was conducted by one abstractor and one verifier. Since this was a scoping review, we did not appraise the methodological quality of the included studies.[25]

Future research

Dose-sparing approaches such as intradermal (ID) immunisation vaccination exhibits similar, or even enhanced, immunogenicity, when using a fractional dose only, as compared to intramuscular or subcutaneous immunisation, and should be explored in future scoping reviews.[26]

CONCLUSIONS

In our scoping review, we found 13 RCTs on the efficacy and safety of fractional doses of influenza vaccine provided via the intramuscular route to healthy adults and children. These studies were used to inform a systematic review with meta-analysis which were commissioned by the PHAC. We found that due to the low number of studies in healthy adults, namely one study assessing laboratory confirmed influenza and two evaluating influenza-like illness in adults, there remains a need for further evaluation of the clinical effectiveness of IM dose-sparing strategies using vaccines currently available in this population.

LIST OF ABBREVIATIONS

PHAC – Public Health Agency of Canada
CIHR – Canadian Institutes of Health Research
DSEN – Drug Safety and Effectiveness Network
MAGIC – Methods and Application Group in Indirect Comparisons
PRISMA-ScR – Preferred Reporting Items for Systematic Reviews and Meta-analysis extension to scoping reviews
ICU – Intensive Care Unit
RCT – Randomized controlled trials
NRCTs – non-randomized controlled trials
TIV – Trivalent Influenza Vaccine
AE – Adverse Events
SAE – Serious adverse events
QIV – Quadrivalent Influenza Vaccine
PFS – Pre-filled syringe
MDV – Multi-dose vial

DECLARATIONS

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

The dataset(s) supporting the conclusions of this article is(are) included within the article (and its additional file(s)).

Competing interests

The authors have no competing interests to declare.

Funding

This work was supported through the Drug Safety and Effectiveness Network funded by the Canadian Institutes of Health Research, the funders had no involvement in the design, conduct, or publication of this study. SES is funded by a Tier 1 Canada Research Chair in Knowledge Translation and the Mary Trimmer Chair in Geriatric Medicine; ACT is funded by a Tier 2 Canada Research Chair in Knowledge Synthesis.

Authors' contributions

CL wrote and revised the final manuscript. JA and PR screened citations and full-text articles, abstracted and verified data, interpreted results and wrote the first draft manuscript. CW and NR screened citations and full-text articles, abstracted data, and reviewed the manuscript. SES and ACT developed the protocol, obtained funding, interpreted results, and edited the manuscript.

Acknowledgements
The authors would like to thank Jessie McGowan for her assistance in developing literature searches, Tamara Radar for PRESS of literature search, Alissa Epworth for her assistance executing searches and retrieving articles, and Navjot Mann for her assistance in contacting author's and formatting this manuscript.

Additional files
File Format: Microsoft Word (.docx)
Title of Data: Additional File 1 (Appendices 1-7)
Description of Data: The appendices include the following additional information:
Appendix 1 – MEDLINE search strategy
Appendix 2 – EMBASE search strategy
Appendix 3 – Cochrane search strategy
Appendix 4 – List of eligible vaccines
Appendix 5 – Excluded dose-sparing studies
Appendix 6 – Study and patient data
Appendix 7 – Treatment and outcome data

FIGURE LEGEND

Figure 1. Flow chart of studies included in the review
Study flow diagram.

REFERENCES

1. PHAC. Seasonal Influenza Vaccination Coverage in Canada, 2019-2020. 2020.
2. PHAC. Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2019–2020. 2019.
3. PHAC. Recommendations on fractional influenza vaccine dosing. 2021. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-fractional-influenza-vaccine-dosing.html
4. Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. *JBI Evid Synth*. 2020;18(10):2119-26.
5. World Health Organization AfHPaSR. Rapid reviews to strengthen health policy and systems: a practical guide 2017. Available from: https://www.who.int/alliance-hpsr/resources/publications/rapid-review-guide/en/.
6. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018;169(7):467-73.
7. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. *Clin Infect Dis*. 2013;58(3):e44-e100.
8. Hervé C, Laupèze B, Del Giudice G, et al. The how's and what's of vaccine reactogenicity. *npj Vaccines*. 2019;4(1):39.
9. Synthesi.SR. Toronto, Canada: Knowledge Translation Program, St. Michael's Hospital; 2012.
10. Della Cioppa G, Vesikari T, Sokal E, et al. Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: a dose-and schedule-finding study. *Vaccine*. 2011;29(47):8696-704.
11. Skowronski DM, Hottes TS, Chong M, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. *Pediatrics*. 2011;128(2):e276-89.
12. Langley JM, Vanderkooi OG, Garfield HA, et al. Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6–35 months: a randomized, controlled trial. *J Pediatric Infect Dis Soc*. 2012;1(1):55-63.
13. Pavia-Ruz N, Angel Rodriguez Weber M, Lau Y-L, et al. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. *Hum Vaccin Immunother*. 2013;9(9):1978-88.
14. Halasa NB, Gerber MA, Berry AA, et al. Safety and immunogenicity of full-dose trivalent inactivated influenza vaccine (TIV) compared with half-dose TIV administered to children 6 through 35 months of age. *J Pediatric Infect Dis Soc*. 2015;4(3):214-24.
15. Clinical Trial Results: A Phase IIIB, observer-blind, randomized, parallel groups, extension study to evaluate the immunogenicity and safety following a single intramuscular dose of FLUAD or Agrippal S1 influenza vaccines in healthy children previously vaccinated in the V70P5 study. [Internet]. 2016 [cited July 6, 2020]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021644-18/results.
16. Jain VK, Domachowske JB, Wang L, et al. Time to change dosing of inactivated quadrivalent influenza vaccine in young children: evidence from a phase III, randomized, controlled trial. *J Pediatric Infect Dis Soc*. 2017;6(1):9-19.
17. Ojeda J, Arredondo JL, Salcedo P, et al. Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial. *Hum Vaccin Immunother*. 2019:1-5.

18. Robertson CA, Mercer M, Selmani A, et al. Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial. *Pediatr Infect Dis J*. 2019;38(3):323-8.
19. A Phase IIIB, observer-blind, randomized, parallel groups, extension study to evaluate the immunogenicity and safety following a single intramuscular dose of FLUAD or Agrippal S1 influenza vaccines in healthy children previously vaccinated in the V70P5 study. [Internet]. 2015 [cited July 14, 2020]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021644-18/results.
20. Kramer JS, Durham C, Schroeder T, et al. Effectiveness of half-dose versus full-dose influenza vaccine in health care workers. *Am J Health Syst Pharm*. 2006;63(21):2111-5.
21. Engler RJ, Nelson MR, Klote MM, et al. Half-vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. *Arch Intern Med*. 2008;168(22):2405-14.
22. Belshe RB, Newman FK, Wilkins K, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. *Vaccine*. 2007;25(37-38):6755-63.
23. Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. *Clin Infect Dis*. 2010;50(10):1331-8.
24. Thomas RE. Is influenza-like illness a useful concept and an appropriate test of influenza vaccine effectiveness? *Vaccine*. 2014;32(19):2143-9.
25. Peters MD, Godfrey C, McInerney P, et al. Chapter 11: scoping reviews (2020 version). *JBI manual for evidence synthesis, JBI*. 2020;2020.
26. Schnyder JL, De Pijper CA, Garcia Garrido HM, et al. Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis. *Travel Med Infect Dis*. 2020;37:101868.



APPENDIX 1 – MEDLINE search strategy

Database: Ovid MEDLINE(R) ALL <1946 to May 29, 2020>

Search Strategy:

---

1 influenza, human/ or exp influenza a virus/ or exp influenzavirus b/ or influenzavirus c/
2 (flu or flue or influenza* or grippe).tw,kf.
3 1 or 2
4 exp Vaccines/ or Immunization/
5 (vaccin* or immuni* or inocula* or shot or jab).tw,kf.
6 4 or 5
7 3 and 6
8 influenza vaccines/ or Adjuvants, Immunologic/
9 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).tw,kf.
10 7 or 8 or 9
11 Injections, Intramuscular/
12 (intramuscular or intra-muscular).tw,kf.
13 or/11-12
14 10 and 13
15 limit 14 to yr=2000-current
16 animals/ not humans/
17 15 not 16
18 ad.fs.
19 11 or 12 or 18
20 10 and 19
21 exp dose-response relationship, immunologic/
22 dose-Response Relationship, Drug/
23 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).tw,kf.
24 ((reduc* or lower or less) adj2 (quantity or strength or standard)).tw,kf.
25 ((dos* adj3 change) or (half adj3 dos*)).tw,kf.
26 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).tw,kf.
27 or/21-26
28 20 and 27
29 animals/ not humans/
30 28 not 29
31 limit 30 to yr=2000-current
32 17 or 31

APPENDIX 2 – EMBASE search strategy

Database: Ovid MEDLINE(R) Embase <2000 to June 11, 2020>

Search Strategy:

---

1 influenza, human/ or exp influenza a virus/ or exp influenzavirus b/ or influenzavirus c/
2 (flu or flue or influenza* or grippe).tw,kf.
3 1 or 2
4 exp Vaccines/ or Immunization/
5 (vaccin* or immuni* or inocula* or shot or jab).tw,kf.
6 4 or 5
7 3 and 6
8 influenza vaccines/ or Adjuvants, Immunologic/
9 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).tw,kf.
10 7 or 8 or 9
11 Injections, Intramuscular/
12 (intramuscular or intra-muscular).tw,kf.
13 or/11-12
14 10 and 13
15 limit 14 to yr=2009-current
16 animals/ not humans/
17 15 not 16
18 ad.fs.
19 11 or 12 or 18
20 10 and 19
21 exp dose-response relationship, immunologic/
22 dose-Response Relationship, Drug/
23 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).tw,kf.
24 ((reduc* or lower or less) adj2 (quantity or strength or standard)).tw,kf.
25 ((dos* adj3 change) or (half adj3 dos*)).tw,kf.
26 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).tw,kf.
27 or/21-26
28 20 and 27
29 animals/ not humans/
30 28 not 29
31 limit 30 to yr=2009-current
32 17 or 31
33 32 use ppez
34 exp Influenza virus/ or exp influenza/
35 (flu or flue or influenza* or grippe).tw.
36 34 or 35
37 exp vaccine/
38 exp immunization/
39 influenza vaccination/ or vaccination/
40 (vaccin* or immuni* or inocula* or shot or jab).tw.
41 or/37-40
42 36 and 41
43 influenza vaccination/

44 immunological adjuvant/
45 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).tw.
46 or/42-45
47 intramuscular drug administration/
48 (intramuscular or intra-muscular).tw.
49 47 or 48
50 46 and 49
51 limit 50 to yr="2009 -Current"
52 animals/ not humans/
53 51 not 52
54 ad.fs.
55 49 or 54
56 46 and 55
57 dose response/ or drug response/
58 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).tw.
59 ((reduc* or lower or less) adj2 (quantity or strength or standard)).tw.
60 ((dos* adj3 change) or (half adj3 dos*)).tw.
61 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).tw.
62 or/57-61
63 56 and 62
64 animals/ not humans/
65 63 not 64
66 limit 65 to yr="2009 -Current"
67 53 or 66
68 67 use emczd
69 33 or 68
70 remove duplicates from 69

APPENDIX 3 – Cochrane search strategy

Database: Database: EBM Reviews - Cochrane Database of Systematic Reviews <2005 to June 03, 2020>, EBM Reviews - ACP Journal Club <1991 to May 2020>, EBM Reviews - Database of Abstracts of Reviews of Effects <1st Quarter 2016>, EBM Reviews - Cochrane Clinical Answers <May 2020>, EBM Reviews - Cochrane Central Register of Controlled Trials <May 2020>, EBM Reviews - Cochrane Methodology Register <3rd Quarter 2012>, EBM Reviews - Health Technology Assessment <4th Quarter 2016>, EBM Reviews - NHS Economic Evaluation Database <1st Quarter 2016>
Search Strategy:
----

1 (influenza, human or influenza a virus or influenzavirus b or influenzavirus c).kw.
2 (flu or flue or influenza* or grippe).ti,ab.
3 1 or 2
4 (Vaccines or Immunization).kw.
5 (vaccin* or immuni* or inocula* or shot or jab).ti,ab.
6 4 or 5
7 3 and 6
8 (influenza vaccines or Adjuvants, Immunologic).kw.
9 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).ti,ab.
10 7 or 8 or 9
11 Injections, Intramuscular.kw.
12 (intramuscular or intra-muscular).ti,ab.
13 11 or 12
14 10 and 13
15 dose-response relationship, immunologic.kw.
16 dose-Response Relationship, Drug.kw.
17 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).ti,ab.
18 ((reduc* or lower or less) adj2 (quantity or strength or standard)).ti,ab.
19 ((dos* adj3 change) or (half adj3 dos*)).ti,ab.
20 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).ti,ab.
21 or/15-20
22 10 and 21
23 14 or 22
24 limit 23 to yr="2009 -Current" [Limit not valid in DARE; records were retained]

Database: EBM Reviews - Cochrane Database of Systematic Reviews <2005 to June 03, 2020>, EBM Reviews - ACP Journal Club <1991 to May 2020>, EBM Reviews - Database of Abstracts of Reviews of Effects <1st Quarter 2016>, EBM Reviews - Cochrane Clinical Answers <May 2020>, EBM Reviews - Cochrane Central Register of Controlled Trials <May 2020>, EBM Reviews -

Cochrane Methodology Register <3rd Quarter 2012>, EBM Reviews - Health Technology Assessment <4th Quarter 2016>, EBM Reviews - NHS Economic Evaluation Database <1st Quarter 2016>
Search Strategy:

---

1 (influenza, human or influenza a virus or influenzavirus b or influenzavirus c).kw.
2 (flu or flue or influenza* or grippe).ti,ab.
3 1 or 2
4 (Vaccines or Immunization).kw.
5 (vaccin* or immuni* or inocula* or shot or jab).ti,ab.
6 4 or 5
7 3 and 6
8 (influenza vaccines or Adjuvants, Immunologic).kw.
9 (LAIV or Fluenz or FluMist or Afluria or Fluad or Fluzone or Flulaval or Fluarix or Flublok or Flucelvax or FluQuadri or Vaxigrip or Influvac or Fluvirin or Agrippal or Begrivac or Fluad or agriflu or fluviral).ti,ab.
10 7 or 8 or 9
11 Injections, Intramuscular.kw.
12 (intramuscular or intra-muscular).ti,ab.
13 11 or 12
14 10 and 13
15 dose-response relationship, immunologic.kw.
16 dose-Response Relationship, Drug.kw.
17 (Dos* sparing or Dose -sparing or half-dose or dose-response or dose response or dose effect* or dose-effect* or fractional dos*).ti,ab.
18 ((reduc* or lower or less) adj2 (quantity or strength or standard)).ti,ab.
19 ((dos* adj3 change) or (half adj3 dos*)).ti,ab.
20 ((down adj3 titrat*) or (dose adj3 titrat*) or (dose adj3 reduc*) or (dose adj3 "de-escalat*") or (dose adj3 taper*)).ti,ab.
21 or/15-20
22 10 and 21
23 14 or 22
24 limit 23 to yr="2000 - 2008" [Limit not valid in DARE; records were retained]
25 from 24 keep 1-173

APPENDIX 4 – List of eligible vaccines

Product name (manufacturer)	Vaccine Characteristic				
	Vaccine type	Route of administration	Authorized ages for use	Antigen content for each vaccine strain	Formats available
Flulaval Tetra (GSK)	IIV4-SD (split virus)	IM	6 months and older	15 µg HA /0.5 mL dose	5 mL multi-dose vial Single dose pre-filled syringe
Fluzone Quadrivalent (Sanofi Pasteur)	IIV4-SD (split virus)	IM	6 months and older	15 µg HA /0.5 mL dose	5 mL multi-dose vial Single dose vial Single dose pre-filled syringe without attached needle
Afluria Tetra (Seqirus)	IIV4-SD (split virus)	IM	5 years and older	15 µg HA /0.5 mL dose	Up to expiry date indicate on vial label
Influvac Tetra (BGP Pharma ULC, operating as Mylan)	IIV4-SD (subunit)	IM or deep subcutaneous injection	3 years and older	15 µg HA /0.5 mL dose	Single dose pre-filled syringe with or without a needle
VaxigripTetra	IIV4	IM	6 months and older	Pediatric: 7.5 µg HA /0.25 mL dose Adult: 15 µg HA /0.5 mL dose	0.5 mL pre-filled syringe
Fluarix Tetra/ Influsplit Tetra (GSK)	IIV4	IM	6 months and older	15 µg HA /0.5 mL dose	0.5 mL pre-filled syringe
Agriflu (Seqirus)	IIV3-SD (subunit)	IM	6 months and older	15 µg HA /0.5 mL dose	5 mL multi-dose vial Single dose pre-filled syringe without attached needle
Fluad Pediatric and Fluad (Seqirus)	IIV3-Adj (subunit)	IM	Pediatric: 6-23 months Adult: 65 years and older	Pediatric: 7.5 µg HA /0.25 mL dose Adult: 15 µg HA /0.5 mL dose	Single dose pre-filled syringe without a needle
Fluviral (GSK)	IIV3-SD (split virus)	IM	6 months and older	15 µg HA /0.5 mL dose	5 mL multi-dose vial
Fluzone TIV (Sanofi Pasteur)	IIV3-HD (split virus)	IM	65 years and older	Adult: 15 µg HA /0.5 mL dose	0.5 mL pre-filled syringe
Vaxigrip TIV	IIV3-SD	IM	6 months and older	Pediatric: 7.5 µg HA /0.25 mL dose Adult: 15 µg HA /0.5 mL dose	0.5 mL pre-filled syringe

Note: list of vaccines included in the review is based on feedback from PHAC and the 2020-2021 seasonal vaccine availability in Canada found here: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2020-2021.html#appA

APPENDIX 5 – Excluded dose-sparing studies

	Reference	Reason for exclusion
1	Euctr, H. U. A Randomized, Double-blind, Multi-Center Study to Evaluate Safety and Immunogenicity of One Dose of Four FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccines Containing 3.5[micro]gHA, 6[micro]gHA, 9[micro]gHA or 1. 2011. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=EUCTR2011	exclude - dose-sparing but vaccine not of interest
2	Vajo Z, Tamas F, Jankovics I. A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial. *Clin Vaccine Immunol*. 2012;19(3):313-318. doi:10.1128/CVI.05619-11	exclude - dose-sparing but vaccine not of interest
3	Treanor J, Keitel W, Belshe R, et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002;20(7-8):1099-1105. doi:10.1016/s0264-410x(01)00440-6	exclude - dose-sparing but vaccine not of interest
4	Euctr. A Randomized, Active Controlled, Double-blind, Multi-Centre Study to Evaluate Safety and Immunogenicity of One Dose of FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccine Containing 6µgHA of Seasonal A/H1N1, A/H3N2 and B Influenza Antigens in Non-elderly Adult and Elderly Subjects. 2011. Available from: http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011-003314-16-HU	exclude - dose-sparing but experimental vaccine
5	Euctr, E. S. Clinical study to compare the safety of two influenza vaccines in children and adolescents of 3 to less than 18 years of age at risk for influenza-related complications. 2013. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=EUCTR2013	exclude - dose-sparing but experimental vaccine
6	Pillet S, Aubin É, Trépanier S, et al. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol. 2016;168:72-87. doi:10.1016/j.clim.2016.03.008	exclude - dose-sparing but experimental vaccine
7	Lee JH, Cho HK, Kim KH, et al. Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months. J Korean Med Sci. 2019;34(46):e279. Published 2019 Dec 2. doi:10.3346/jkms.2019.34.e279	exclude - dose-sparing but experimental vaccine
8	Treanor JJ, Taylor DN, Tussey L, et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine. 2010;28(52):8268-8274. doi:10.1016/j.vaccine.2010.10.009	exclude - dose-sparing but experimental vaccine
9	Vajo Z, Balaton G, Vajo P, Kalabay L, Erdman A, Torzsa P. Dose sparing and the lack of a dose-response relationship with an influenza vaccine in adult and elderly patients - a randomized, double-blind clinical trial. Br J Clin Pharmacol. 2017;83(9):1912-1920. doi:10.1111/bcp.13289	exclude - dose-sparing but vaccine not of interest
10	Ctri. Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India. 2015. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=CTRI	exclude - dose-sparing but unclear vaccine (waiting for author response)
11	Euctr, F. I. Safety and Immunogenicity of the Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Children Aged 3 to 8 Years. 2011. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=EUCTR2011	exclude - dose-sparing but unclear vaccine (waiting for author response)
12	Euctr, C. Z. A randomized, double-blind, placebo-controlled, multi-country and multi-center, phase IV study to demonstrate the efficacy of GSK Biologicals' influenza vaccine (Fluarix[TM])	exclude - dose-sparing but unclear vaccine (waiting for author response)

	administered intramuscularly in adults. - FluarixUS-006. 2006. Available from: http://www. who. int/trialsearch/Trial2. aspx?TrialID=EUCTR2006	

APPENDIX 6 – Study and patient data

Author, Year [Study design]	Study period; Setting and Country	Objective of study	Eligibility criteria	Sample size; % Female, % previously immunized	Ethnicities
Kramer, 2006 [RCT][1]	October 2004 – November 2004; 760-bed tertiary care community teaching hospital in the USA	To compare the effectiveness of half-dose versus full dose TIV in health care workers	Age 18 years or older, hospital employee, staff member, or volunteer, and signed informed consent and authorization to use and disclose protected health information for research purposes	444; NR, NR	NR
Belshe, 2007 [RCT][2]	USA; NR	To compare the immunogenicity and safety of injection of IM and ID TIV across different dose levels (3, 6, 9, and 15µg/antigen/dose)	Healthy adults 18-49 years of age	125; 71.2%, 0%	American Indian/Alaskan Native (0%), Asian (2.4%), Black/African American (9.6%), Hawaiian/Pacific Islander (0%), Hispanic (0%), Multi-racial (0.8%), Non-Hispanic (97.6%), Other/unknown (0%), White (87.2%)
Engler, 2008 [RCT][3]	November 2004 – December 2004; Allergy-Immunology-Immunization Clinic, WRAMC, and Pentagon/DiLorenzo Health Clinic, Arlington, Virginia in the USA	To determine the effects of age, sex, and dose on the immunogenicity of intramuscular TIV	Healthy adults aged 18-64 years. Inclusion criteria were based on the remaining CDC and/or DoD priority prior to the shortage announcement which includes all children aged 6--23 months; adults aged >65 years; persons aged 2--64 years with underlying chronic medical conditions; all women who will be pregnant during the influenza season; residents of nursing homes and long-term--care facilities; children aged 2--18 years on chronic aspirin therapy; health-care workers involved in direct patient care; and out-of-home caregivers and household contacts of children aged <6 months	1316; 43.4%, 0%	African American (9%), Asian (2%), Hispanic (2%), Other/unknown (1.4%), White (85%)
	August 2007-2008; Seattle Division of the Department of	To determine pre vaccination and 4- week post-vaccination changes in antibody titer, and	Community-dwelling adults 65 years and older living in Puget Sound area in Washington State	129; 17.8%, 94.6%	African American (4.7%), Asian (1.6%), Hispanic (0.8%), Not reported

Author, Year [Study design]	Study period; Setting and Country	Objective of study	Eligibility criteria	Sample size; % Female, % previously immunized	Ethnicities
Chi, 2010 [RCT][4]	Veterans Affairs Puget Sound Health Care System in Washington State, USA.	local and systemic reactions of full-dose compared to 60% dose of TIV by IM injection			(2.3%), Other (0.8%), White (90%)
Cioppa, 2011 [RCT][5]	October 2008 – March 2009; 10 study centers in Finland and 5 centers in Belgium	To evaluate the safety, tolerability and immunogenicity of different vaccine formulations with different doses of MF59 adjuvant and/or a second B strain (QIV) when added to either high or low doses of a purified subunit influenza vaccine	Healthy children aged 6 to <36 months	126; 43.5%, NR	Asian (1.68%), Black (6.54%), White (84.2%)
Skowronski, 2011 [RCT][6]	September 2008 – December 2008; 5 sites in 3 Canadian provinces (British Columbia, Quebec, and Nova Scotia)	To determine whether giving 2 full doses of split TIV to previously unimmunized infants and toddlers can improve immunogenicity without increasing reactogenicity compared with 2 half-doses	Healthy children 6–23 months of age	267; 53.2%, 0%	Asian (7.9%), Other (14.3%), White (77.8%)
Langley, 2012 [RCT][7]	November 2008 – August 2009; 17 centers in Canada	To assess the immunogenicity and safety of a preservative-free, prefilled syringe formulation of TIV provided as the full adult dose of 0.50 mL compared with the usual children's dose of 0.25 mL in young children	Healthy children 6–35 months at the time of vaccination	390; 47.9%, 42.6%	Other (13.9%), White (86.1%)
Pavia-Ruz, 2015 [RCT][8]	October 2008 – March 2009; Hong Kong, Mexico, Taiwan, Thailand, and the USA	To evaluate Fluarix at both the standard recommended TIV dose for young children in the US (0.25 ml) and also at double this dose (0.5 ml)	Healthy children aged 6 to 35 months at the time of the first vaccination; without acute illness at the time of enrollment and who had not been vaccinated during the 2008-2009 influenza season. Administration of influenza vaccine in a previous season was not however an exclusion criteria	3318; 51%, 30.1%	African heritage/African American (3.5%), American Indian or Alaskan native (0.1%), Asian-Central/South Asian heritage (0.1%), Asian-East Asian heritage (14.5%), Asian-Japanese heritage (0.1%), Asian-South East Asian heritage

Author, Year [Study design]	Study period; Setting and Country	Objective of study	Eligibility criteria	Sample size; % Female, % previously immunized	Ethnicities
					(9.2%), Native Hawaiian or other Pacific Islander (0.2%), White - Arabic/North African heritage (0.5%), White-Caucasian/European heritage (29.9%), Hispanics and children of mixed race (42.1%)
Halasa, 2015 [RCT][9]	2010-2012; 6 study sites in USA	To determine whether a higher dose of influenza vaccine would be safe in the 6 through 35 months age group. In addition, to determine whether immunization with 0.5 mL doses of TIV (15 µg of each HA) would improve the immunogenicity without increasing the reactogenicity of TIV when administered to children 6 through 35 months of age with and without a history of previous TIV vaccination	Healthy children 6 to 35 months of age (naïve cohort) or 12 through 35 months of age (fully primed cohort) who were available for the entire study period and whose parents or guardians provided informed consent were eligible to participate. Children who were eligible in the fully primed cohort also required a history of receiving 2 doses of 2009–2010 H1N1 influenza vaccine and 2 doses of TIV at any time in the past	243; 52%, 13.2%	African (26%), Asian (1%), Multiracial (5%), other (0%); Ethnicity: Hispanic (2%), Non-Hispanic (98%), White (67%)
Phung, 2016 [RCT][10]	September 2010-January 2011; Finland	To evaluate the immunogenicity and safety following a single intramuscular dose of FLUAD or Agrippal S1 influenza vaccines in healthy children previously vaccinated	Healthy children 6–35 months at the time of vaccination	197; 55.8%, 85.7%	NR
Jain, 2017 [RCT][11]	2014-2015 influenza season; 66 study locations in USA and Mexico	To compare the safety and immunogenicity of a double-dose IIV4 manufactured by GSK Vaccines with the United States-approved standard-dose IIV4 in children 6–35 months of age	Healthy children aged 6-35 months regardless of influenza vaccination history, but could not have received any seasonal or pandemic influenza vaccine within 6 months before the first dose of study vaccine	2424; 46.9%, 57.5%	African/African American (13.9%), American Indian or Alaskan Native (2.0%), Caucasian (64.3%), Other (17.9%), South East Asian (1.8%)
Ojeda, 2019 [RCT][12]	December 2017 – January 2018; 3 study sites in Mexico	Reported the results of an open-label, randomized phase III study designed to evaluate the immunogenicity and safety	Children aged 6 months to 17 years of age	302; 46.4%, NR	NR

Author, Year [Study design]	Study period; Setting and Country	Objective of study	Eligibility criteria	Sample size; % Female, % previously immunized	Ethnicities
		of this thiomersal containing MDV format of QIV compared to the licensed thiomersal-free, single-dose PFS format in children and adolescents			
Robertson, 2019 [RCT][13]	September 2016 – March 2017; 38 sites in the USA	To compare the safety and immunogenicity of full and half doses of quadrivalent, split-virion, inactivated influenza vaccine in children 6–35 months of age	Healthy children 6–35 months of age who had not been vaccinated against influenza during the current season (2016–2017). Children 6–11 months of age had to be born at full term of pregnancy (≥37 weeks) or with a birth weight ≥2.5 kg	1950; 49.7%, 47.3%	Race: American Indian or Alaska Native (0.98%), Asian (0.46%), Black (19.2%), Native Hawaiian or Other Pacific Islander (0.46%), White (74.3%), Ethnicity: Hispanic or Latino (22%), not Hispanic or Latino (77%)

Abbreviations: CDC- Centers for Disease Control and Prevention; DoD- Department of Defense; GSK -GlaxoSmithKline; HA-hemagglutinin; IIV4 – inactivated influenza vaccine; ID - intradermal; IM - intramuscular; MDV- multi-dose vial; PFS – pre-filled syringe; QIV-quadrivalent influenza vaccine; TIV-trivalent influenza vaccine; NR – not reported

APPENDIX 7 – Treatment and outcome data

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
Kramer, 2006 [RCT][1] *Adults and Seniors (>18 years)*	Fluzone (Aventis Pasteur), **15-µg/strain** [1 x 0.5mL dose (Intramuscular into the deltoid region)] *A/Wyoming/3/2003 (H3N2), A/New Caledonia/20/99 (H1N1), and a new B strain, B/Jiangsu/10/2003*	**Effectiveness** *Lab confirmed influenza* (Laboratory confirmation of influenza diagnosis was sought in participants reporting a clinical diagnosis by their physicians): 1/222 *Influenza like illness* (Clinical diagnosis of influenza. Participants self-reported four or more symptoms consistent with influenza-like illness (i.e., headache, extreme tiredness, dry cough, fever, muscle or body aches)): 8/222	▪ There was no significant difference between the full-dose and half-dose groups in the diagnosis of influenza or in the proportion of participants self-reporting four or more symptoms consistent with influenza-like illness. ▪ No adverse events were noted by participants from either group or reported to the IRB during the course of the study
	Fluzone (Aventis Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (Intramuscular into the deltoid region)] *A/Wyoming/3/2003 (H3N2), A/New Caledonia/20/99 (H1N1), and a new B strain, B/Jiangsu/10/2004*	**Effectiveness** *Lab confirmed influenza* (Laboratory confirmation of influenza diagnosis was sought in participants reporting a clinical diagnosis by their physicians): 0/222 *Influenza like illness* (Clinical diagnosis of influenza. Participants self-reported four or more symptoms consistent with influenza-like illness (i.e., headache, extreme tiredness, dry cough, fever, muscle or body aches)): 15/222	
Belshe, 2007 [RCT][2] *Adults (18-49 years)*	Fluzone (Sanofi-Pasteur), **15-µg/strain** [1 x 0.5mL dose (Intramuscular in the non-dominant arm)]	**Reactogenicity – injection site** *Pain*[1]: 15/31 *Redness*[2]: 8/31 *Swelling*[2] :7/31 **Reactogenicity – systemic** *Fever*[3]: 1/31 *Headache*[1]: 15/31 *Malaise*[1]: 8/31 *Myalgia*[1]: 10/31	▪ Intradermal vaccine induced significantly more local inflammatory response than Intramuscular vaccine (primary comparison of this study was ID vs IM doses)
	Fluzone (Sanofi-Pasteur), **9-µg/strain** [1 x 0.3mL dose (Intramuscular in the non-dominant arm)]	**Reactogenicity – injection site** *Pain*[1]: 11/31 *Redness*[2]: 11/31 *Swelling*[2] :4/31 **Reactogenicity – systemic** *Fever*[3]: 1/31 *Headache*[1]: 6/31	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Malaise[1]: 8/31 *Myalgia*[1]: 6/31	
	Fluzone (Sanofi-Pasteur), **6-µg/strain** [1 x 0.2mL dose (Intramuscular in the non-dominant arm)]	**Reactogenicity – injection site** *Pain*[1]: 14/31 *Redness*[2]: 9/31 *Swelling*[2] :4/31 **Reactogenicity – systemic** *Fever*[3]: 0/31 *Headache*[1]: 9/31 *Malaise*[1]: 7/31 *Myalgia*[1]: 9/31	
	Fluzone (Sanofi-Pasteur), **3-µg/strain** [1 x 0.[1mL dose (Intramuscular in the non-dominant arm)]	**Reactogenicity – injection site** *Pain*[1]: 15/31 *Redness*[2]: 9/31 *Swelling*[2]:7/31 **Reactogenicity – systemic** *Fever*[3]: 3/31 *Headache*[1]: 8/31 *Malaise*[1]: 3/31 *Myalgia*[1]: 7/31	
Engler, 2008 [RCT][3] *Adults (18-64 years)*	Fluzone (Aventis Pasteur), **15-µg/strain** [1 x 0.5mL dose (Intramuscular injection)] *A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002*	**Effectiveness** *Influenza like illness* (Influenza-like illness and complications resulting in either inpatient or outpatient medical encounters were compared between dose groups (by age)): 61/632 *Hospitalization or Emergency visits*: 0.3% **Reactogenicity – local/injection site** *Any local reactions* (NR): 8.9% *Arm weakness* (NR): 8.3% *Numbness or burning* (NR): 9.7% *Pain* (NR): 5.9% *Redness or swelling* (NR): 13.4% **Reactogenicity – systemic** *Joint and/or muscle pain* (NR): 4.5%	▪ The relative risk of medical visits and hospitalizations for influenza-like illnesses were similar in the half- and full-dose group regardless of age, and there was no evidence of ILI symptom differences by sex or dose during the 21 days after immunizations. ▪ Although injection site pain was greater for full vs half dose (19.9% vs 14.4%; p=.01), when analyzed for clinically significant pain levels significant dose-dependent

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Adverse events *SAE*: 2/554	pain differences were not identified. ▪ Joint and/or muscle pain were significantly different (p=.02 and p=.03, respectively) by dose. ▪ No other adverse event differed significantly by dose
	Fluzone (Aventis Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (Intramuscular injection)] *A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2003*	**Effectiveness** *Influenza like illness* (Influenza-like illness and complications resulting in either inpatient or outpatient medical encounters were compared between dose groups (by age): 64/644 *Hospitalization or Emergency visits*: 0.2% **Reactogenicity – local/injection site** *Any local reactions* (NR): 7.5% *Arm weakness* (NR): 6.5% *Numbness or burning* (NR): 7.8% *Pain* (NR): 4.6% *Redness or swelling* (NR): 8.6% **Reactogenicity – systemic** *Joint and/or muscle pain* (NR): 2.2% **Adverse events** *SAE*: 1/556	
Chi, 2010 [RCT][4] *Seniors (>65 years)*	Fluzone (Sanofi Pasteur), **15-µg/strain** [1 x 0.5mL dose (intramuscular in deltoid of arm)] *A/Solomon Islands/3/ 2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), and B/Malaysia/2506/2004*	**Reactogenicity – injection site, N=64** *Arm motion limitation*: 1 (grade I)[4] *Itching:* 4 (grade I)[4] *Pain:* 7 (grade I)[4] *Redness or discoloration:* 9 (grade I)[4] *Swelling:* 13 (grade I)[4] **Reactogenicity - systemic, N=64** *Chills:* 1 (grade I)[4], 1 (grade II/III)[5] *Fatigue:* 4 (grade I)[4], 2 (grade II/III)[5] *Fever:* 0 *General body ache/pain:* 6 (grade I)[4], 1 (grade II/III)[5] *Headache:* 10 (grade I)[4] *Nausea:* 3 (grade I)[4], 1 (grade II/III)[5] **Adverse events**	▪ The two SAEs were acute coronary syndrome and appendicitis and neither were judged to be related to influenza vaccination

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		SAE[6]: 0/64	
	Fluzone (Sanofi Pasteur), **9-µg/strain** [1 x 0.3mL dose (intramuscular in deltoid of arm)] *A/Solomon Islands/3/ 2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), and B/Malaysia/2506/2004*	**Reactogenicity – injection site, N=64** *Arm motion limitation:* 1 (grade I)[4] *Itching:* 5 (grade I)[4] *Pain:* 11 (grade I)[4] *Redness or discoloration:* 7 (grade I)[4] *Swelling:* 4 (grade I)[4] **Reactogenicity - systemic, N=64** *Chills:* 1 (grade I)[4], 1 (grade II/III)[5] *Fatigue:* 6 (grade I)[4], 1 (grade II/III)[5] *Fever:* 1 (grade I)[4] *General body ache/pain:* 5 (grade I)[4], 2 (grade II/III)[5] *Headache:* 5 (grade I)[4], 1 (grade II/III)[5] *Nausea:* 2 (grade I)[4], 1 (grade II/III)[5] **Adverse events** *SAE*[6]*:* 2/64	
Cioppa, 2011 [RCT][5] *Infants/ Toddlers (6-36 months)*	NR - TIV, **7.5-µg/strain** [2 x 0.25mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)] *A/Brisbane/59/2007 (A/H1N1)-like virus, A/Brisbane/10/2007 (A/H3N2)-like virus, and B/Florida/4/2006-like virus (of the influenza B/Yamagata lineage)*	**Reactogenicity** *Any local reaction*[7]: 47% *Any systemic reaction*[8]: 68% **Adverse events** *AE* (solicited/spontaneously reported): 84% *SAE*: 0/25	▪ Reactogenicity of the 7.5-µg TIV/QIV formulations was slightly lower than for the corresponding 15-µg formulations. ▪ The majority of unsolicited AEs were mild or moderate in severity and none of the SAEs was considered to be related to the study vaccine.
	Agrippal - TIV, **15-µg/strain** [2 x 0.5mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)] *A/Brisbane/59/2007 (A/H1N1)-like virus, A/Brisbane/10/2007 (A/H3N2)-like virus, and B/Florida/4/2006-like virus (of the influenza B/Yamagata lineage)*	**Reactogenicity** *Any local reaction*[7]: 59% *Any systemic reaction*[8]: 50% **Adverse events** *AE* (solicited/spontaneously reported): 82% *SAE*: 0/22	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
	NR - QIV, **7.5-µg/strain** [2 x 0.25mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)] *A/Brisbane/59/2007 (A/H1N1)-like virus, A/Brisbane/10/2007 (A/H3N2)-like virus, B/Florida/4/2006-like virus (of the influenza B/Yamagata lineage), and B/Malaysia/2506/2004-like antigen virus (Victoria lineage)*	**Reactogenicity** *Any local reaction*[7]: 25% *Any systemic reaction*[8]: 50% **Adverse events** *AE* (solicited/spontaneously reported): 92% SAE: 1/25	
	NR - QIV, **15-µg/strain** [2 x 0.5mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)] *A/Brisbane/59/2007 (A/H1N1)-like virus, A/Brisbane/10/2007 (A/H3N2)-like virus, B/Florida/4/2006-like virus (of the influenza B/Yamagata lineage), and B/Malaysia/2506/2004-like antigen virus (Victoria lineage)*	**Reactogenicity** *Any local reaction*[7]: 39% *Any systemic reaction*[8]: 54% **Adverse events** *AE* (solicited/spontaneously reported): 71% *SAE*: 1/28	
	Vaxigrip pediatric - TIV (Sanofi Pasteur), **7.5-µg/strain** [2 x 0.25mL dose (intramuscular in deltoid of arm (children 24-35 mo of age) or the anterolateral aspect of the thigh (children <24 mo of age) using prefilled syringes)]	**Reactogenicity** *Any local reaction*[7]: 50% *Any systemic reaction*[8]: 46% **Adverse events** *AE* (solicited/spontaneously reported): 73% *SAE*: 1/26	
Skowronski, 2011 [RCT][6] *Infants/ Toddlers (6-23 months)*	Vaxigrip (Sanofi-Pasteur), 15-µg/strain **[2 x 0.5mL dose** (Intramuscular injection)] *A/Brisbane/10/07 (H3N2); A/Brisbane/59/07 (H1N1); and B/Florida/4/06 (Yamagata lineage)*	**Reactogenicity – injection site** *Induration* (NR): 13.7% *Redness* (NR): 22.6% *Swelling* (NR): 15.3% *Tenderness* (NR): 22.6% **Reactogenicity – systemic** *Fever* (>37.5°C): 8.06% *Irritability* (NR): 59.7% *Decreased appetite* (NR): 38.7%	▪ Local reactions generally were less common in infants than toddlers and more common with full doses versus half doses, but none of these differences were significant. ▪ One serious adverse event was reported: a toddler in the half dose group was

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Drowsiness (NR): 39.5% *Sleep disturbance* (NR): 54.8% **Adverse events** *SAE:* NR	hospitalized with pneumonia 28 days after the first vaccination. The event was deemed unlikely related to the vaccine.
	Vaxigrip (Sanofi-Pasteur), 15-µg/strain **[2 x 0.25mL dose** (Intramuscular injection)] *A/Brisbane/10/07 (H3N2); A/Brisbane/59/07 (H1N1); and B/Florida/4/06 (Yamagata lineage)*	**Reactogenicity – injection site** *Induration* (NR): 6.3% *Redness* (NR): 20.3% *Swelling* (NR): 8.6% *Tenderness* (NR): 25.8% **Reactogenicity – systemic** *Fever* (>37.5°C): 11.7% *Irritability* (NR): 60.2% *Decreased appetite* (NR): 43% *Drowsiness* (NR): 41.4% *Sleep disturbance* (NR): 50% **Adverse events** *SAE:* 1/128	▪ All of the rate differences were significantly below the allowed 10% increase in reactogenicity for the full dose ($p < 0.001$ for infant and combined analyses, $p < .005$ for toddlers). ▪ This randomized controlled trial in infants and toddlers shows that compared with 0.25-mL half-dosing, administration of 2 full 0.5-mL doses of trivalent inactivated influenza vaccine can increase antibody response without increasing reactogenicity in previously unimmunized infants aged 6 to 11 months.
Langley, 2012 [RCT][7] *Infants/ Toddlers (6-35 months)*	Fluviral F1 (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (Intramuscularly in the anterolateral part of the thigh (if the participant was less than 12 months) or in the deltoid region of the arm)] *A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (an A/Brisbane/10/2007 [H3N2]–like virus), and B/Florida/4/2006*	**Reactogenicity – injection site** *Pain* (NR): 45/164 *Redness* (NR): 49/164 *Swelling* (NR): 22/164 **Reactogenicity – systemic** *Drowsiness* (NR) – 44/164 *Fever* (NR) – 10/164 *Irritability* (NR) – 62/164 *Loss of appetite* (NR) – 37/164 **Adverse events** *SAE:* 1/164	▪ Fluviral F1 group had 1 case of pneumonia resolved ▪ Fluviral F2 group had 1 case of bronchial hyper-reactivity in resolving stage ▪ The 0.5-mL dose of the study vaccine, when administered to children aged 6–35 months, resulted in a modest but not statistically significant improvement in

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Unsolicited adverse events (NR): 108/164 *Medically attended events* (NR): 52/164	immunogenicity with clinically similar safety and reactogenicity compared with the 0.25-mL dose.
	Fluviral F2 (Sanofi-Pasteur), **15-µg/strain** [1 x 0.5mL dose (Intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm)] *A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (an A/Brisbane/10/2007 [H3N2]–like virus), and B/Florida/4/2006*	**Reactogenicity – injection site** *Pain* (NR): 55/167 *Redness* (NR): 54/167 *Swelling* (NR): 24/167 **Reactogenicity – systemic** *Drowsiness* (NR) – 52/167 *Fever* (NR) – 6/167 *Irritability* (NR) – 69/167 *Loss of appetite* (NR) – 43/167 **Adverse events** *SAE*: 1/167 *Unsolicited adverse events* (NR): 112/167 *Medically attended events* (NR): 40/167	
	Vaxigrip (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (Intramuscularly in the anterolateral part of the thigh (if the participant was less than 12 months) or in the deltoid region of the arm)] A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (an A/Brisbane/10/2007 [H3N2]–like virus), and B/Florida/4/2006	**Reactogenicity – injection site** *Pain* (NR): 17/43 *Redness* (NR): 13/43 *Swelling* (NR): 5/43 **Reactogenicity – systemic** *Drowsiness* (NR) – 11/43 *Fever* (NR) – 2/43 *Irritability* (NR) – 15/43 *Loss of appetite* (NR) – 9/43 **Adverse events** *SAE:* NR/43 *Unsolicited adverse events* (NR): 24/43 *Medically attended events* (NR): 9/43	
Pavia-Ruz, 2013 [RCT][8] *Infants/ Toddlers*	Fluarix (GSK), **15-µg/strain** [1 x 0.5mL dose (intramuscular injection into the right deltoid muscle or anterolateral thigh)]	**Reactogenicity – injection site** *Any injection site reactions*[9]: 514/1086 *Pain:* 406/1086 *Redness*: 249/1086 *Swelling:* 170/1086	▪ The reactogenicity and safety profile of the study vaccine did not appear to be affected by doubling the dose.

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
(6-35 months)	*A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) and B/Brisbane/3/2007*	**Reactogenicity – systemic** *Any general reactions*[10]: 575/1086 *Drowsiness:* 317/1086 *Fever:* 69/1086 *Irritability:* 387/1086 *Loss of appetite:* 273/1086 **Adverse events** *Any AE*: 729/1086 *SAE*: 29/1086	▪ One subject in the Flu-15µg group had two SAEs, (apnea and cyanosis) which were considered by the investigator to be possibly related to vaccination. The participant was hospitalized and the events resolved on the same day as they occurred.
	Fluarix (GSK), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular injection into the right deltoid muscle or anterolateral thigh)] *A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) and B/Brisbane/3/2007*	**Reactogenicity – injection site** *Any injection site reactions*[9]: 492/1081 *Pain:* 403/1081 *Redness*: 259/1081 *Swelling:* 152/1081 **Reactogenicity – systemic** *Any general reactions*[10]*:* 598/1081 *Drowsiness:* 293/1081 *Fever:* 67/1081 *Irritability:* 386/1081 *Loss of appetite:* 281/1081 **Adverse events** *Any AE*: 724/1081 *SAE*: 35/1081	
	Fluzone (Sanofi-Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular injection into the right deltoid muscle or anterolateral thigh)] *A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) and B/Florida/4/2006*	**Reactogenicity – injection site** *Any injection site reactions*[9]*:* 467/1090 *Pain:* 363/1090 *Redness:* 253/1090 *Swelling:* 129/1090 **Reactogenicity – systemic** *Any general reactions*[10]: 592/1090 *Drowsiness:* 298/1090 *Irritability:* 375/1090 *Fever:* 72/1090 *Loss of appetite:* 270/1090	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
		Adverse events *Any AE:* 722/1090 *SAE:* 31/1090	
Halasa, 2015 [RCT][9] *Infants/ Toddlers (6-35 months)*	Fluzone (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular)] *A/California/7/09 (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/ 60/2008-like virus*	**Reactogenicity** *Redness at injection site*: 8/48 *Fever* (temperature >39°C after the first dose): 7/80	▪ No significant differences between the full-dose or half-dose groups for either the fully primed or naive cohorts for systemic reactions or local reactions when both seasons were combined. ▪ The only significant difference in the 2011–2012 season was that 8 of 48 (16.7%) participants in the half-dose group compared with 32 of 96 (33.3%) in the full-dose group had increased redness at the injection site (P < .05). ▪ No significant differences between the groups in unsolicited AEs, serious adverse events (SAEs), or onset of chronic medical conditions between the dose groups in either the naive or fully primed cohorts, and none of the SAEs were deemed related to the vaccine.
	Fluzone (Sanofi Pasteur), **15-µg/strain** [1 x 0.5 mL dose (intramuscular)] *A/California/7/09 (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/ 60/2008-like virus*	**Reactogenicity** *Redness at injection site*: 32/96 *Fever* (temperature >39°C after the first dose): 19/161	
Phung, 2016 [RCT][10] *Infants/ Toddlers (6-35 months)*	FLUAD (NR), NR [**1 x 0.5mL dose** (Intramuscular injection)] *A/H1N1, A/H3N2, Strain B*	**Reactogenicity** *Any local reaction*[11]: 45/61 *Any systemic reaction*[12]: 36/61 **Adverse events** *SAE* (based on MedDRA v 17.1 definition): 2/61	
	FLUAD (NR), NR [**1 x 0.25 mL dose** (Intramuscular injection)]	**Reactogenicity** *Any local reaction*[11]: 63/75	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
	A/H1N1, A/H3N2, Strain B	*Any systemic reaction*[12]: 42/75 **Adverse events** *SAE* (based on MedDRA v 17.1 definition): 2/75	
	Agrippal S1 (NR), NR [**1 x 0.5mL dose** (Intramuscular injection)] *A/H1N1, A/H3N2, Strain B*	**Reactogenicity** *Any local reaction*[11]: 42/51 *Any systemic reaction*[12]: 24/51 **Adverse events** *SAE* (based on MedDRA v 17.1 definition): 0/51	
	Agrippal S1 (NR), NR [**1 x 0.25mL dose** (Intramuscular injection)] *A/H1N1, A/H3N2, Strain B*	**Reactogenicity** *Any local reaction*[11]: 6/10 *Any systemic reaction*[12]: 5/10 **Adverse events** *SAE* (based on MedDRA v 17.1): 0/10	
Jain, 2017 [RCT][11] *Infants/ Toddlers (6-35 months)*	Flulaval Quadrivalent (GSK), **15-µg/strain** [1 x 0.5mL dose (intramuscular in deltoid region)] *A/California/7/2009 (A/H1N1), A/Texas/50/2012 (A/H3N2), B/Brisbane/60/2008 (B/Victoria), and B/Massachusetts/2/2012 (B/Yamagata)*	**Reactogenicity – injection site (within 7 days)** *Pain*: 44.0% *Redness*: 1.4% *Swelling*: 1.0% **Reactogenicity – systemic (within 7 days)** *Drowsiness:* 40.6% *Fever (>=38.0C):* 7.9% *Irritability/fussiness:* 54.4% *Loss of appetite:* 33.7% **Adverse events** *Any AE*: 45.5% *Vaccine-related AE*: 5.9% *Any SAE*[13]: 1.8% *Febrile seizures*: 0.4% *Medically attended event*[14]: 60.2%	▪ None of the febrile seizures or the SAEs were considered by the investigator to be related to vaccination ▪ Double-dose IIV4 may improve protection against influenza B in some young children and simplifies annual influenza vaccination by allowing the same vaccine dose to be used for all eligible children and adults.
	Fluzone Quadrivalent (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular in deltoid region)]	**Reactogenicity – injection site (within 7 days)** *Pain*: 40.1% *Redness:* 1.4% *Swelling*: 0.4% **Reactogenicity – systemic (within 7 days)**	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
	A/California/7/2009 (A/H1N1), A/Texas/50/2012 (A/H3N2), B/Brisbane/60/2008 (B/Victoria), and B/Massachusetts/2/2012 (B/Yamagata)	*Drowsiness:* 40.9% *Fever (>=38.0C):* 7.5% *Irritability/fussiness:* 50.5% *Loss of appetite:* 33.4% **Adverse events** *Any AE:* 44.1% *Vaccine-related AE:* 5.8% *Any SAE*[13]*:* 1.7% *Febrile seizures*: 0.3% *Medically attended event*[14]: 59.1%	
Ojeda. 2019 [RCT][12] *Infants/ Toddlers and Children (6 months – 17 years)*	Vaxigrip Tetra (Sanofi Pasteur) – **PFS**, 15-µg/strain [1 x 0.5mL dose (intramuscular or deep subcutaneous injection)] *A/Michigan/45/2015 (H1N1)pdm09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, /Brisbane/60/2008-like virus (B/Victoria lineage), and B/Phuket/3073/2013 (B/Yamagata lineage)*	**Reactogenicity, N=142** *Any injection-site reaction* (solicited within 7 days)*:* 26 (6-35mo), 16 (3-8yr), 42 (9-7yr) *Any systemic reaction* (solicited within 7 days): 25 (6-35mo), 15 (3-8yr), 35 (9-7yr) **Adverse events, N=147** *AE* (immediate unsolicited): 1 (9-17 years) *Non-serious AE:* 25 (6-35mo), 9 (3-8yr), 8 (9-7yr) *Vaccine-related non-serious AE*: 1 (9-17 years) *AE leading to study discontinuation*: 0 *SAE*: 0	▪ Solicited reactions were mostly grade 1 (mild) in intensity and resolved within 3 days. ▪ Solicited systemic reactions were reported in more infants aged 6 − 35 months in the MDV group than in the PFS group however, because the 95% CIs were overlapping, this was not thought clinically significant. ▪ None of these unsolicited AEs were considered related to a study vaccine by the investigators. ▪ There were no differences in reactogenicity or safety between the two vaccine formats. These results showed that the MDV format of QIV was as safe and immunogenic as the PFS format in infants, children, and adolescents. These findings support the use of MDV QIV
	Vaxigrip Tetra (Sanofi Pasteur) - **MDV,** 15-µg/strain [1 x 0.5mL dose (intramuscular or deep subcutaneous injection)] *A/Michigan/45/2015 (H1N1)pdm09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, /Brisbane/60/2008-like virus (B/Victoria lineage), and B/Phuket/3073/2013 (B/Yamagata lineage)*	**Reactogenicity, N=139** *Any injection-site reaction*(solicited within 7 days)*:* 27 (6-35mo), 16 (3-8yr), 26 (9-7yr) *Any systemic reaction*(solicited within 7 days): 33 (6-35mo), 13 (3-8yr), 30 (9-7yr) **Adverse events, N=150** *AE* (immediate unsolicited): 0 *Non-serious AE:* 31 (6-35mo), 14 (3-8yr), 5 (9-7yr) *Vaccine-related non-serious AE*: 0 *AE leading to study discontinuation*: 0 *SAE:* 0	

Author, Year; [Study design] *Population*	**Treatment arms** Brand name (manufacturer), HA/strain [dosing (administration)] *Included strains*	**Effectiveness and Safety** *Outcome* (definition): n/N (unless otherwise indicated)	**Conclusions**
			as a resource-saving alternative for seasonal influenza vaccination.
Robertson, 2019 [RCT][13] *Infants/ Toddlers (6-35 months)*	Fluzone Quadrivalent (Sanofi Pasteur), **15-µg/strain** [1 x 0.5mL dose (intramuscular single-dose syringes in deltoid of arm)] *A/California/07/2009 X-179A (H1N1), A/Hong Kong/4801/2014 X-263B (H3N2), B/Brisbane/60/2008 (Victoria lineage), B/Phuket/3073/2013 (Yamagata lineage)*	**Reactogenicity** *Any injection-site reaction*[15]: 533/939 *Any systemic reaction*[16]: 561/941 **Adverse events** *Vaccine-related AE* (immediate within 30 mins): 0/992 *Vaccine-related AE* (within 28 days): 30/992 *AE leading to study discontinuation*: 0/992 *SAE*: 5/992	▪ Proportions of participants reporting solicited injection-site reactions, solicited systemic reactions, vaccine-related unsolicited AEs were similar for the full- and half-dose groups ▪ None of the AEs leading to study discontinuation or the SAEs were considered related to vaccination ▪ A single AE of special interest (chronic urticaria first appearing 3 days post-vaccination and continuing for >6 weeks) was considered by the investigator to be related to vaccination ▪ In children 6–35 months of age, a full dose of IIV4 was immunogenic and had a safety profile comparable to that of a half dose with no new safety concerns observed.
	Fluzone Quadrivalent (Sanofi Pasteur), **7.5-µg/strain** [1 x 0.25 mL dose (intramuscular single-dose syringes in deltoid of arm)] *A/California/07/2009 X-179A (H1N1), A/Hong Kong/4801/2014 X-263B (H3N2), B/Brisbane/60/2008 (Victoria lineage), B/Phuket/3073/2013 (Yamagata lineage)*	**Reactogenicity** *Any injection-site reaction*[15]: 480/909 *Any systemic reaction*[16]: 533/909 **Adverse events** *Vaccine-related AE* (unsolicited within 30 mins): 1/949 *Vaccine-related AE* (unsolicited within 28 days): 29/949 *AE leading to study discontinuation*: 3/949 *SAE*: 5/949	

Abbreviations: AE – adverse events, ID – intradermal; ILI – influenza-like illness; IM – intramuscular; MDV – multi-dose vials, n – number of people with condition, N – sample size of treatment arm, NR – not reported, PFS – prefilled syringe, SAE – serious adverse events

[1] Defined as mild (easily tolerated), moderate (interferes with normal behaviour or activities), severe (incapacitating, unable to perform usual activities, may require medical attention)
[2] Present at or near the approximate point of needle entry; small <2.5cm, medium >2.5cm to <5cm, large >5cm
[3] Oral temperature >37.5 C; mild >37.5 to 38 C, moderate >38.1 to 39 C, severe >39.1 C
[4] Grade I reactions defined as “present but easily tolerated” for fatigue, muscle ache, headache, itching or pain at injection site; oral temperature >/=38 and <39 degrees Celsius; some limitation to arm motion due to stiffness or discomfort but easily tolerated; redness or swelling >/= 8cm

[5] Grade II/III reactions defined as “interferes with normal activity” to “severe and incapacitating” for fatigue, muscle ache, headache, itching or pain at injection site; oral temperature >/=39 degrees Celsius; limitation to arm motion due to stiffness or discomfort that interferes with normal activity; redness or swelling > 8cm

[6] Defined as serious adverse events resulting in hospitalization

[7] Solicited local reactions included ecchymosis, erythema, induration, swelling, and tenderness at injection site

[8] Solicited systemic reactions included sleepiness, diarrhea, vomiting, irritability, change in eating habits, shivering, and unusual crying

[9] Included injection site reactions of Grade 1, “minor reaction to touch”, Grade 2, “cries/protests on touch”, and Grade 3, “cries when limb moved/spontaneously painful”

[10] Included systemic reactions of Grade 1, “no effect on normal activity”, Grade 2, “interferes with normal activity”, and Grade 3, “prevents normal activity”

[11] Included injection site ecchymosis, injection sit erythema, injection site induration, injection site swelling, tenderness, injection site pain

[12] Included change in eating habits, sleepiness, unusual crying, irritability, vomiting, diarrhea, chills/shivering, malaise, myalgia, arthralgia, headache, fatigue, fever (>37.3 C)

[13] Defined serious adverse events as any untoward medical occurrence that results in death, is life-threatening, requires/prolongs hospitalization, or results in disability or incapacity during entire study period

[14] Defined as hospitalization, emergency room visit, and/or medical practitioner visit during entire study period

[15] Included tenderness, redness and/or swelling solicited within 7 days

[16] Included fever, vomiting, abnormal crying, drowsiness, loss of appetite, and/or irritability solicited within 7 days

PRISMA ScR checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	4
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	4
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	4
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	5-6
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	5
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Appendix 1-3
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	6
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	6

Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	N/A
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	6
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	6
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	7, Appendix 6-7
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	N/A
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	8-25
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	25
DISCUSSION			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	25-27
Limitations	20	Discuss the limitations of the scoping review process.	26
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	27
FUNDING			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	28

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with information sources (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).